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ABSTRACT 
 
The AF9 gene is one of the most common chromosomal translocation partners of 
the MLL (Mixed Lineage Leukemia) gene in MLL leukemia. Wild-type AF9 is a member 
of the pTEFb transcription elongation complex, and interacts with gene regulatory 
proteins such as AF4/AF5q31, H3K79 histone methyltransferase DOT1L, Polycomb 
repressive protein Pc3/CBX8 and BCL-family co-repressor protein BCoR. These 
interactions are retained in the oncogenic MLL-AF9 fusion protein, and may be required 
for leukemic transformation.  
Using bone marrow progenitor cells isolated from conditional Af9 knockout mice, 
we examined in vitro differentiation of hematopoietic progenitor cells to the erythroid, 
myeloid and megakaryocytic lineages in the presence or absence of Af9. Based on 
previously published studies, we hypothesized that loss of Af9 would result in a loss of 
erythroid colony formation. However, our results indicate no significant difference in 
erythroid, myeloid or megakaryocytic colony formation ability in cells expressing or null 
for Af9. Expression of transcription factor genes associated with erythroid or myeloid 
lineage commitment were also unaltered in cells null for Af9 compared to control. There 
was, however, a statistically significant decrease in cell surface expression of early 
erythroid cell surface marker Ter119 in Af9-null cells compared to control mice, 
indicating a potential role for Af9 in early erythroid lineage commitment. 
 xvi 
 
To examine the role of AF9-mediated protein interactions in MLL-AF9-mediated 
leukemic transformation, we engineered point mutants in the C-terminus of AF9 in the 
context of MLL-AF9 fusion protein predicted to disrupt specific protein-protein 
interactions. Amino acid substitutions were selected in collaboration with the laboratories 
of Dr. Hemenway and Dr. Bushweller based on structural studies and previously 
published results.  
Hematopoietic progenitor cells were isolated from the bone marrow of wild type 
mice and retrovirally transduced with constructs encoding wild type or mutant MLL-AF9 
fusion proteins, or empty vector control. In vitro colony assay experiments indicate that 
mutants MLL-AF9(D544R) and MLL-AF9(D546R) dramatically  reduced colony 
formation ability and expression of MLL target genes Hoxa9 and Meis compared to 
MLL-AF9(WT). Coimmunoprecipitation studies show that the D546R mutation in the 
context of amino acids 376-568 of AF9 significantly reduces binding to Dot1l while 
maintaining interaction with Af4, complementing biophysical studies performed in the 
Bushweller lab at the University of Virginia. Previous work by Dr. Bhavna Malik 
indicate that the D544R mutation in the context of AF9 amino acids 376-568 disrupts 
binding to Af4 but maintains binding to Dot1l.  
These results indicate that disruption of AF9 interaction with AF4 and DOT1L 
decreases colony formation and target gene expression in in vitro leukemia assays. These 
interactions are attractive targets for designing small molecule inhibitors for the treatment 
of MLL leukemia.  
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CHAPTER ONE 
 
INTRODUCTION 
 
 Blood is composed of four components: plasma, platelets, red blood cells, and 
white blood cells. Together, these cells are responsible for delivering oxygen to tissues 
and forming the immune system that protects against invading pathogens. All blood cells 
arise from a hematopoietic stem cell (HSC) that has the ability to differentiate to any 
mature hematopoietic cell.  
Leukemia is a cancer of the blood or bone marrow, resulting from the 
accumulation of abnormal hematopoietic cells. DNA damaging mutations that occur in 
early hematopoietic stem or progenitor cells cause these abnormal cells to proliferate 
without properly differentiating to the necessary effector cells of the hematopoietic 
system. In 2013, over 48,000 people in the United States were diagnosed with leukemia, 
and over 23,000 people died from the disease
1
. Leukemia is also the most common 
cancer in children and adolescents, accounting for one-third of all cancer-related deaths 
in individuals 15 years old or younger.  
Patients with leukemia involving the MLL (Mixed Lineage Leukemia) gene 
develop leukemia that is particularly aggressive and correlated with a poor prognosis
2
. 
MLL leukemias result from the chromosomal translocation of the MLL gene with one of 
over 79 fusion proteins
3
. This results in the expression of an oncogenic fusion protein that 
drives leukemic development of either acute myeloid (AML) or lymphoid (ALL) 
2 
 
 
 
phenotype. Understanding the mechanisms of leukemogenesis is necessary in order to 
develop targeted therapeutics to treat this heterogeneous disease. 
AF9 is one of the most common fusion partners in MLL leukemia
4
. The wild-type 
AF9 protein is a member of the P-TEFb elongation complex that aids RNA Polymerase II 
during gene transcription
5-7
. The C-terminus of AF9 directly interacts with at least four 
proteins: AF4
8
 and DOT1L
9
, which are considered activators of gene expression, and 
CBX8
10
 and BCoR
11
, associated with repression of gene targets. The overall goal of this 
project was to first, understand the role of Af9 in normal hematopoiesis, and second, to 
examine which protein interactions mediated by Af9 are required for leukemic 
development.  
In the first aim of this study, we utilized a conditional Af9 knockout mouse to 
elucidate the role of Af9 in normal hematopoietic lineage commitment. Based on 
previously published data, we hypothesized that Af9 is required for erythroid and 
megakaryocytic differentiation, and that loss of Af9 in this system would result in a loss 
of these cells. To test this hypothesis, we isolated hematopoietic progenitor cells from the 
conditional Af9 knockout mouse and induced deletion of the Af9 gene in vitro. These 
cells were then cultured in vitro under conditions which promoted erythroid, myeloid or 
megakaryocytic lineage differentiation. Examining colony formation, expression of 
lineage-specific transcription factors, and cell surface marker analysis, we concluded that 
contrary to our hypothesis, Af9 expression is not required for normal hematopoiesis in 
vivo.   
3 
 
 
 
The second aim of this study examined the role of AF9 interactions with Dot1l 
and Af4 in leukemic development. In collaboration with structural biologists in the 
laboratory of Dr. John Bushweller at the University of Virginia, we engineered point 
mutations in the C-terminus of AF9 predicted to specifically disrupt binding to one 
protein while maintaining interaction with the other. These mutants were expressed in the 
oncogenic MLL-AF9 fusion protein that has been shown to transform bone marrow and 
cause rapid leukemia development when introduced into mice.                                   
 Results from this study indicate that AF9 interactions with Af4 and Dot1l are 
critical for in vitro transformation ability of an MLL fusion. Amino acid substitutions 
disrupting either Af4 or Dot1l binding to AF9 result in a loss of leukemic potential as 
measured by colony formation and MLL target gene expression. These structurally-
informed point mutations identified critical residues mediating interactions between AF9 
and AF4 or DOT1L that can be used to develop targeted therapeutics in the treatment of 
MLL leukemia.  
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CHAPTER TWO 
LITERATURE REVIEW 
Hematopoiesis 
Hematopoiesis is the process of generating the blood and immune cells found 
within an organism from a common pluripotent hematopoietic stem cell (HSC). The 
hematopoietic system consists of three main groups of cells: red blood cells 
(erythrocytes), white blood cells, and platelets. Red blood cells compose the majority of 
blood, with 2-3 million new cells being produced in the bone marrow per second 
12
. 
White blood cells are sub-divided into three types: lymphocytes, monocytes, and 
granulocytes. Lymphocytes include T and B cells that together coordinate the immune 
response to foreign pathogens. Monocytes, which mature into macrophages once they 
escape the blood and enter into a specific tissue, are responsible for phagocytosing 
invading pathogens as a first line of innate immune defense. Granulocytes include 
neutrophils, basophils and eosinophils.  These cells have enzyme-containing granules 
that, when released, aid in digesting pathogens. Platelets are cell fragments shed from 
megakaryocytes that are responsible for forming blood clots. Maintaining the balance of 
hematopoietic cells circulating in the body is essential for delivering oxygen to tissues, 
protecting the organism from invading pathogens, and in maintaining hematopoiesis 
 
.  
5 
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The Hematopoietic Hierarchy of Differentiation 
All hematopoietic cells originate from HSCs in the bone marrow. The “true” HSC 
is the long-term hematopoietic stem cell, or LT-HSC. These cells are found at a very low 
frequency in the bone marrow, and exhibit lifelong self-renewal capability and 
differentiation potential to all hematopoietic lineages. The short-term hematopoietic stem 
cell (ST-HSC) still exhibits multilineage differentiation potential, but has a decreased 
capacity for self renewal.  
Differentiation from an HSC to a progenitor cell requires a loss of self-renewal 
ability concurrent with an activation of genes that enforce differentiation. According to 
the classical model of hematopoiesis described by the Weissman group (Figure 1)
13
, the 
earliest progenitor cell capable of differentiating to all hematopoietic lineages is the 
Multipotent Progenitor, or MPP
13
. The Common Lymphoid Progenitor (CLP) and 
Common Myeloid Progenitor (CMP) arise from the MPP. As their names suggest, the 
CLP can form all cells of the lymphoid lineage but lose all myeloid potential, whereas the 
CMP can give rise to all cells from the myeloid lineage but lack lymphoid differentiation 
potential
13
.  
B and T cells terminally differentiate from the CLP, while the CMP gives rise to 
two additional progenitor cells. The Megakaryocyte/Erythroid Progenitor (MEP) gives 
rise to megakaryocytes and erythrocytes, or red blood cells (Figure 1). The 
Granulocyte/Monocyte Progenitor (GMP) gives rises to the granulocytes and 
monocytes
13
, although a second study has supported the existence of a shared 
macrophage and dendritic cell precursor, the Macrophage/Dendritic Progenitor (MDP)
14
.  
6 
 
 
 
Figure 1. Weissman Model of the Hematopoietic Hierarchy 
 
Canonical model of hematopoietic differentiation from the LT-HSC to terminally 
differentiated hematopoietic cell
13
. Key transcription factors required for lineage 
specification are indicated.  
 
7 
 
 
 
While this is considered the classical model of hematopoiesis, a second model 
proposed by Adolfsson and colleagues is gaining supporting evidence
15
. On the basis of 
Flt3 expression levels, a surface marker associated with early hematopoietic progenitor 
cells, these authors propose that the MEP arises directly from the ST-HSC without transit 
through the CMP (Figure 2)
15
. In this case, the ST-HSC can give rise to either a 
Lymphoid Primed Multipotent Progenitor (LMPP) or the MEP directly. The LMPP 
terminally differentiates to cells of the lymphoid and myeloid lineage but lacks all 
erythroid potential, whereas the MEP gives rise to only megakaryocytes and red blood 
cells.  
This hypothesis is supported by studies of a SpiI knockout mouse. SpiI encodes 
for the Pu.1 transcription factor necessary for myeloid lineage differentiation. Mice 
deficient for Pu.1 exhibit a loss of the CLP and CMP, but have a normal MEP 
compartment and normal numbers of erythroid cells
16
. This supports the hypothesis that 
the erythroid lineage does not arise from a shared progenitor with the myeloid lineage, 
but diverts directly from an earlier progenitor or stem cell.  
Transcriptional Control of Hematopoietic Differentiation 
While the precise hematopoietic hierarchy is still under investigation, the 
mechanisms by which cells are signaled to differentiate is well understood, especially in 
the murine system. Genome-wide expression analyses as well as knock-out mouse 
models have identified several master regulators of hematopoietic differentiation.  
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Figure 2. Adolfsson Model of the Hematopoietic Hierarchy 
 
 
Revised model of hematopoietic differentiation as described by Adolfsson et al. 
Contrasting to the Weissman model, the ST-HSC gives rise to a lymphoid-myeloid 
primer progenitor cell or a megakaryocytic/erythroid progenitor cell, diverting all 
megakaryocytic/erythroid development from a shared myeloid progenitor.  
9 
 
 
 
As mentioned previously, Pu.1 is required for myeloid lineage differentiation. The 
Pu.1 protein is a member of the ETS family of transcription factors. This protein binds to 
purine-rich DNA sequences termed the PU-box in the promoter of genes involved in 
myeloid differentiation. Deletion of Spi1 in mice results in a fatal loss of B cells and 
macrophages
17, 18
.  
Pu.1 is required not only for the maturation of HSCs to CMPs and CLPs (Figure 
1), but for the repopulation of HSCs in chimeric mice transplanted with fetal liver cells 
16, 
19, 20
. SpiI expression is high in HSCs, CMPs, B cells, monocytes and granulocytes, and is 
downregulated during erythroid and T cell differentiation
21
.  
The maturation of the CMP to the GMP is controlled by expression of Cebpα 
(Figure 1). CCAAT/Enhancer Binding Protein alpha, encoded by the Cebpα gene, is a 
basic leucine zipper (bZIP) domain transcription factor that binds in a sequence-specific 
manner to DNA to regulate the transcription of myeloid differentiation genes. Cebpα is 
expressed in HSCs, myeloid progenitor cells and granulocytes, but is not expressed in 
macrophages 
22, 23
. Genetic knockout of this gene results in normal numbers of CMPs but 
a lack of GMPs
24, 25
, indicating a critical role for this protein in the differentiation of 
CMPs to GMPs. 
GMPs have the potential to differentiate to granulocytes or monocytes. This 
decision is controlled by the expression of interferon-(IFN)-responsive transcription 
factor 8 (Irf8)(Figure 1). While the mechanism by which Irf8 controls myeloid 
differentiation is not well understood, results from a knockout mouse model highlight the 
10 
 
 
 
importance of this gene in monocytic versus granulocytic differentiation. Mice null for 
Irf8 had increased numbers of granulocytes but fewer macrophages, and developed a 
myeloproliferative syndrome resembling human chronic myeloid leukemia (CML)
26
. Re-
expression of Irf8 in myeloid progenitors isolated from the Irf8
-/-
 mice shifted 
differentiation back toward macrophages
27
.  
Final maturation from the GMP stage to terminally differentiated granulocytes is 
controlled by the expression of Gfi1 and Cebp (Figure 1). Gfi1 is expressed in HSCs, 
neutrophils, and early B and T cells 
28, 29
. Neutrophil differentiation was completely 
blocked in mice lacking Gfi1 expression
28, 29
. Similarly, Cebp is expressed in myeloid 
and lymphoid cells, and mice null for Cebp also exhibited abnormal granulocyte 
maturation
30
.  
The divergent branch stemming from the CMP is the MEP, giving rise to 
erythrocytes and megakaryocytes (Figure 1). As mentioned above, recent studies have 
also supported the emergence of the MEP directly from the ST-HSC, bypassing a shared 
progenitor with granulocyte/macrophage potential altogether (Figure 2)
15
. There are 
several major transcription factors involved in the regulation of erythroid/megakaryocytic 
differentiation, but the GATA family of transcription factors plays a central role. The 
members of this family bind to a consensus DNA sequence through a conserved C-
terminal zinc finger motif. A second conserved zinc finger is found at the N-terminus and 
stabilizes binding to the DNA.  
11 
 
 
 
Gata2 is highly expressed in HSCs and early progenitors
31-33
, but is 
downregulated as cells begin to differentiate to erythroid or megakaryocytes. As Gata2 
levels decrease, Gata1 levels increase 
34
. This is termed the GATA-switch, and is 
required for terminal differentiation of the MEP. 
The N-terminal zinc finger of GATA1 has been shown to interact with several 
proteins including FOG-1 (Friend of Gata-1)
35
. FOG-1 is also a zinc finger-containing 
transcription factor, and exhibits an expression pattern that mimics GATA1. Both 
proteins are required for erythroid and megakaryocytic development, as is evident by 
knock-out gene studies in mice. Gata1
-/-
 mice are embryonic lethal between E10.5-11.5, 
and die of lack of primitive erythropoeisis 
36
. Conditional deletion of Gata1 in mice 
resulted in thrombocytopenia and a delay in megakaryocyte differentiation 
37
, as well as a 
lack of red blood cells 
38
. Similarly, Fog-null mice exhibit delayed megakaryocytic 
development 
39
. It is the interaction of Gata1 and Fog-1 that is thought to downregulate 
expression of Gata2 to initiate terminal differentiation of progenitor cells
40
. Interestingly, 
mutations in the N-terminus of GATA1 that prevent interaction with FOG-1 have been 
found in patients with X-linked disorders of megakaryocytic development 
41-43
.  
After the GATA switch occurs, additional transcription factors are necessary to 
promote differentiation to erythrocytes or megakaryocytes. While the Gata1/Fog-1 
complexes are necessary for lineage specification of both erythrocytes and 
megakaryocytes, it is the presence of additional factors that determine the specificity. 
Interaction of Gata1/Fog-1 with the Ets family transcription factors Fli1 and Tel are 
essential for megakaryopoiesis 
44-47
, whereas interaction with zinc finger transcription 
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factor Eklf (Klf1) is essential for erythropoiesis (Figure 1)
48
. Fli-1 and Eklf directly 
interact with and inhibit each other, as Eklf binding to Fli-1 alters the conformation of the 
Fli-1 DNA binding domain, preventing it from binding to its target genes 
49
.  
More recent studies have added additional levels of complexity to the 
transcriptional regulation of erythroid and megakaryocytic differentiation. Chromatin 
immunoprecipitation (ChIP) studies followed by massively parallel sequencing (ChIP-
seq) in human erythroleukemic cell lines have shown that GATA1 binding most often 
occurs not at promoters, but at distal enhancer elements 
50-52
. Interestingly, studies of the 
chromatin occupancy of GATA1-associated transcription factor EKLF indicate the vast 
majority of binding also occurs more than 10kb away from known genes, but within 1kb 
of GATA1 localization 
53
. Further analysis of chromatin conformation using the 
circularized chromatin conformation capture (4C) technique suggests that EKLF assists 
in localizing actively transcribed chromatin to transcription factories 
54
. Additionally, 
FOG-1 has been shown to immunoprecipitate with the NuRD chromatin remodeling 
complex
55
, providing yet another mechanism for GATA1-FOG1 complexes to regulate 
target gene expression. 
Divergent from myeloid differentiation from the MPP is the lymphoid branch of 
the hematopoietic hierarchy. MPP differentiation to the common lymphoid progenitor (or 
the lymphoid-primed multipotent progenitor according to the Adolfsson model) 
correlates with an increase in expression of both Flt3  and of the α chain of the 
interleukin 7 receptor (IL-7Rα)56-59, although signaling via IL-7R is not required for the 
generation of CLPs. Mice deficient in Flt3 have HSCs that are unable to differentiate to 
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myeloid and lymphoid cells, and mice deficient for Il7Rα expression show a three-fold 
decrease in the number of CLPs 
60, 61
(Figure 1).  
Additional factors thought to be involved in the maturation to the CLP/LMPP 
from the MPP include Pu.1 and Ikaros (Figure 1). As mentioned previously, mice null for 
Spi1, the gene encoding the Pu.1 protein, die during embryogenesis or perinatally, and 
exhibit defects in myeloid and lymphoid differentiation
17, 18
. These mice do not have 
detectable T cells in the thymus, nor do they have B cells in the liver, suggesting that 
Pu.1 acts at the levels of a progenitor common to both B and T cell development 
17, 62
.  
Ikaros is a zinc finger-containing transcription factor that, like Eklf, is associated 
with the NuRD chromatin remodeling complex as well as the SWI-SNF complex 
63, 64
. 
While Ikaros has been shown to be both an activator and a repressor 
65, 66
, its activity is 
essential for lymphoid differentiation. Mice lacking Ikaros completely lack B cells and 
have impaired fetal T cell development, although adult T cell differentiation is 
unaffected
67
. 
B cell differentiation occurs through several steps, each of which requires a 
specific transcriptional regulatory program. B cells proceed through a series of 
maturation stages, from the early lymphoid progenitor to the pre-pro-B cells, to the pro-B 
cells, and finally to the pre-B cell prior to mature B cells. The major player in 
commitment to the B cell lineage is Pax5, which is stably expressed throughout all stages 
of B cell maturation 
68
(Figure 1). Loss of Pax5 expression results in an arrest of B cell 
development at the pro-B stage 
69
.  Pax5 has been shown to both activate target genes 
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required for B cell maturation such as Lef1 and Irf8, and to repress target genes including 
Flt3, the previously described CLP-associated marker 
70, 71
.  
T lymphopoiesis is equally complex. T-progenitor cells mature in the thymus, and 
are marked by expression of CC-chemokine receptor 9 (CCR9), stem-cell antigen 1 
(SCA1), and FLT3 
72-74
. Early T cell progenitors mature through several steps of 
differentiation, from the early T-cell lineage progenitor (ETP), to the double CD4, CD8 
negative 2a (DN2a) cells, then to DN2b, DN3a, DN3b, DN4, double CD4, CD8 positive 
(DP), to the T cell receptor positive DP cells, and finally to terminally differentiated 
CD4+ or CD8+ T cells. Each maturation stage requires expression of a specific 
combination of transcription factors, but initiation of the entire T lineage differentiation 
program requires Notch signaling (Figure 1). Expression of constitutive Notch leads to T 
cell-Acute Lymphoblastic Leukemia (T-ALL) in mice, whereas knockout of Notch target 
gene Rbpj results in a loss of all T cell development 
75, 76
. Additional transcription factors 
play important roles at later stages of T cell differentiation, including GATA3, MYB, and 
TCF1 
77-83
.  
It is clear that differentiation from hematopoietic stem cell to a terminally 
differentiated cell is very complex, involving an intricate network of tightly regulated 
transcription factors that turn on and off target genes necessary for lineage maturation. 
More recent studies have begun to examine the mechanisms by which gene expression is 
controlled at the epigenetic level, or how DNA accessibility affects which genes can be 
turned on and off by the above described transcription factors. The mechanisms that 
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regulate these epigenetic modifications are as critical as the transcription factors that 
control proper hematopoietic development.   
Chromatin and Epigenetics 
The human body is composed of over 200 different cell types that work in concert 
to support a living human being. Each of these cells has 46 chromosomes containing over 
3 billion base pairs of DNA. Stretched out end-to-end, the amount DNA in each cell 
would reach over two meters. In order to efficiently pack this much DNA within the 
nucleus of every cell in the body, a complex organization system has evolved.  
Chromatin refers to the packaging of DNA around proteins in the nucleus of a 
cell. At the most basic level, approximately 146 base pairs of DNA wrap around a core of 
eight histone proteins: two each of histone H2A, H2B, H3, and H4 
84
. The DNA wraps 
around the octamer core approximately 1.7 times. Between the DNA-wrapped histone 
proteins are approximately 20-60 base pairs of DNA that can associate with a fifth 
histone protein, the linker histone H1, forming a nucleosome. When viewed by electron 
microscopy, this level of DNA organization, approximately 10nm in diameter, resembles 
beads on a string with the DNA-wrapped histone octamer being the bead and the spacer 
DNA being the string. Nucleosomes further fold upon each other forming 30nm 
chromatin fiber up to 300nm fibers. 
The extent to which nucleosomes are compacted, and how tightly the DNA is 
wrapped around the histone octamer, determines, in part, whether genes are actively 
transcribed or not. Only loosely packed, accessible DNA can be targeted by the DNA 
transcription machinery and transcribed. Tightly wound, compacted DNA is not 
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accessible to the transcription machinery and therefore is not active. These regions are 
termed euchromatin and heterochromatin, respectively 
85
.  
Chromatin can be compacted and expanded by ATP-dependent chromatin 
remodeling complexes which contain proteins with ATPase enzymatic domains. The 
energy from ATP hydrolysis is used to restructure or shift the nucleosome along the 
DNA, or to expel nucleosomes altogether to make the DNA accessible to the 
transcription machinery. 
The stable inheritance of a phenotype resulting from changes in chromosome 
structure without alterations in the DNA sequence itself is termed epigenetics 
86
. Proteins 
involved in placing epigenetic marks can be activators that turn on gene expression, or 
repressors that turn off gene expression. It is through epigenetics that cells can adopt 
specific functions. As discussed above, each cell in the body contains exactly the same 
DNA. It is the combination of genes that are expressed and repressed that gives a cell 
identity and function.  
One mechanism of epigenetic regulation is though modification of the histone 
proteins themselves. Histone proteins have flexible N-terminal tails that extend beyond 
the octamer core 
84
 that can be post-translationally modified by proteins
87
. Such 
modifications include acetylation, phosphorylation, methylation, ubiquitylation, 
sumoylation, and ADP ribosylation. Modification of histone tails can serve different 
purposes, from changing the charge in the tail to alter DNA-protein or nucleosome-
nucleosome interactions, or to providing a binding surface for proteins to localize to the 
histone and carry out additional functions.  
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The residue of the histone tail that is modified, and the modification itself can 
determine the functional outcome 
85
. While these marks are vast and varied, a few have 
been very well studied. For example, di- or tri-methylation of histone H3 at lysine 9 
(H3K9me2/3) within the gene body, and tri-methylation of H3K27 in the promoter region 
are associated with transcriptionally repressed genes. Tri-methylation of H3K4 in the 
promoters of genes is associated with transcriptional activation
88
. Understanding the 
function associated with these marks, and the proteins that place these marks, is critical 
for understanding complex gene regulation.  
A second mechanism of epigenetic regulation is DNA methylation. DNA 
methylation occurs on the fifth carbon of cytosine rings in CG dinucleotides 
89
. Cytosines 
located 5’ to guanine nucleotides, termed CpG for cytosine-phosphate backbone-guanine, 
are represented less than statistically predicted in the genome 
90
. Methylated cytosines 
can spontaneously undergo a deamination reaction, resulting in a transition mutation to 
thymine. This process has been evolutionarily selected against, thus the CG dinucleotide 
exhibits a decreased representation throughout the genome.  
CpGs are, however, found at an observed-to-expected ratio of >60% in the 
promoters of approximately 70% of human protein coding genes 
91
. Clusters of CG 
dinucleotides making up >50% GC content in a 300-3,000 base pair range of DNA are 
termed CpG islands. These clusters are mostly unmethylated, and the genes associated 
with these promoter regions are transcribed
92
. Methylation of these CpGs by DNA 
methyltransferase enzymes is associated with transcriptional repression, and these methyl 
marks are maintained throughout cell division by maintenance DNA methyltransferase 
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enzymes, thus preserving the silencing of the gene 
93
. DNA methylation is often exploited 
by cancer cells, in which the promoters of tumor suppressor genes can be methylated and 
therefore silenced. Conversely, the promoters of developmental genes that are silenced as 
cells differentiate may become unmethylated, allowing for expression of genes that 
should otherwise be turned off.  
MLL 
 The MLL (Mixed Lineage Leukemia) protein is a member of the Trithorax group 
of proteins that positively regulate gene transcription by modifying chromatin structure, 
among other functions. MLL is an ortholog of the Drosophila melanogaster Trithorax 
protein, so named for the transformation of abdominal segments that occurs when the 
gene is mutated 
94
. Further research identified a role for trithorax in the positive 
regulation of homeotic genes that determine the spatial body plan during development 
95
.  
 Studies in mice further elucidated a role for Mll in development and 
hematopoiesis. A lacZ reporter gene was inserted in-frame in exon 3 of mouse Mll, 
located just downstream of the AT-hooks shown to be required for trithorax activity in 
Drosophila, resulting in a loss of Mll activity. β-galactosidase staining indicated that Mll 
is widely expressed in the developing embryo from the first time point examined (E7.0) 
into adulthood, with highest expression levels in found in the nervous system and the 
somites that give rise to mature cells of the mesoderm lineage. These regions are 
regulated by the expression of Hox genes, indicating an overlap between Mll expression 
and regions regulated by Hox genes in the developing mouse 
96
.   
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 Wild-type, Mll
+/-
 and Mll
-/-
 mice were generated to study the function of Mll. Mll
-
/- 
mice died during embryonic development by E10.5, indicating that expression of Mll is 
essential for viability. Further examination of the Mll
+/-
 mice showed that Mll is a 
haploinsufficient gene; expression from only one allele does not produce enough protein 
product to achieve a wild-type phenotype. These mice were smaller at birth compared to 
the wild-type mice and had retarded growth. In addition, the Mll
+/-
 mice also exhibited 
skeletal abnormalities. Both anterior and posterior homeotic transformations were 
present, similar to those seen in Hox-deficient mice 
96
.  
 As Trithorax group (TrxG) proteins are known to positively regulate Hox 
expression, whole-mount embryo hybridization and RNA in situ hybridization were used 
to assess any alterations in Hox gene expression upon loss of Mll. Reduced boundaries of 
expression were evident for Mll targets Hoxc9 and Hoxa7 in the Mll
+/- 
mice, and 
expression was absent altogether in E10.5 embryos from Mll
-/-
 mice, indicating that Mll is 
required for the proper maintainence of Hox gene expression 
96
. 
 Mll
+/-
 mice also exhibited defects in hematopoiesis such as anemia, a reduction in 
platelets, and reduced numbers of B-cells 
96
. The role of Mll in hematopoiesis was further 
studied by in vitro differentiation of yolk sac progenitor cells isolated from wild-type, 
Mll
+/-
 and Mll
-/-
 mice. Cells lacking Mll produced fewer colonies containing smaller cells 
than heterozygous and wild-type controls, indicating that Mll is required for maintenance 
of the both the numbers of hematopoietic progenitors and for their proper differentiation 
into mature hematopoietic cells, particularly the myeloid and macrophage lineages 
97
.   
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Conditional loss of Mll in the hematopoietic lineage did not alter the steady state 
levels of mature blood cells in adult mice. However, when cultured in methylcellulose, 
the conditional Mll knockout cells exhibited a reduced ability to form myeloid and 
lymphoid colonies compared to control cells 
98
. When injected into lethally irradiated 
recipient mice, the conditional knockout cells failed to reconstitute the bone marrow, 
indicating that Mll is required for adult HSC self-renewal
98
.  
Similarly, hematopoietic lineage-restricted inducible loss of Mll in adult mice 
caused rapid and fatal cytopenia within 19 days 
99
. Loss of Mll in the hematopoietic 
lineage resulted in a loss of hematopoietic stem and early progenitor cells, but more 
mature, lineage-committed progenitor cells were unaffected
99, 100
. A recent study 
identified a network of genes specifically regulated by MLL in HSCs. These genes, 
including Prdm16, Pbx1, and Hoxa9, are involved in the self-renewal and proliferative 
capacity of HSCs 
101
. The results of these studies indicate a critical role for MLL in the 
maintenance of hematopoietic stem cells.  
MLL Protein Domains  
 It is thought that MLL regulates expression of genes necessary for development 
and hematopoiesis, at least in part, through its chromatin modifying ability. The C-
terminus of MLL contains a histone methyltransferase domain with specificity for histone 
H3 lysine 4
102
(Figure 3A). Trimethylation of H3K4 is associated with positive gene 
expression, although it is still debated whether the placement of this mark initiates gene 
transcription, or if it is just associated with genes that are already being activity 
transcribed.   
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 There are many other important protein domains of MLL that govern its role in 
gene regulation (Figure 3A). The MLL gene, located at chromosome 11 band q23, 
encodes a full length protein of 3,969 amino acids that is post-translationally cleaved by 
taspase-1 into a 320 kilo-Dalton (kDa) N-terminal and 180 kDa C-terminal fragment that 
remain associated non-covalently via the FYRN and FYRC domains 
103, 104
(Figure 3B).  
 The N-terminus of MLL contains a motif that binds the protein Menin. Menin 
directly binds LEDGF, a protein with a PWWP DNA binding domain. MLL, through its 
interaction with Menin, is bridged to LEDGF and recruited to target DNA sequences. 
Loss of the Menin binding motif of MLL in the context of a MLL fusion protein results 
in decreased transformation ability
105
.  
 Three A-T hooks are located just downstream from this region. A-T hooks 
recognize and bind to bent, A-T rich DNA sequences 
106
. This region has been shown to 
interact with SET, protein phosphatase 2A (PP2A) and GADD34 proteins 
107, 108
. The A-
T hooks precede two speckled nuclear localization domains. These domains are required 
for localizing MLL to punctuate structures within the nucleus 
109, 110
.  
 The Repression Domain of MLL was identified in a study in which this region of 
the protein was shown to have repressive activity in a reporter assay 
106
. Additional 
studies have found that corepressor proteins such as CtBP, BMI-1 and CBX4 (HPC2) 
bind to this region, as does Histone Deacetylase 1/2 (HDAC1/2)
111
. Recent studies have 
shown that the Polymerase Associated Factor (PAF) complex, associated with gene 
activation, also binds to this region 
112, 113
. 
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Located within the Repression Domain of MLL is the CXXC domain, so named 
for the conserved spacing of eight cysteine resides. The CXXC domain was identified for 
its homology to the CXXC domain of the DNA Methyltransferase 1 (DNMT1) protein 
114
. Studies from our lab and others have shown that the CXXC domain binds to 
unmethylated CpG DNA, protecting it from DNA methylation. The ability of the CXXC 
domain to bind unmethylated DNA is required for transformation by the MLL-AF9 
fusion protein in MLL leukemia 
115, 116
.  
 Downstream of the CXXC domain is an atypical bromodomain and four plant 
homodomain (PHD) zinc fingers. The second of the four PHD fingers is involved in 
homodimerization of MLL 
117
. The third PHD finger has been shown to bind to H3K4 
trimethyl marks or the cyclophilin CYP33 in a mutually exclusive manner 
118, 119
. The 
ability of MLL to both “read” histone marks and “write” the H3K4 methyl mark on 
histones is thought to promote the maintenance of histone modifications.  
 The C-terminus of MLL contains a transactivation domain (TAD) that is 
associated with coactivator protein CBP binding
120
. And, as mentioned previously, the 
most carboxy-terminal protein domain in the wild type MLL protein is the SET domain 
with H3K4 histone methyltransferase ability. Together, the multiple functional domains 
of MLL provide the protein with a multitude of ways to participate in gene regulation, 
both with activating and repressive functions.  
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Figure 3. Protein Domains of MLL and MLL Fusion Proteins 
A 
 
B 
 
 
 
C 
 
 
(A) Domain schematic of the human MLL protein with protein domains and 
corresponding amino acids indicated. Alternate names and chromosomal location are 
noted. (B) After cleavage by Taspase 1, the N-terminal and C-terminal fragments of MLL 
associate through the FYRN and FYRC domains. (C) MLL fusion proteins express the N-
terminus of MLL through the breakpoint cluster region and the C-terminus of one of 79 
known fusion partner proteins.  
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MLL Target Genes 
 The HOX genes are very well-studied gene targets of MLL. HOX proteins are 
DNA-binding transcription factors that bind DNA via a homeodomain located at their C-
terminus. HOX proteins function to regulate body segment identity as well as determine 
embryonic cell fate. Expression of HOX genes is positively regulated by the Trithorax 
group of proteins including MLL, whereas expression is repressed by the Polycomb 
group of proteins
96, 121, 122
. 
These genes are highly evolutionarily conserved, so much so that loss of a Hox 
gene in Drosophila melanogaster could be rescued by re-expression of the chicken 
ortholog
123
. In humans and mice, the HOX genes are divided into four clusters: A, B, C 
and D, located on four separate chromosomes. Within these clusters, there are 13 
paralogous groups totaling 39 genes in whole
124, 125
. The HOX genes are regulated 
spatially and temporally such that the genes located 3’ in the clusters are transcribed 
earlier in development and at the anterior end of the organism. Conversely, genes located 
5’ in the clusters are transcribed later in development and in the posterior end 124.  
HOX genes are also critical regulators of hematopoiesis. Genes in the A, B and C 
cluster are highly expressed in hematopoietic stem and early progenitor cells, and 
expression of these genes is decreased as the cells differentiate and mature. 
Overexpression of HOX genes such as HOXA9 is a characteristic of certain types of 
leukemia, and coexpression of Hoxa9 and Meis1 is sufficient to transform normal mouse 
myeloid progenitor cells
126
.  
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MEIS1, another target of MLL, is a member of the three amino acid loop 
extension (TALE) group of proteins that also contain a homeodomain. Like HOX 
proteins, MEIS1 plays a role in development and hematopoiesis, although its role is less 
well understood. Similar to HOX genes, MEIS1 expression is highest in early 
hematopoietic stem and progenitor cells, and expression decreases as cells differentiate 
127
. Meis1
-/-
 mice die at E14.5 and exhibit a lack of megakaryocytes and subsequently, 
extensive hemorrhaging
128
. MEIS1, like HOXA9, is overexpressed MLL-rearranged 
leukemias
129-131
.  
 In addition to MEIS1 and HOX genes, more recent genome-wide studies have 
identified a role for MLL as a potential master regulator of gene transcription. Chromatin 
immunoprecipitation studies have examined the binding of MLL at loci throughout the 
genome. One of the earliest reports found MLL bound at the promoter of 5,186 genes in 
U937 monocytic cells with coincident binding of RNA Polymerase II at 90% of the 
genes, and H3K4 trimethylation at 92% of the genes 
132
. However, a separate study used 
Mll
+/+
 and Mll
-/-
 murine embryonic fibroblasts (MEFs) to further examine the correlation 
between Mll localization, H3K4me3 and gene activation. The authors found peaks of 
H3K4me3 at 10,041 genes in the wild type cells, with a loss of H3K4me3 at only 525 
promoters, or approximately 5% of genes, in the Mll
-/-
 cells 
133
. These results suggest that 
Mll maybe be responsible for H3K4me3 at only a subset of genes.  
Another study comparing the localization of MLL and MLL fusion proteins found 
wild-type MLL bound at the promoter and 5’ region of 2,595 genes 134. While the exact 
number of genes regulated by MLL is still being examined, it is clear that MLL plays a 
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critical role in regulating specific target genes involved in development and 
hematopoiesis. 
MLL Leukemia 
 The transcriptional activation role of MLL is exploited in a specific type of 
leukemia termed MLL Leukemia. Patients with MLL leukemia express oncogenic fusion 
proteins that result in the aberrant transcription of MLL target genes such as the HOX 
genes described above (Figure 3C). Additionally, amplifications of the MLL gene are 
found in patients with AML and myelodysplasia, and partial tandem duplication of 
amino-terminal exons of MLL are found in approximately 10% of all AML cases 
135, 136
.  
In MLL fusion genes, a double strand break in the DNA occurs within the 
breakpoint cluster region (BCR) of the MLL gene. As these breaks are deleterious to a 
cell, mechanisms of DNA repair are employed. In this case, non-homologous end joining 
(NHEJ) fuses the broken MLL gene to one of over 79 translocation partner genes 
3
(Figure 3C). The cause for breakage of MLL within the BCR, as well as the cause for 
breakage within the fusion partner, is not well understood. While there is little sequence 
homology within the breakpoint cluster regions of both MLL and the known fusion 
partners, the BCRs share several structural elements including topoisomerase II cleavage 
sites, DNAse I hypersensitivity sites and scaffold attachment regions that serve to 
associate proteins involved in transcription and replication
137-140
. These regions may be 
more susceptible to breakage and subsequent aberrant repair by NHEJ. 
MLL translocations are found in approximately 10% of all Acute Myeloid or 
Lymphoid Leukemias diagnoses, but the incidence of MLL leukemia is higher in infants. 
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Approximately 70% of infant ALL and 35-50% of infant AML patients express MLL 
fusion genes 
141
. While the five year event free survive (EFS) in infants with ALL 
without MLL recombination is 74-96%, infants with ALL with a MLL recombination 
have a five year EFS of only 19% 
2
.  
MLL fusions are also present in a subset of leukemias that arise after treatment for 
a primary cancer, termed therapy-related MLL leukemia
142
. Cells require expedient 
replication of DNA for cell division to occur. As the double helix unwinds to separate the 
strands for replication, tension builds in the DNA proximal to the replication fork and if 
not relieved, would halt the DNA polymerase. Topoisomerase enzymes introduce breaks 
in the DNA phosphodiester backbone to allow for unwinding of the DNA to alleviate the 
tension, and then reanneal the cut DNA back together.  Topoisomerase enzymes play a 
similar role in RNA transcription. 
Topoisomerase II inhibitors such as etoposide, doxorubicin and daunorubicin are 
often administered to cancer patients to block the activity of the topoisomerase enzyme in 
rapidly dividing cancer cells, notably preventing the reannealing of broken DNA strands. 
This triggers the DNA damage response pathway and induces apoptotic cell death. The 
11q23 locus has been shown to be highly susceptible to double strand breaks, and 
inhibition of topoisomerase enzymes prevents repair at this locus 
143, 144
. Aberrant repair 
of the broken DNA by NHEJ can then result in the production of oncogenic fusion 
proteins. Approximately 5-10% of all MLL leukemias are therapy-related, almost all of 
which are AML
141
.  
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While almost 80 MLL fusion partners have been characterized, over 85% of all 
MLL leukemias involve one of 6 partner genes
3
: AF4, AF9, ENL, AF10, ELL and AF6.  
These proteins belong to one of three gene families, all of which are involved in 
transcription regulation. Of note, new nomenclature has been instituted for genes in these 
families: AF4/AFF1, AF9/MLLT3, ENL/MLLT1, AF10/MLLT10, and AF6/MLLT4. 
However, as much of the literature regarding these genes references the original gene 
names, they will be used throughout this dissertation.  
Results from several studies support the hypothesis that the fusion partner dictates 
the leukemic phenotype. For example, MLL-AF9 fusion proteins are highly associated 
with AML, whereas MLL-AF4 fusions often given rise to ALL or acute biphenotypic 
leukemia (ABL). Retroviral transduction of MLL-AF9 transforms both early 
hematopoietic progenitors 
145
 and committed myeloid progenitors 
146
, and when 
transplanted into mice, results in proliferation and accumulation of myeloblasts. 
Similarly, a knock-in MLL-AF9 mouse model in which expression of the MLL-AF9 
fusion protein is under control of the endogenous Mll promoter also leads to development 
of acute myeloid leukemia in the majority of the mice 
147, 148
.  
Conversely, knock-in of the MLL-AF4 fusion resulted in mice with a mixed 
lymphoid and myeloid phenotype, with a predominance of B220+ or CD19+ B lymphoid 
cells
148
. These mice developed hematologic malignancies with a median of 520 days 
compared to 220 days for mice with a knock-in of the MLL-AF9 fusion 
148
. These results 
support the hypothesis that the fusion partner is responsible for dictating the leukemic 
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phenotype. However, additional studies suggest that the microenvironment is the critical 
regulator of myeloid versus lymphoid leukemic fate. 
Wei et al examined the leukemic phenotype of MLL-AF9-transduced CD34+ 
human cord blood cells cultured under myeloid or lymphoid cytokine conditions in vitro 
and in vivo. When cultured in the presence of myeloid cytokines, cells expressed 
myelomonocytic surface markers. However, switching these myeloid-conditioned, long 
term-cultured MLL-AF9 cells to media promoting erythroid or lymphoid development 
failed to differentiate the cells, as indicated by decreased surface marker expression of 
lienage-specific markers compared to control CD34+ cells 
149
. Interestingly, when MLL-
AF9 transduced CD34+ cells were cultured under conditions to promote B cell 
differentiation, the cells exhibited a mixed lineage phenotype, suggesting that the 
cytokine environment plays a critical role in determining the leukemic phenotype of these 
cells 
149
. 
To examine the role of the microenvironment on leukemogenesis in vivo¸ MLL-
AF9-expressing CD34+ cells were either directly injected after retroviral transduction 
into mice, or were cultured for an extended period of time in the presence of myeloid or 
lymphoid cytokines prior to injection into mice. Non-obese Diabetic/Severe Combined 
Immunodeficiency (NOD-SCID) or NOD-SCID β2-microglobulin-/- mice injected with 
MLL-AF9-transduced cells cultured under myeloid conditions only developed AML with 
a latency of 10 weeks. Injection with cells cultured under lymphoid conditions resulted in 
mice with AML, B-ALL or Acute Biphenotypic Leukemia (ABL) with a latency of 
approximately 13.5 weeks. Direct injection of newly-transduced cells caused mice to 
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develop B-ALL or ABL, but no mice developed AML. However, injection of these same 
cells into mice transgenic for IL-3, SCF and GM-CSF expression resulted in only AML 
development in mice within 7 weeks. Similarly, injection of MLL-AF9 cell lines cultured 
under myeloid or lymphoid conditions into these transgenic mice resulted in development 
of AML exclusively within 5 weeks. These results suggest that it is not the fusion partner 
per se, but the microenvironment in which the fusion-expressing cell is located that 
determines the leukemic phenotype 
149
.  
While the interplay between the function of the partner brought into MLL fusion 
genes and the microenvironment in which they are expressed is still being elucidated, it is 
clear that MLL fusion proteins are key drivers of leukemogenesis. MLL-AF9 fusions in 
particular are highly leukemogenic, and understanding the mechanism by which AF9 
functions in wild-type cells is necessary understanding how it contributes to misregulated 
hematopoiesis in MLL leukemia.  
AF9 
 The AF9 gene, located at chromosome band 9p22, is fused to MLL in 
approximately 25% of de novo AML in children and 2-5% of all AMLs
4
. Patients with 
MLL-AF9 translocations have a median survival of four years
4
. Understanding the 
function of AF9 is necessary to understanding its role in MLL leukemia in order to 
develop efficacious therapeutics. 
 AF9 is a member the YEATs (Yaf9, ENL, AF9, Taf1, Sas5) domain-containing 
family of proteins, so named for the conservation of the domain in both yeast (Yaf9, 
Taf1, Sas5) and mammalian (AF9, ENL) proteins. AF9 and ENL are highly homologous 
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to each other, sharing approximately 50% amino acid identity overall and 80% identity in 
conserved N and C terminal regions
150
, but these proteins show little homology to other 
mammalian gene families (Figure 4A).  
The YEATs domain is located at the N-terminus of both AF9 and ENL (Figure 
4A, B). This domain is often found in proteins with chromatin-modifying ability
151
. As is 
further discussed in the review on transcription elongation, the YEATS domain of AF9 
and ENL interact with the Polymerase Associated Factor complex (PAFc), which recruits 
the Super Elongation Complex (SEC) to poised polymerases, facilitating productive 
elongation of nascent RNA 
152, 153
.  
A nuclear localization signal (NLS) is located downstream of the YEATs domain 
and allows for translocation of the protein from the cytoplasm to the nucleus. This region 
is also proximal to a serine/proline rich region. The C-terminus of AF9 encodes a 94 
amino acid AHD domain [actin non-complementing gene 1 budding yeast (Anc1) 
homology domain] involved in protein-protein interactions
154
. This region of AF9 is 
highly conserved with ENL, and to a lesser degree, to the yeast ANC1 
155
. It has been 
shown to interact with at least four other proteins: AF4, DOT1L, CBX8 and BCoR in 
mammals
8-11
(Figure 5).  
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Figure 4. Protein Domains of AF9 and ENL 
A 
 
  
 
B 
 
 
 
C 
 
 
 
 
D 
 
 
Protein domain schematic of (A) AF9 and (B) ENL with alternate names and 
chromosomal location noted. Lines below the protein structure indicate the approximal 
fragment of the protein present in MLL fusions. (C) ) Solved NMR structure of AF4 
peptide in complex with the C-terminal AHD of AF9 (figure from Leach 2013). (D) 
Amino acid sequence of a segment of the AF9 region known to interact with AF4, 
DOT1L, CBX8 and BCoR is highly conserved in homolog ENL. The bolded aspartic 
acid mediates an electrostatic interaction with AF4 family members.   
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Recent studies by Leach et al showed that the AHD of AF9 is highly disordered 
with a structure that is almost entirely random coil with a minimal beta structure in its 
unbound state
156
. The addition of an AF4 peptide corresponding to the known AF9-
interacting sequence 
157
 resulted in a structural rearrangement of the AHD, forming the 
alpha-beta structure shown in Figure 4C. A beta strand in AF4 residues 761-766 is 
located next to the beta hairpin of AF9 residues 535-546, together forming a three-
stranded antiparallel beta sheet. AF9 also forms three alpha helices around the AF4 
peptide
156
(Figure 4C). 
At least one electrostatic interaction between AF9(D544) and AF4(K764) exists 
(Figure 4D, 6B). This interaction is the focus of further studies presented in this 
dissertation. The interface between AF9 and AF4 is otherwise primarily hydrophobic, 
mediated by several aliphatic residues within the region. Interestingly, while the 
sequences of the proteins that interact with AF9 are highly dissimilar, DOT1L, CBX8 
and BCoR proteins all have conserved spacing of the aliphatic residues present in AF4 
that mediate the AF4-AF9 interaction. Coexpression of AF9 and any one of the four 
binding partners resulted in highly similar chemical shifts, suggesting that AF9 adopts a 
similar structure when bound to any of the four proteins, and that the binding partners all 
share a common binding site on AF9 
156
. These results support the hypothesis that the C-
terminus of AF9 remains highly disordered until binding to a partner protein. As the 
binding partners of AF9 are considered both transcriptional activators (AF4, DOT1L) and 
repressors (CBX8, BCoR), it is plausible that the interaction of AF9 with one of these 
proteins may allow for differential regulation of genes targeted by AF9.  
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Figure 5. AF9-Containing Protein Complexes 
 
 
The AHD of AF9 has been shown to interact with at least four known proteins: CBX8, 
DOT1L, BCoR and AF4/AF5q31. Shaded regions of the interacting protein denote 
approximate region of AF9 interaction. CBX8 is a member of the PRC1 repressive 
complex. DOT1L is the only known H3K79 histone methyltransferase. BCoR has been 
shown to associate with BCL-6 to repress gene targets. AF4/AF5q31 are associated with 
P-TEFb, and with additional proteins (not shown) form the Super Elongation Complex 
(SEC).  
 
To further investigate the functional role of Af9, a constitutive knockout mouse 
was engineered by disrupting the second exon of Af9 with a lacZ-neo cassette. Af9
+/-
 mice 
were normal and fertile
158
. Breeding with these mice produced homozygous offspring at 
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the expected ratio, indicating that the homozygous null Af9 mice survive embryogenesis. 
However, 50% of these Af9
-/-
 mice were found dead at birth or died within hours after. 
The remaining surviving mice were severely runted and died within two weeks. These 
mice did not exhibit any gross external malformations, nor did they have internal changes 
in organ structure. Hematopoiesis appeared normal in the Af9
-/-
 mice as assessed by 
histology and flow cytometry
158
.  
Further examination of whole-skeleton preparations showed that the homozygous 
mutants exhibited axial skeletal abnormalities, lacking a pair of floating ribs and the 
associated vertebrae. The Af9
-/-
 mice also had deformed sternums, and often had extra 
cervical vertebrae compared to wild type controls. These malformations, in addition to 
other subtle changes, indicated that anterior homeotic transformation of the axial skeletal 
had occurred in mice lacking Af9 expression comparable to the phenotype of Mll
+/-
 mice 
96
. Lumbar and caudal vertebrae, and the appendicular skeleton were normal
158
.  
β-galactosidase staining of embryos taken from heterozygous mice between E10.5 
and E14.5 indicated widespread Af9 expression in the mouse including the skeletal 
system, neural system, gut, forming genital organs, in the caudal hindbrain and at the 
midbrain-hindbrain border. Slight differences in the expression pattern of B-
galactosidase were seen in the homozygous null embryos, with decreased staining at the 
anterior cervical region compared to the heterozygous embryos, as well as more broad 
lateral expression in this region compared to the Af9
+/-
 embryos
158
. 
The widespread expression pattern of Af9 in developing tissues and the homeotic 
transformations seen upon loss of Af9 suggested a role for Af9 as a master regulator of 
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early embryonic development, similar to Mll. As proper expression of Hox genes is 
critical for normal development, the authors examined the expression patterns of several 
Hox genes in wild-type, heterozygous and homozygous null Af9 embryos. The expression 
of Hoxd4 in Af9
-/-
 embryos was reduced and did not reach the anterior boundary 
compared to wild-type or Af9
+/-
 E9.5 embryos. This altered expression pattern was not 
seen with other Hox genes
158
. From this study, the authors concluded that Af9 is required 
for normal embryonic development, at least in part by Hox gene regulation. 
Pina and colleagues sought to further elucidate the role of Af9 in hematopoietic 
development. Global transcriptome analysis of long term culture-initiating cells (LTC-IC) 
was performed, and identified AF9 as one of the most highly upregulated genes in the 
quiescent human LT-HSC
159
, consistent with other published microarray data 
160-162
. The 
expression of AF9 was further analyzed in the various progenitor compartments of 
human cord blood. Results indicated that AF9 expression was highest in the HSC, and 
that expression diminished at each stage of differentiation with a 2-3 fold reduction from 
HSC to CMP and again to GMP, suggesting a role for AF9 in early lineage commitment 
159
. 
 Forced expression of AF9 by lentiviral transduction in human CD34
+
CD38
-
 cord 
blood cells resulted in an increase in erythroid progenitors (BFU-E) at the expense of the 
granulocyte/macrophage progenitors (CFU-GM). The earlier multipotent CFU-GEMM 
population that gives rise to the CFU-GM was unaffected. Overexpression of AF9 
proteins lacking the YEATS domain or AHD, respectively, produced colony numbers 
similar to vector control, indicating that the entire full-length protein is necessary to 
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mediate the expansion of the erythroid progenitor compartment. Similarly, 
overexpression of AF9 resulted in an increase in CD41
+
 colonies in a megakaryocyte-
CFC assay. Conversely, knockdown of AF9 with short hairpin RNAs produced an almost 
complete loss of BFU-E and CFU-GEMM and a reduction in CD41
+
 colonies, suggesting 
that AF9 plays a critical role in early erythroid/megakaryocyte (E/Meg) lineage fate 
determination
159
.  
To test the effect of AF9 overexpression in vivo, the authors injected NOD/SCID 
β2-microglobulin-/- mice with CD34+ cord blood cells transduced with lentivirus 
encoding GFP-tagged AF9. Two weeks after intratibial injection, engraftment of GFP-
positive cells within the erythroid (CD71
+
), megakaryocyte (CD41
+
) and 
lymphoid/myeloid (CD45
+
) compartments was examined. The results correlated with the 
in vitro data, indicating an increase in GFP-positive cells in the erythroid and 
megakaryocytic populations upon forced expression of AF9 with a concurrent decrease in 
GFP-positive cells in the lymphoid/myeloid compartments
159
.  
Expression of transcription factors associated with the E/Meg lineage such as 
GATA1 and GATA2 were increased upon overexpression of AF9 in CD34
+
 cord blood 
cells, while expression of transcription factors associated with the GM lineage (PU.1, 
CEBPA, GFI1) were decreased upon forced expression of AF9
159
. Together, the results of 
this study support a role for AF9 in early hematopoietic commitment to the erythroid and 
megakaryocytic lineage.  
 
 
38 
 
 
 
AF9 Homolog ENL 
Interestingly, the AF9 homolog ENL (MLLT1) shows an opposing pattern of 
expression despite highly conserved sequence similarity throughout regions of the 
protein. ENL is expressed in most tissues with the exception of the liver, with the highest 
expression levels found in the testis and brain. In terms of hematopoietic expression, 
ENL is highly expressed in lymphoid cells but not in myeloid cells, the opposite pattern 
of AF9 
150
.  
The ENL protein is structurally very similar to AF9, sharing 50% of amino acid 
sequence overall, with an increase to 80% identity within the YEATS and AHD domains 
(Figure 4B, 4D). However, the 5’ regulatory region of Enl shows no sequence similarity 
to the Af9 promoter region, suggesting that the expression of these genes is distinctly 
regulated. The 5’ regulatory region of Enl does not contain a consensus TATA element, 
but includes several Sp1 binding sites as well as potential N-myc, c-Ets, c-Rel and GATA 
binding sites  
150
. 
Enl-deficient mice were engineered by insertion of a neomycin-resistance cassette 
with a stop codon in reverse orientation into exon six of Enl, resulting in a protein less 
than 40% of full length
150
. Heterozygous mice did not exhibit any developmental defects; 
however, crosses with these mice did not yield any homozygous null offspring, indicating 
an essential role for Enl in embryonic development. Genotyping analysis of developing 
embryos using timed matings indicated the absence of Enl
-/-
 mouse embryos as early as 
E8.5, the earliest time point examined
150
.  
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Drosophila melanogaster express a gene called ear (Enl/Af9-related) that is 
equally homologous to both human AF9 and ENL, suggesting that these genes arose from 
a common ancestor. Like AF9 and ENL, ear is highly expressed in early Drosophila 
embryos, consistent with the role of this protein and the human homologs in early 
transcriptional regulation 
163
. However, it is possible that AF9 and ENL diverged from a 
single gene to fulfill separate roles in development. 
AF9 and ENL in Transcriptional Elongation 
 Both AF9 and ENL are found in protein complexes associated with transcriptional 
elongation 
5-7
.  During transcription, RNA Polymerase II (Pol II) is recruited to target 
gene promoters and initiates transcription of approximately 12 nucleotides before it 
becomes paused (promoter-proximal pausing)
164
. Elongation is halted by two factors: 
DSIF [5,6-dichloro-1--ᴅ-ribofuranoslbenzimidazole (DRB) sensitivity-inducing factor] 
and NELF (negative elongation factor) 
165, 166
. Genome-wide ChIP-seq studies have 
shown that the major peak of Pol II is at about +50bp, with Pol II also found at low levels 
downstream of the poised promoter peak, and absent in the -2000 to -10,000 region
167
. 
The distribution of DSIF follows that of Pol II, and indeed DSIF has been shown to track 
along the gene with Pol II. NELF is primarily found only at the poised Pol II peak
167
. 
Association of Pol II with DSIF and NELF has been shown to significantly reduce the 
elongation rate of Pol II in in vitro transcription assays
168
.  
 Poised Pol II can be released to initiate productive elongation through the 
association with P-TEFb
169
. P-TEFb is composed of CDK9 and a cyclin T1/2 subunit. 
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Binding of cyclin T1/2 to CDK9 induces a conformational change in CDK9 that, along 
with phosphorylation of CDK9 threonine 186, is required for activation of the kinase
170
. 
P-TEFb then phosphorylates the serine 2 residue of the C-terminal domain (CTD) of the 
largest subunit of Pol II
171
, as well as the hSpt5 subunit of DSIF
172, 173
 and the E subunit 
of NELF
174
 to release inhibition by DSIF and NELF allowing for productive elongation 
169, 172, 174
. At this point, additional factors associated with Pol II act to stabilize the 
complex and promote elongation at a rate of 3.8kb/min for up to 2 million base pairs
175
. 
These factors include transcription factor IIS (TFIIS), which helps Pol II restart after 
backtracking on the DNA
176
, TFIIF and ELL 1-3, which stimulate the elongation rate of 
Pol II
177
, as well as the PAF complex and the Super Elongation Complex (SEC) defined 
below
178
.   
 The members of the SEC were first identified through studies of viral gene 
activation upon HIV infection. P-TEFb, prior to recruitment to Pol II, is sequestered by 
binding to the 7SK snRNP. In HeLa cells, approximately 90% of P-TEFb is bound in an 
inactive form to the 7SK snRNP complex
179-181
. This complex includes the RNA-binding 
protein HEXIM 1 or 2, the La-related protein LARP7, and the 7SK methyl phosphate 
capping enzyme (MePCE). HEXIM1/2 binds the 7SK snRNP as well as P-TEFb, and 
LARP7 and MePCE act to stabilize this complex. The HIV Tat protein releases P-TEFb 
from the 7SK snRNP and recruits it to the poised Pol II at the HIV LTR through a 
mechanism not yet well understood
182
. Tandem affinity purification of CDK9 and Tat 
first identified SEC components AF9, ENL, ELL2, and AF5q31
183
, all of which are 
known fusion partners in MLL leukemia. 
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 Subsequent biochemical analyses using different methologies have identified 
additional components and distinct complex formations composed of the proteins in the 
SEC. Biswas et al biochemically purified proteins associated with AF9, AF4 and ELL 
and identified the associated proteins by mass spectrometry. Reconstitution of these 
complexes using purified proteins lead the authors to identify distinct complexes 
involved in transcription regulation. First, AF4 or AF5q31 directly interact with Cyclin 
T1 of P-TEFb. AF4/AF5q31 then recruits AF9, an interaction that will be further 
discussed. P-TEFb links ELL and ELL-Associated Factors 1 and 2 (EAF1/2) to the AF4-
P-TEFb complex. DOT1L was shown to interact with AF9 in a complex distinct from the 
AF4-P-TEFb complex, which aligns with the finding that DOT1L and AF4 bind to the 
same region of AF9
6
(Figure 5).  
 A separate study by Yokoyama and colleagues purified endogenous AF4 from 
leukemic K562 cells and identified AF5q31, ENL, CDK9 and Cyclin-T1 in the 
immunoprecipitates. The authors termed this complex the AEP for AF4 family/ENL 
family/P-TEFb complex
7
. Unlike the Biswas study, DOT1L was not found to be present 
in this complex.   
 A third study by Mueller et al immunoprecipitated Flag-ENL in HEK293 cells 
and detected 15 associated proteins with ENL. These included CDK9, Cyclin T1, 
AF5q31 and AF4, as did the other studies. Additional associated proteins included BCoR 
and CBX8 which will be further discussed, as well as nine other proteins. This complex 
was termed the EAP for ENL Associated Proteins
5
.  
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 While the techniques used and the final components identified between these 
studies have some differences, it is clear that multi-protein complexes including AF9 are 
involved in the intricate regulation of RNA transcription. Understanding the role of AF9, 
and those proteins with which AF9 interacts, is necessary for understanding the 
regulation and misregulation of gene expression in normal and neoplastic development.  
AF9 Interacting Proteins 
 As indicated earlier, multiple proteins have been shown to interact with AF9, 
including AF4
8
, DOT1L
9
, CBX8
10
 and BCoR
11
. These interactions are mediated by the 
C-terminal AHD of AF9 which is retained in MLL-AF9 fusion proteins.  
AF4 
AF4 (AFF1) is a member of the AFF/ALF family of nuclear proteins including 
AF5q31, LAF4, and FMR2. These proteins contain conserved N and C-terminal 
homology domains, a serine/proline-rich transactivation domain and an 
AF4/LAF4/FMR2 (ALF) homology domain (Figure 6A).  The ALF domain, specifically 
residues 273-289, interacts with E3 ubiquitin ligase proteins of the Drosophila seven in 
absentia (sina) homologues (Siah)-1a and Siah-2a family
184, 185
.  
A specific mutation in the Siah-binding motif of Af4 was identified in a screen of 
chemically mutagenized mice
186
. Male mice were injected with N-ethyl-N-nitrosurea 
(ENU) which targets spermatagonial stem cells. These mice were then bred, and 
offspring with dominant motor phentoypes were screened to identify the mutated gene. 
Mice with jerky, ataxic gaits, termed “robotic mice” were found to express Af4 protein 
with a V280A mutation in the Siah-binding motif of Af4. These mice also exhibited a 
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rapid loss of Purkinje cells in the cerebellum and developed complete, bilateral 
cataracts
186
. The mutation expressed in the robotic mouse reduces binding between AF4 
and the SIAH E3 ubiquitin ligases, significantly decreasing AF4 protein turnover and 
subsequently leading to an accumulation of AF4 protein. This mouse has therefore acted 
as a useful model of AF4 overexpression.  
 
Figure 6. Protein Domains of AF4 
 
A 
 
 
 
 
 
 
B 
 
 
(A) Protein domain schematic of AF4 with alternate names and chromosomal location 
noted. Line below the protein structure indicates the approximal fragment of the protein 
present in MLL fusions. (B)  The AF9 interacting sequence is highly conserved among 
AF4 family members. A conserved lysine (indicated in bold) mediates an electrostatic 
interaction with AF9 residue D544. 
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As previously discussed, AF4 directly interacts with both the kinase and cyclin 
subunits of P-TEFb
5, 187
. Specifically, AF4 residues 1-308 are necessary for binding to 
Cyclin T1
188
. AF4 is a direct phosphorylation target of P-TEFb, a modification which 
was shown to decrease the transcriptional activity of AF4 in a reporter assay
187
. Recent 
studies have shown that AF4 is also present in the 7SK snRNP complex that sequesters 
inactive P-TEFb, as well as a member of the P-TEF-b-AFF1(AF4)-BRD4 (PAB) 
complex that delivers active P-TEFb to target genes
188
. These authors argue that AF4 
should be considered a member of all P-TEFb complexes, not just the P-TEFb-associated 
SEC.  
AF4 residues 766-779, highly conserved in all AF4 family members, interact with 
AF9 and ENL (Figure 6B). Binding to either one of these proteins protects AF4 from 
SIAH-mediated degradation
187
. Inhibition of the AF4-AF9 interaction by a synthetic AF4 
mimetic peptide results in necrotic cell death of MLL leukemia cells, the mechanism of 
which is not yet understood
157, 189
.  
 Isnard and colleagues engineered a constitutive Af4 knockout mouse to examine 
the role of Af4 in development
190
. Mice heterozygous for the null allele appeared normal 
and were fertile. Homozygous mice were born at the expected proportion and 80% of 
those Af4
-/-
 mice appeared normal. The remaining 20% were significantly smaller, the 
smallest of which did not survive beyond ten days. These mice exhibited defects in 
lymphoid development with decreased thymic cellularity, a reduction in CD4+CD8+ T 
cells, and a reduction in pre-B and mature B cells. All other hematopoietic compartments 
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appeared normal. Interestingly, MLL-AF4 leukemias are of lymphoid phenotype in 95% 
of the cases
191
, further supporting a role for AF4 in lymphoid development.  
DOT1L 
The DOT1L (Dot1-like, KMT4) protein was identified through its N-terminal 
sequence homology to the yeast Dot1 protein, which was discovered in a genetic screen 
as a suppressor of telomeric silencing (Dot1, disruptor of telomere silencing)
192
. This 
region of shared homology encodes a conserved methyltransferase domain. DOT1L is the 
only member of the class I methyltransferase family, in contrast to all other known 
histone methyltransferases (HMTs) of the class V family. The Class V 
methyltransferases, including MLL, contain a conserved SET domain at the C-terminus 
and target residues on the protruding histone tail
193, 194
. DOT1L is the only identified non-
SET domain-containing HMTase and exhibits specificity for methylation of histone H3 at 
lysine 79 (H3K79), a residue located within the globular structure of the H3 protein
195-
197
(Figure 7). DOT1L is also the only enzyme identified thus far that methylates H3K79, 
and knockout of Dot1 in yeast and Drosophila, and Dot1l in mice all result in a global 
loss of H3K79 methylation
197-199
.  
Studies in yeast suggest that Dot1 is a distributive enzyme—depositing both 
mono-, di-, and tri-methyl marks on H3K79 after one round of catalysis
200
. Most of the 
class V methyltransferases are processive enzymes, requiring methyl marks to be placed 
sequentially from mono to di to trimethyl
201
. These results also suggest that all 
methylation states of H3K79—mono, di and trimethyl—mark loci of active 
transcription
200
. Genome-wide studies support the association of H3K79 methylation with 
46 
 
 
 
highly transcribed genes
202
, with hypomethylation of H3K79 associated with regions of 
repressed chromatin
195, 197
.  
 
Figure 7. Protein Domains of DOT1L 
 
Protein domain schematic of DOT1L with alternate names and chromosomal location 
noted. 
 
However, there are specific examples in which H3K79 marks repressed genes, 
including transcription factors Tbr1 and CTGF, and the epithelial sodium channel gene 
ENaCα. Overexpression of AF9, which binds to DOT1L residues 479-1222, results in 
hypermethylation of H3K79 in the promoter region of ENaCα and reduced ENaCα 
expression. The requirement of the Af9-Dot1l interaction in ENaCα promoter H3K79 
methylation was further supported by knock-down of Af9, which resulted in a decrease in 
H3K79 methylation at the ENaCα promoter region and subsequent increase in gene 
transcription
9
.  
Dot1l expression is ubiquitous and essential for development, as Dot1l
-/-
 mice do 
not survive beyond E10.5.  These embryos exhibit cardiovascular defects including an 
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enlarged heart and decreased vasculature
199
. Conditional cardiac-specific deletion of 
Dot1l caused dilated cardiomyopathy, at least in part due to the loss of Dot1l-mediated 
H3K79 methylation and decreased expression of dystrophin, a protein necessary for 
supporting cardiac smooth muscle cells from mechanical stress during contraction
203
. 
Embryos from Dot1l
-/-
 mice also exhibit severe anemia, indicating a role for Dot1l 
in erythropoiesis
204
. Loss of Dot1l expression resulted in delayed development of 
erythroid, but not myeloid or lymphoid, progenitor cells. Expression of Gata2, which as 
discussed previously is required for maturation of the HSC to the CMP, was 
downregulated in Dot1l-deficient mice. Pu.1 expression, associated with myeloid lineage 
differentiation, was significantly increased in Dot1l null mice
204
. These results suggest 
that H3K79 methylation by Dot1l regulates the lineage commitment of early progenitor 
cells. In a separate study, conditional loss of Dot1l resulted in pancytopenia, including 
loss of HSCs and lineage progenitor cells
205
.  
Additionally, DOT1L has been shown to play a role in regulating heterochromatin 
formation at telomeres
206
. DNA silencing at telomeres is mediated by the recruitment of 
Sir (silent information regulator) proteins
207
. These proteins bind only to unmethylated 
H3K79, and methylation at this histone residue precludes Sir binding and affects 
heterochromatin formation. 
DOT1L is also involved in DNA double strand break repair
208
. The DNA damage 
response protein 53BP1 binds to methylated H3K79 at DNA double strand breaks, and 
either mutation of the H3K79 residue or knockdown of DOT1L inhibits recruitment of 
53BP1 to sites of DNA damage. In regard to cell cycle progression, DOT1L H3K79 
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methylation levels have been shown to fluctuate during the cell cycle in both yeast and 
humans
204, 209
. Dot1l-null embryonic stem cells show defects in proliferation and are 
blocked in the G2/M phase of the cell cycle
210
. DOT1L is also involved in transcriptional 
elongation. As previously discussed, Dot1l has been found to be in complex with proteins 
associated with the P-TEFb elongation complex
5, 187
 including AF9. Studies by Biswas 
suggest that the DOT1L-AF9 complex is mutually exclusive of the AF9-P-TEFb 
complex
6
.  
In MLL leukemias expressing the MLL-AF9 fusion, it is hypothesized that the 
AF9-DOT1L interaction aberrantly recruits the histone methyltransferase to MLL target 
genes, promoting H3K79 methylation and productive elongation of MLL target genes 
associated with leukemogenesis such as Hoxa9 and Meis1. Indeed, loss of Dot1l 
expression in MLL-AF9 transformed bone marrow cells results in a loss of colony 
formation and Hoxa9 expression compared to wild-type cells
211
. 
This finding extends beyond MLL-AF9 fusions to other MLL-rearranged fusion 
proteins; loss of Dot1l in MLL-GAS7 or MLL-AFX, but not E2a-PBX-transformed cells 
also results in a decrease in colony formation, although not as dramatically as with the 
MLL-AF9 expressing cells
211
. Genome-wide ChIP-seq studies indicate that of 139 genes 
targeted by the MLL-AF9 fusion protein, 120 genes are enriched in H3K79 
dimethylation
212
. Loss of Dot1l in MLL-AF9 leukemia cells resulted in a specific 
decrease in expression of genes targeted by MLL-AF9, and these cells were unable to 
induce leukemia when transplanted into mice
212
.  
49 
 
 
 
Targeting DOT1L has thus been identified as a potential therapeutic approach in 
patients with MLL-rearranged leukemias. Several inhibitors have been developed, 
including one compound engineered by Epizyme Inc. This inhibitor, EPZ004777, 
competes for binding with the DOT1L cofactor S-adenyosylmethionine (SAM) to a 
specific pocket in the DOT1L structure. SAM is the substrate for DOT1L; upon binding, 
DOT1L catalyzes the methylation of lysine 79 at histone H3 and releases S-adenosyl-L-
homocysteine (SAH) as the product. Inhibitors that prevent SAM binding to the DOT1L 
SAM-binding pocket would thus prevent methylation of target residues by DOT1L. 
While all histone methyltransferases use SAM as the methyl group donor, EPZ004777 is 
highly selective for DOT1L over other histone methyltransferases
213
. 
Treatment of leukemic cell lines with EPZ004777 resulted in a specific decrease 
in H3K79 dimethylation without altering other histone modifications. Expression of MLL 
target genes HOXA9 and MEIS1 were reduced in treated cells compared to control, 
whereas genes associated with hematopoietic differentiation were increased. Mice 
injected with leukemic MV4-11 cells harboring the MLL-AF4 fusion gene exhibited a 
significant increase in median survival when treated with the DOT1L inhibitor compared 
to control treated mice
213
. A derivative of this compound is now in phase I clinical trials.  
CBX8 
AF9 was also shown to interact with Polycomb group (PcG) protein CBX8 
(HPC3) in a yeast two-hybrid screen and subsequently validated by other techniques
10
. 
Further characterization of this interaction mapped amino acids 202-333 of Cbx8 binding 
to the C-terminal 94 amino acids of AF9 (Figure 8). Members of the CBX family encode 
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a conserved N-terminal chromodomain and a C-terminal C-box involved in interaction 
with other proteins such as RING1A/B 
214-216
. The AF9 interacting region is located 
between these two domains, in a region of the Cbx8 protein that shows no homology to 
other Cbx family members
10
. 
 
Figure 8. Protein Domains of CBX8 
 
Protein domain schematic of DOT1L with alternate names and chromosomal location 
noted. 
 
The Polycomb group (PcG) of proteins act to silence gene targets in opposition to 
the activating Trithorax group of proteins, which includes MLL. Polycomb proteins exert 
their function through two complexes: the Polycomb Repressive Complex (PRC) 1 and 
PRC2. In the canonical model of PRC-mediated repression, PRC2 containing EED, 
SUZ12 and EZH2 is recruited to target genes. EZH2, a SET-domain containing histone 
methyltransferase, then catalyzes methylation of histone H3 lysine 27. This mark, 
associated with gene repression
217-219
, then provides a docking site for PRC1 which is 
composed of PHC, RING1A/B, BMI1 or MEL18, and a CBX protein (CBX 2, 4, 7 or 
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8)
220, 221
. The exact composition of this complex is tissue-and differentiation-stage 
specific 
222-224
. RING1 is an E3 ubiquitin ligase that catalyzes mono-ubiquitination of 
H2A at lysine 119, which is a mark associated with transcriptional repression. Additional 
proteins such as DNA methyltransferase (DNMTs) or histone deacetylases (HDACs) can 
also be recruited to mediate additional silencing.  
Maintaining the proper balance between the activity of the Trithorax group of 
proteins and the Polycomb group of proteins is necessary for appropriate self-renewal and 
differentiation of tissues
219
. The HOX genes, as previously described, are very well 
studied targets of TRX and PcG. The promoters of these and other genes involved in 
development are often marked by both the TRX-associated H3K4 methylation and 
PRC2-associated H3K27 methylation marks. These bivalent genes are poised for either 
rapid activation or repression following removal of one of the two marks. Polycomb 
group proteins also play a role in cell cycle checkpoints. For example, members of both 
PRC1 and PRC2 bind to and repress the p
16Ink4a
/p
19Arf
 locus at the G1/S checkpoint
220
. 
Studies have also identified roles for PcG proteins in the DNA damage response pathway, 
as H2AK119Ub accumulates at DNA damage foci
225, 226
. As both PcG and TRX proteins 
play critical roles in development and homeostasis, it is not surprising that PRC and TRX 
proteins are often mutated in cancer.   
The role of CBX proteins in hematopoiesis and leukemogenesis has been a 
rapidly emerging area of study. Klauke and colleagues showed the overexpression of 
Cbx7 enhances the self-renewal of hematopoietic stem cells and leads to leukemia, 
whereas overexpression of Cbx 2, 4, or 8 leads to stem cell exhaustion. PRC complexes 
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containing difference Cbx proteins are differentially recruited to a subset of target 
genes
227
.  
In regard to MLL leukemias, CBX8 has been shown to be required for MLL-AF9 
mediated transformation and leukemogenesis. Tan and colleagues retrovirally transduced 
bone marrow cells with MLL-AF9 fusion proteins encoding mutations that prevented 
binding to Cbx8. Cells expressing these mutants were unable to serially replate in a 
colony forming assay compared to the wild-type MLL-AF9 fusion
228
. These results were 
further confirmed by expressing the MLL-AF9 fusion in bone marrow isolated from 
wild-type or conditional Cbx8 knockout mice. Loss of Cbx8 resulted in a loss of colony 
formation of MLL-AF9 transformed cells compared to control cells still expressing Cbx8. 
Loss of transformation ability was associated with a decrease in activation of a luciferase 
reporter gene under the control of the Hoxa9 promoter. While CBX8 is generally thought 
to be a repressive protein, these results support a role for CBX8 in transcriptional 
activation in MLL leukemia, possibly through association with the histone 
acetyltransferase (HAT) TIP60
228
.  
AF9 has also been shown to be present in a complex with additional members of 
the PRC1 family. Immunoprecipitation of FLAG-tagged AF9 in HEK293 cells showed 
association with endogenous PRC1 proteins CBX8, RING1A, RING1B and BMI1. 
Knockdown of CBX8 with shRNA resulted in decreased association of AF9 with 
RING1B and BMI1, indicating that interactions are mediated by the AF9-CBX8 
complex
229
.   
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 Gel filtration experiments indicated that other AF9 binding partners, such as 
DOT1LL, AF4 and BCoR, are not present in the AF9-PRC1 complex. Overexpression of 
CBX8 results in decreased recruitment of DOT1LL to the ENaCα locus, which as 
discussed, is mediated by AF9. As H3K79 methylation is associated with repression of 
this gene, overexpression of CBX8 resulted in increased expression of ENaCα. Co-
overexpression of CBX8 with AF9 restored levels to control. Conversely, shRNA-
mediated knockdown of CBX8 resulted in a decrease in ENaCα expression229. These 
results highlight the importance of the distinct functions of AF9 that depend on the 
proteins with which it is associated, the last known of which is BCoR. 
BCoR 
The BCL-6 Corepressor (BCoR) protein was identified as a transcriptional 
repressor through its interaction with the oncoprotein BCL-6
230
(Figure 9). In a reporter 
gene assay, coexpression of BCoR and BCL-6 resulted in potentiation of the 
transcriptional repression mediated by BCL-6
230
. These proteins are found to localize at 
the same BCL-6 target genes in germinal center B cells
231
.  
BCoR itself is widely expressed throughout mouse and human cells, in both 
embryonic development and in adult tissues
230, 232
. High levels of expression are present 
in the developing tooth primordium, eye, limb buds, branchial arches and nervous system 
tissues
232
, all of which are abnormal in patients with X-linked Oculofaciocardiodental 
Syndrome (OFCD) characterized by mutations in BCoR
233, 234
.  
Whole exome sequencing of a patient with acute myeloid leukemia with a normal 
karyotype (CN-AML) identified a clonal somatic mutation in BCoR
235
. Further analysis 
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of 553 CN-AML patients found that BCoR mutations were present in 3.8% of the cases. 
These mutations often resulted in reduction or loss of BCoR expression. AML patients 
with BCoR mutations had 7.5% Event Free Survival (EFS) compared to 41.4% of 
patients with wild-type BCoR, with 25.6% and 56.7% Overall Survival, respectively
235
.  
 
Figure 9. Protein Domains of BCoR 
 
Schematic of domains in BCoR. Alternate names and chromosomal location are noted. 
 
A yeast two-hybrid screen seeking to identify proteins that interact with the C-
terminal 94 amino acids of AF9 identified BCoR as a potential interacting protein
10
. 
Further analysis identified the minimal AF9 binding domain to be located at BCoR amino 
acids 1127-1251(Figure 9). Within this region is a stretch of 34 amino acids that is 
present in two, but not all four mouse BCoR splice variants. Only isoforms containing 
this region were able to bind to AF9, whereas all isoforms can bind to BCL-6 as the 
regions affected by alternative splicing are located downstream of the BCL-6 binding 
domain. These results suggest that the interaction of specific BCoR isoforms with AF9 
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can modulate the transcriptional activation activity of AF9, both in the context of the full 
length protein and perhaps in the context of MLL-AF9 fusions.  
Collectively these studies all indicate a critical role for AF9 and AF9 interacting 
partners AF4, DOT1LL, CBX8 and BCOR in gene regulation and development (Figure 
5). The function of interactions mediated by AF9 is less well understood. Here, we seek 
to elucidate the role of AF9 and AF9-mediated interactions in normal hematopoiesis and 
leukemogenesis.  
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CHAPTER THREE 
METHODS 
 
Cloning of Full-length AF9 
To clone full-length AF9 into a FLAG vector, the 3XFLAG tag was PCR 
amplified from the p3xFLAG vector (courtesy of Dr. C. Hemenway) with the high 
fidelity Phusion polymerase (Finnzymes/Thermo Scientific) using a forward primer 
including a Xho1 site and a reverse primer with Xba1 and BamHI sites, as well as a stop 
codon sequence (1U/50μl reaction Phusion Polymerase, 10mM dNTPs, 10uM each 
forward and reverse primer, 5x HF Buffer)(Table 1). The amplicon was digested with 
XhoI overnight in NEB Buffer 4, followed by digestion with BamHI the next day for an 
additional two hours. The digested amplicon was then purified by gel extraction with the 
Qiaex II Gel Extraction kit (Qiagen). The pMSCV.YFP vector (courtesy of Dr. J. Zhang) 
was digested in parallel with the insert with XhoI overnight in NEB Buffer 3, followed by 
a two hour digestion the next day with BglII. The digested vector was treated with 2μl 
calf intestine alkaline phosphatase (CIP) enzyme (NEB), incubated at 37°C for 30 
minutes and gel purified.  
The 3xFLAG fragment was ligated into the digested MSCV.YFP vector overnight 
at 14°C at a 3:1 insert-to-vector molar ratio. The following day, 1μl of the ligation 
reaction was transformed into DH5α chemically competent cells. The ligation mix was 
added to 50μl of cells on ice, gently flicked 5-6 times, and placed on ice for 30 minutes. 
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Bacteria were heat shocked at 42°C for 30 seconds and returned to the ice for 5 
minutes. 950μl of room temperature SOC was added to the cells, and they were incubated 
at 37°C, rotating at 225 rpm for 1 hour. The transformed bacteria were plated on LB 
plates containing 100μg/mL ampicillin and placed in a 37°C incubator overnight. 
The following day, isolated transformants were inoculated into 5mL of LB broth 
containing ampicillin (100μg/ml) and were grown overnight shaking at 225 rpm, 37°C. 
The plasmid DNA was isolated from the bacteria using the GeneJet Therrmo Scientific 
Miniprep Kit and was screened by PCR using the MSCV vector forward sequencing 
primer and the reverse primer used for cloning. Positive clones verified by sequencing. 
Full length AF9 was PCR amplified from the p3xFLAG.AF9 vector (courtesy of 
Dr. C. Hemenway) with a forward primer containing an EcoRI restriction site and a 
reverse primer including a XhoI restriction site (Table 1). The PCR product was digested 
sequentially with XhoI overnight followed by the addition of EcoRI enzyme the next day 
for an additional two hours. The enzymes were heat inactivated for 10 minutes at 65°C 
and the PCR product was purified by gel extraction (Qiagen Gel Extraction Kit).  
Table 1. Primer Sequences for Cloning of MSCV.YFP.AF9.3xFLAG 
Amplicon Primer Sequence (5’3’) 
3xFLAG 
Forward: CCGCTCGAGGACTACAAAGACCATG 
Reverse: CGGGATCCTCTAGACTAGTCATCGTCATC 
AF9 
Forward: GGAATTCCATGGCTAGCTCG 
Reverse: CCGCTCGAGGGATGTTCCAGATG 
 
To clone full length AF9 into the newly constructed MSCV.YFP.3xFLAG vector, 
the above mentioned digested AF9 was ligated into MSCV.YFP.3xFLAG vector digested 
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with EcoRI and XhoI as previously described, yielding the final 
MSCV.YFP.AF9.3xFLAG vector. The final construct was screened by digestion with 
EcoRI, and positive clones were verified by sequencing. 
Site-Directed Mutagenesis to Introduce Mutations into Full-length AF9 
Primers were designed according to the Agilent Quik-Change Site Direct 
Mutagenesis kit recommended protocol to introduce one of eight single amino acid 
changes in full length AF9. The MSCV.YFP.AF9.3xFLAG plasmid was used as a 
template in a PCR reaction containing 1μl of each site directed mutagenesis primer 
(Table 2), 5μl 10x reaction buffer, 1μl dNTP mix, 1μl PfuTurbo and water to 50μl total 
volume. A control reaction using pWhiteScript template and provided primers was 
assembled in parallel. The reactions were incubated in a ThermoHybaid PCR Express 
Thermocycler for one cycle at 95°C for 30 seconds, followed by 12-18 cycles of 95°C 
for 30 seconds, 55°C for 1 minute, and 68°C for 8 minutes or 5 minutes for the 
mutagenized construct and the pWhiteScript control, respectively. After the PCR was 
completed, the samples were cooled to 37°C followed by digestion with Dpn1 for 1 hour 
at 37°C.  
Dpn1-treated mutagenized DNA (1μl) was transformed into 50μl XL1-Blue cells 
(Agilent). The mixture was swirled and incubated on ice for 30 minutes. The samples 
were then heat shocked at 42°C for 45 seconds and returned to the ice for 2 minutes. 
500μl pre-warmed SOC was added to the reaction and incubated at 37° C, shaking at 225 
rpm. After 1 hour, the transformed bacteria were plated on LB plates containing 
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100μg/mL ampicillin supplemented with 2% X-Gal and IPTG for blue-white selection. 
Plates were placed in the 37°C incubator overnight. 
The next day, 5ml of LB broth containing ampicillin was inoculated with a single 
colony and grown overnight at 37°C shaking at 225rpm. After 12-16 hours of growth, 
DNA was extracted from the transformants and screened by double digestion with Xho1 
and EcoR1 to digest AF9 from the vector. Clones were sent for sequence verification.  
After confirming the presence of the desired mutation, AF9 was cut out of the 
vector and ligated into the MSCV.YFP.3xFLAG backbone. The plasmid DNA was 
incubated with XhoI enzyme, BSA and NEBuffer 4 in a 50μl reaction overnight at 37°C. 
The following day, EcoRI enzyme was added to the reaction mixture and the digestion 
proceeded for 2 hours at 37°C. The digested product was run on a 2% gel and extracted.  
The digested mutant AF9 was ligated into MSCV.YFP.3xFLAG vector digested 
with XhoI and EcoRI, CIP-treated and gel extracted as described previously. The mutant 
full-length AF9 was ligated into MSCV.YFP.3xFLAG in a 2μl insert:1μl vector 10μl 
total reaction. Ligation reactions were placed in a 16°C water bath overnight.  
The following day, 1μl of the ligation reaction was transformed into DH5α 
chemically competent cells as previously described. Transformants were selected and 
inoculated into 5ml LB broth containing ampicillin. Cultures were grown at 37°C shaking 
at 225rpm overnight. After 12-16 hours of growth, DNA was extracted from the bacteria. 
Clones were screened by EcoRI restriction enzyme digestion and sent for sequencing 
using the MSCV Reverse primer.  
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Table 2. Primer Sequences for Site Directed Mutagenesis 
Mutation 
Nucleotide 
Change 
Primer Sequence 
E506R GAAAGA 
Sense:         tgaatgtgacaaggcatacctagatagactggtagagcttcac  
Antisense: gtgaagctctaccagtctatctaggtatgccttgtcacattca 
I538A ATCGCC 
Sense:        tgaaccttatagaagaaactggacactttcatgccacaaacacaacatttg 
Antisense: caaatgttgtgtttgtggcatgaaagtgtccagtttcttctataaggttca 
D544R GATCGT 
Sense:         acactttcatatcacaaacacaacatttcgttttgatctttgctcgctggac 
Antisense: gtccagcgagcaaagatcaaaacgaaatgttgtgtttgtgatatgaaagtgt 
D546R GATCGT 
Sense:        ctttcatatcacaaacacaacatttgattttcgtctttgctcgctggac 
Antisense: gtccagcgagcaaagacgaaaatcaaatgttgtgtttgtgatatgaaag 
K557E AAAGAA 
Sense:        gacaaaaccacagtccgtgaactacagagttacctgg 
Antisense: ccaggtaactctgtagttcacggactgtggttttgtc 
L526A CTGGCG 
Sense:        ccgtaaactacagagttacgcggaaacatctggaacatcc 
Antisense: ggatgttccagatgtttccgcgtaactctgtagtttacgg 
S565A TCTGAT 
Sense:        cgtaaactacagagttacctggaaacagatggaacatccctcg 
Antisense: cgagggatgttccatctgtttccaggtaactctgtagtttacg 
S565D TCTGCT 
Sense:         agagttacctggaaacagctggaacatccctcgag 
Antisense: ctcgagggatgttccagctgtttccaggtaactct 
 
Cloning of the MSCVneoMLL-AF9(D546R) Fusion Protein 
The region containing amino acids 376-568 of AF9(D546R) was amplified using 
the full length MSCV.YFP.AF9(D546R).3xFLAG construct as a template. The forward 
primer contained a SalI restriction site, and a reverse primer contained a BamHI 
restriction site (Table 3). The PCR amplicon was gel purified and digested with SalI 
overnight. The following day, BamHI enzyme was added to the digestion reaction and 
the digested AF9 fragment was gel extracted. The MSCVneo vector was digested with 
EcoRI and BglII for two hours, CIP-treated to prevent re-ligation and gel extracted. The 
5’ fragment of MLL (amino acids 1-1403 corresponding to the fragment found in MLL 
fusions) was cut out of MSCVneoMLL-AF9 plasmid with EcoRI and SalI for two hours.  
1μl MSCVneo vector, 2μl 5’ MLL and 3μl 3’ AF9(D546R) were ligated with 1μl DNA 
ligase enzyme and buffer at 14°C overnight. The following day, 1μl of the ligation 
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reactions was transformed into DH5α electrocompetent cells by electroporation. 
Transformants were screened by PCR with primers amplifying the MLL-AF9 fusion 
junction, and positive clones were verified by sequencing.  
Table 3. Primer Sequences for Cloning of MSCVneoMLLAF9(D546R)3xFLAG 
Primer Primer Sequence (5’3’) 
AF9 Forward AAAGCGGTCGACTTTAAGATTCTTGAAGTGAAAAGTCCAATAAAG 
1x FLAG Reverse 
AAAGGATCCTCACTTGTCGTCATCGTCTTTGTAGTCGGATGTTCCAG
ATGTTTCCAG 
 
Cloning of AF9(D546R) 376-568 and 470-568 into pCMV3xFLAG 
The region containing amino acids 376-568 and 470-568 of AF9 were PCR 
amplified from MSCV.YFP.AF9(D546R) with an AF9 forward primer containing an 
EcoRI restriction site and a reverse AF9 primer containing a KpnI restriction site (Table 
4). Digested amplicons were isolated by gel purification and ligated into the 
pCMV3xFLAG vector (courtesy of Dr. C. Hemenway) digested with EcoRI and KpnI for 
two hours followed by CIP treatment, heat inactivation and gel purification. Ligation 
reactions and transformations were performed as described above. Transformants were 
screened using EcoRI digest, and positive clones were sent for sequencing for 
verification. 
Table 4. Primer Sequences for Cloning AF9(D546R) 376-568 and 470-568 
Primer Primer Sequence (5’3’) 
AF9(376-568) Forward  GCGAATTCATCTGAACAACCCAGTCCT 
AF9(470-568) Forward GCGAATTCATTACTAAAAACCAACAAC 
AF9 Reverse ATGGTACCTCAGGATGTTCCAGATGT 
 
Retrovirus Production, Concentration, and Titering 
Five 10cm tissue culture dishes of Phoenix Ecotropic cells were seeded at 2 x10
6
 
cells in DMEM supplemented with 10% fetal bovine serum and 1% 
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penicillin/streptomycin for each retrovirus construct. The following day, the media was 
changed 2-3 hours before calcium phosphate transfection with 22.5μg retroviral construct 
and 2.5μg pCL-Eco packaging plasmid following the manufacturers’ protocol 
(ClonTech). Sixteen hours post-transfection, the transfection media was removed and 7ml 
of DMEM + 10% FBS was added. Cells were placed at 32°C, 5% CO2 overnight. The 
following day, the supernatant was collected, 7ml of fresh media was added and the cells 
were returned to the 32°C incubator. The viral supernatant was again harvested the 
following day and pooled with the previously collected supernatant. The supernatant was 
spun to pellet any cell debris and concentrated 6x using Centricon Plus 70 filters 
(Millipore) by centrifugation at 1640rpm, 33°C in a swing bucket JS 75 rotor for 
approximately two hours. Concentrated virus was aliquoted, snap frozen, and stored at -
80°C.  
To determine titer of the prepared retroviruses, 2.5x10
4
 Rat1a cells were seeded 
per well of a 6-well tissue culture plate. The following day, the virus preparation was 
serially diluted 1:2 up to 1:1x10
6
 in DMEM + 10% FBS supplemented with 16μg/mL 
polybrene and added to the cells where they were incubated at 37°C, 5% CO2. After two 
hours, an additional milliliter of DMEM + 10% FBS was added to the cells to bring the 
final volume to 2ml and cells were returned to the 37°C incubator. The following day, the 
media was removed and replaced with 2ml DMEM 10% FBS.  
For cells transduced with plasmid encoding a neomycin resistance gene, media 
was supplemented with 0.5mg/ml G418. Selection was maintained for ten days at which 
time media was removed, the cells were washed with PBS and stained with methylene 
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blue (0.1g of methylene blue in 60ml methanol) for 5 minutes. Plates were rinsed in 
diH20 and air dried, after which colonies were enumerated. 
Cells transduced with plasmid encoding yellow fluorescence protein (YFP) and an 
untransduced control were removed from the plate by trypsinization 48 hours after 
retroviral transduction and resuspended in PBS + 2% FBS. The cell suspension was 
passed through a mesh filter to achieve a single-cell suspension, and the percentage of 
YFP+ cells was assessed using flow cytometry.  
Immunoprecipitation and Western Blot Analysis 
Phoenix Ecotropic cells transfected with full-length AF9 point mutants to prepare 
virus as described above were harvested four days after transfection. Cell pellets were 
lysed in 1x SDS Sample Buffer and boiled at 95°C for 5 minutes. Protein lysates were 
resolved on a 10% separating, 4% stacking SDS-PAGE gel at 150 Volts. Proteins were 
transferred onto a nitrocellulose membrane using the Bio-Rad Trans-Blot Turbo Transfer 
System, 1.5mm gel transfer program. Membranes were blocked in 5% milk in Tris 
Buffered Saline + 0.05% Tween (TBS-t) for a minimum of one hour. AF9 proteins were 
detected using a mouse anti-FLAG M2 antibody (Sigma) at a 1:3000 dilution in 5% milk 
for one hour to overnight at 4°C. Membranes were washed four times for five minutes 
each in TBS-t, and then incubated with secondary anti-mouse or anti-rabbit antibody (GE 
Healthcare Life Sciences) at a 1:8000 dilution in milk for two hours. Membranes were 
washed as described and developed using ECL Substrate (Thermo).  
MLL-AF9-transformed c-kit+ bone marrow cells frozen from colony assay 
experiments (as subsequently described) at the end of week one were thawed and plated 
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in RPMI + 10% fetal bovine serum, 10ng/ml IL-3, 10ng/ml IL-6, 100ng/ml SCF and 
10ng/ml GM-CSF overnight. The following day, cells were lysed in 1x SDS sample 
buffer followed by boiling at 95°C for 5 minutes. Lysates were resolved on an 8% SDS-
PAGE gel at 150 volts and transferred on the BioRad Trans-Blot Turbo Transfer System 
using the program for high molecular weight proteins. Membranes were blocked for two 
hours and incubated with primary mouse anti-FLAG M2 antibody overnight, and 
secondary anti-mouse antibody for two hours the following day as described above. 
Membranes were developed using Super-Signal West Dura substrate (Thermo).  
For coimmunoprecipitation experiments, HEK293 cells were cotransfected with 
plasmids encoding either FLAG-tagged full length AF9 or C-terminal fragments of AF9 
(wild type or D546R mutant, amino acid residues 376-568 or 470-568)  and one of five 
GFP-tagged proteins: full length murine Dot1L, murine Dot1L amino acids 479-659, 
human DOT1L amino acids 828-1095, human AF4 RI3A- fragment, corresponding to 
amino acids 647-871 of AF4 or human AF4 amino acids 755-777 using calcium 
phosphate transfection according to the manufacturer’s protocol (ClonTech). Cells were 
harvested 72 hours after transfection and lysed in 1ml IP lysis buffer (500mM Tris-HCl 
pH 7.4, 150mM NaCl, 0.5% Triton-X 100 (v/v) and freshly added Protease Inhibitor 
Cocktail and 1μM DTT). Lysates were sonicated with five pulses at output four, twice, 
before centrifugation at 12,000rpm for 20 minutes to remove the insoluble fraction. 950μl 
of prepared lysate was incubated with 20μl slurry FLAG M2 beads (Sigma) blocked in Z-
Buffer  (25mM HEPES pH 7.5, 12.5mM MgCl2, 150mM KCl, 0.1% NP-40 20% 
Glycerol, BSA [1mg/mL], and freshly added Protease Inhibitor Cocktail 1:1000) 
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overnight, rotating at 4°C. The remaining 50μl were saved for Western Blot to determine 
input amounts. The following day, the bead-bound proteins were pelleted by 
centrifugation at 1500 rpm, 4°C for one minute, followed by four-30 second washes with 
1mL NETN buffer (100mM NaCl, 1mM EDTA, 0.5% NP-40, 20mM Tris-HCl pH 8.0, 
and freshly added Protease Inhibitor Cocktail 1:1000). Proteins were eluted by boiling the 
beads in SDS sample buffer at 95°C for 5 minutes. After a brief centrifugation to pellet 
the beads, the eluate was resolved on a 10% gel as described above.  
RNA Isolation and cDNA Synthesis 
RNA was isolated from cells using TriReagent following the manufacturers’ 
protocol (Sigma). RNA was treated with DNAseI to remove any genomic DNA 
contamination according to the manufacturers’ protocol (Fermentas). Complimentary 
DNA was synthesized using the ABI High Capacity cDNA Synthesis kit (Applied 
Biosystems/Life Technologies). Up to 2μg of RNA was reverse transcribed in a reaction 
following the manufacturers’ protocol. cDNA was stored at -20°C.  
Reverse Transcription-PCR  
RNA was isolated from cells expressing combinations of MLL-AF5(WT or 
K717D) and AF9(WT or D544R) in the genetic complementation experiments 
(subsequently described) at the end of week four, and cDNA was prepared as described. 
RT-PCR followed by sequencing was performed to verify the presence or absence of the 
mutation in these cells. Primers used to amplify these regions are in Table 5. PCR 
reactions were prepared with 1x Buffer, 1x Q Solution, 200μM dNTPs, 0.2μM forward 
and reverse primers, 0.25U/50μl Taq Polymerase and 100ng of cDNA template or 10ng 
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plasmid control. PCR cycling conditions were as follows: 95°C 2 minutes, followed by 
30 cycles of 95°C 30sec/58.3°C 1 min/72°C 1 min, and final extension at 72°C for 10 
min. PCR products were resolved on a 0.8% agarose gel at 90V. Products were sent for 
sequencing with their respective forward primers after clean-up using the Qiagen PCR 
Clean-up Spin Column kit.  
Table 5. Primer Sequences for Amplification of AF5 and AF9 Mutant Sequence 
Amplicon Primer Sequence (5’3’) 
AF9 
(WT or D544R) 
F: AAAGCGGTCGACTTTAAGATTCTTGAAGTGAAAAGTCCAATAAAG 
R: AAAGGATCCTCAATCACCGTCATGGTCTTTGTAGTC 
AF5 
(WT or K717D) 
F: CTTCCTTCCTCACAAACTC 
R: CGTCTCCTTGTTGCTGTTACT 
 
Quantitative Reverse Transcription-PCR (qRT-PCR) 
TaqMan probe technology was used to assess expression of murine Hoxa9, Meis1 
and Hprt control gene expression (Hoxa9: Mm00439364_m1, Meis1: Mm00487664_m1, 
Hprt: Mm01545399_m1; Applied Biosystems/Life Technologies). Reaction mixtures 
containing 1μl 20x Gene Expression TaqMan probe, 10μl of 2x Gene Expression Assays 
master mix (Applied Biosystems/Life Technologies), 2μl of undiluted prepared cDNA 
and water to 20μl volume were prepared for each sample in triplicate. qRT-PCR was 
performed on an Applied Biosystems 7300 Real Time PCR System using the standard 
cycling program of one cycle at 50°C for 2 minutes, one cycle at 95°C for 10 minutes, 
and 40 cycles of 95°C for 15 seconds/60°C for 1 minute. Data were analyzed using the 
ABI Prism 7300 software. Relative target gene expression was normalized to Hprt 
expression using the 2
-∆∆Ct
 method
236
. Experiments were repeated a minimum of three 
times, and data are shown as an average of all experiments with the standard error of the 
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mean. Student’s t-test was performed to determine statistical significance using GraphPad 
Prism software. 
Levels of mRNA encoding transcription factors associated with 
erythroid/megakaryocyte (Gata1, Gata2) and granulocyte/macrophage (PU.1, Cebpa) 
lineages were assessed using SYBR Green technology (Table 6). Reaction mixtures 
containing 10μl SYBR Green Mix (BioRad), 1μl 10uM forward primer, 1μl 10uM 
reverse primer, 1μl cDNA diluted 1:3 in H20 to 20μl total volume were prepared in 
triplicate for each sample. The standard cycling protocol was used with the addition of 
the dissociation step. Target gene expression was normalized to Gapdh expression and 
analyzed as described above.  
Table 6. Primer Sequences for Erythroid and Myeloid Lineage Transcription 
Factors 
Amplicon Primer (5’3’) 
Gapdh 
Forward: GTGAGGCCGGTGCTGAGTAT 
Reverse: TCATGAGCCCTTCCACAATG 
Gata1 
Forward: TCACAAGATGAATGGTCAGA 
Reverse: TGGTCGTTTGACAGTTAGTG 
Gata2 
Forward: CCCAAGCGGAGGCTGTCT 
Reverse: TCAGACGACAACCACCACCTT 
Pu.1 
Forward: CCCCACACCGGCCTCAGTCACCAG 
Reverse: GAGGTGCTGGGCCGTGGGGG 
Cebpa 
Forward: GTAACCTTGTGCCTTGGATACT 
Reverse: GGAAGCAGGAATCCTCCAAATA 
Gata1 primer sequence
237
, Gata2 and Pu.1 primer sequences
52
 
Expression of Meis1 was analyzed using primers specifically designed to amplify 
the 5’ exon 1, exon 8/9, and 3’ exon 12 (Table 7). The protocol for qRT-PCR with SYBR 
Green as described above was followed. Additionally, the Meis1 TaqMan probes 
described were also used in this assay to amplify exons 6/7. 
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Table 7. Primer Sequences for Exon 1, Exon 8/9 and Exon 12 of Meis1  
Amplicon Primer (5’3’) 
5’ Meis1 (Exon 1) 
Forward: CCTGTGCAACACACACTTTAC 
Reverse: GGGAGATTAGAGAGGAGGGTTA 
Meis1 Exons 8/9 
Forward: GTGACGATGATGACCCTGATAA 
Reverse: CAGAAGGGTAAGGGTGTGTTAG 
3’ Meis1 (Exon 12) 
Forward: CTCTCTCTCTCTCTCTCTCTTCTC 
Reverse: TTCCCATCCTTCCCGATTTAC 
  
Genomic DNA isolation 
Genomic DNA was isolated from cell pellets using the Puregene Genomic DNA 
Purification Kit (Gentra) according to the manufacturers protocol. DNA pellets were 
resuspended in 50-250μl DNA Hydration Solution and incubated at 65°C for 1 hour, 
followed by continued hydration overnight at room temperature. Genomic DNA was 
stored at -20°C. 
Af9 Genotyping PCR 
To assess in vitro 4-OHT-mediated deletion of floxed Af9 in the hematopoietic 
progenitor colony forming cell (CFC) assays, polymerase chain reaction was performed 
using primers that anneal to genomic DNA sequences located up and downstream of the 
flanked loxP sites in the Af9
fl/fl
 mouse (Table 8). Approximately 100ng of genomic DNA 
was amplified in a 25μl reaction containing 1X Buffer, 200μM dNTPs, 0.25μM each 
primer, and 1U/50ul Taq Polymerase. The PCR reaction was cycled at 94°C for 5 min, 
followed by 40 cycles of 94°C for 30 seconds, 57°C for 30 seconds, and 72°C for 90 
seconds. A final 10 minutes extension at 72°C completed the reaction. PCR products 
were resolved on a 0.8% agarose gel at 90V.  
 
69 
 
 
 
Table 8. Primer Sequences for Genotyping of Af9 Mice 
Primer Sequence (5’3’) 
Af9 Forward AAACAATAGCTTTGGCAGCG 
Af9 Reverse CCTAGGCAGCGAGGAAGTTT 
 
Primary Mouse Bone Marrow Isolation 
C57Bl/6, Af9(Mllt3)
fl/fl
, or Af9(Mllt3)
fl/fl
 B6.129-Gt(ROSA)Sor
tm1(cre/ERT2)Tyj
/J mice 
were sacrificed by CO2 inhalation. Femurs and tibias were collected in RPMI + 10% 
FBS. Bone marrow was flushed from the bones using a 25g 1.5” needle into a 6-well 
plate containing additional RPMI + 10% FBS. Bones were flushed until all bone marrow 
had been removed and bones appeared white. Bone marrow was collected in a conical 
tube and centrifuged at 1500 rpm for 5 minutes. 
c-kit Positive Selection of Mouse Bone Marrow Progenitor Cells 
Isolated bone marrow cells were resuspended in 2ml PBS + 2% FBS at 100x10
6
 
cells/ml in 5ml polypropylene tubes for c-kit+ selection using the Stem Cell EasySep 
Mouse CD117 Positive Selection kit. All antibody incubations were conducted in the 
tissue culture hood at room temperature for the indicated amounts of time.  
CD117 antibodies were added to the cells at 70μl/ml and incubated for 15 
minutes. EasySep PE Selection cocktail was then added at 70μl/ml for an additional 15 
minutes. Magnetic nanoparticles were mixed by pipeting five times, and were then added 
at 50μl/ml to the cell suspension for 10 minutes. After the final incubation, the cells were 
brought to a total 2.5ml volume with PBS + 2% FBS. Cells were gently mixed by 
pipeting 2-3 times and then placed in a chilled EasySep magnet without the cap for 5 
minutes. While holding the tube in the magnet to retain nanoparticle-bound cells, the tube 
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was inverted and the supernatant was poured off. The tube was removed from the magnet 
and 2.5ml PBS + 2% FBS was added. Cells were resuspended by gently pipeting 2-3 
times and replaced back in the magnet for 5 minutes. The separation protocol was 
repeated for a total of four-5 minute separations. After the final separation, cells were 
counted and plated overnight in a round-bottom 96 well plate in RPMI + 10% FBS, 1% 
penicillin/streptomycin supplemented with 0.05mM -mercaptoethanol, 100ng/ml SCF, 
10ng/ml IL-3 and 10ng/ml IL-6.  
Retroviral Transduction 
c-kit+ cells were transduced with retroviruses in RPMI 10% FBS supplemented 
with 100mM HEPES and 4μg/mL polybrene by centrifugation at 3000 rpm, 33°C for four 
hours on one or two days. The specific protocol was adjusted based on the experimental 
design as described below.  
Colony Replating Assay  
For MLL-AF9 point mutants, 30,000 c-kit+ cells were transduced with 750μl high 
titer MSCVneoMLL-AF9(wild type or mutant) virus in a 1mL total volume (750μl viral 
supernatant, 7.5mM HEPES, 4μg/ml Polybrene and RPMI 10% FBS to volume) for two 
consecutive days. After the first spinoculation, cells were plated overnight in RPMI + 
10% FBS, 1% penicillin/streptomycin supplemented with 0.05mM -mercaptoethanol, 
100ng/ml SCF, 10ng/ml IL-3 and 10ng/ml IL-6 in 96 well plates. The spinoculation 
procedure was repeated on the second day, after which cells were plated at 10,000 
cells/1.1mL in methylcellulose supplemented with glutamine, 100ng/ml SCF, 10ng/ml 
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IL-3, 10ng/ml IL-6, 10ng/ml GM-CSF, 1.25mg/ml G418 and RPMI in 35mm dishes. The 
dishes were placed in a larger 15cm dish humidified with an uncovered 35mm dish 
containing H20 and placed in a 37°C, 5% CO2 incubator for seven days. After one week, 
colonies were counted using a Leica DMIL model microscope (Wetzlar, Germany) and 
enumerated as colonies/10,000 cells. Photographs of the colonies were taken using a 
Nikon Diaphot inverted fluorescence microscope with an Olympus DP21 digital camera.  
For replating, the cells were collected in tubes containing 20mL of 1x PBS, 
washed one time, resuspended at an appropriate volume and counted. One-to-ten 
thousand cells were replated as described above for a total of four times. Experiments 
were repeated three to six times and statistical significance was assessed using a 
Student’s t-test with p<0.05.  
Genetic Complementation Assay 
c-kit+ bone marrow progenitors were isolated from C57Bl/6 mice as described 
above. 50,000 cells were retrovirally transduced with a combination of AF9(WT or 
D544R) and MLL-AF5(WT or K717D) virus in a 2ml total transduction volume, three 
tubes per construct. Each spinoculation tube contained 50,000 cells, 750μl of 
MSCVYFPAF9 virus, 750μl MSCVneoMLL-AF5 virus, polybrene and HEPES as 
described. The virus combinations were as follows: MLL-AF5(WT) + AF9(WT), MLL-
AF5(K717D)  + AF9(WT), MLL-AF5(WT) + AF9(D544R), or MLL-AF5(K717D) + 
AF9(D544R). 
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Cells were centrifuged at 3000rpm, 33°C for four hours on two consecutive days. 
At the end of the last spin, cells were plated in methylcellulose with G418 for one week 
to select for cells expressing the MSCVneoMLL-AF5(WT or K717D) construct.   
After one week, cells were harvested from methylcellulose and sorted for YFP+ 
using the FACsAria III instrument (BD Biosciences). The YFP+G418
R
 cells were 
divided evenly and plated in methylcellulose for a colony replating assay as described 
above.  
Murine Colony-Forming Cell (CFC) Assays 
CFC Assays with Af9
fl/fl
 c-kit+ Bone Marrow Progenitor Cells  
For experiments using untransduced c-kit+ bone marrow cells, cells were 
harvested and immediately pre-treated with 200nM 4-hydroxytamoxifen (Sigma) or 
ethanol control in a 96-well plate for four hours at 37°C. After the four hour pre-
treatment, cells were plated for myeloid, erythroid or megakaryocytic lineage 
differentiation.  
For erythroid lineage differentiation, 10,000 cells in RPMI + 2% FBS 
supplemented with 10ng/ml IL-3, 50ng/ml SCF, 3U/ml rhEPO, 1% P/S, 100nM 4-OHT 
or ethanol control, were plated in 2.4mL aliquots methylcellulose (M3234, Stem Cell) to 
a total volume of 3.3mL. 1.5mL, or approximately 4,500 cells, were plated in two-35mm 
dishes and placed in a covered 15cm plated with a 35mm uncovered dish of water for 
humidity. Erythroid colonies were enumerated per 10,000 cells plated and photographed 
at day four. 
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For myeloid lineage differentiation, cells were plated in 900μl RPMI + 10% FBS, 
10ng/ml IL-3, 10ng/ml IL-6, 50ng/ml SCF, 10ng/ml GM-CSF, and 100nM 4-OHT or 
ethanol control.  The cell suspension was added to 2.4ml methylcellulose aliquots 
supplemented to yield a total volume of 3.3ml. 1.1ml of the methylcellulose suspension 
containing approximately 6,800 cells was plated in 35mm dishes. Cells were placed along 
with an uncovered 35mm dish of water in a 15cm plate in a 37°C incubator for 12 days. 
Colonies were enumerated per 10,000 cells plated.   
For megakaryocytic lineage differentiation, 11,000 cells in 300μl IMDM 
containing 100nM 4-OHT or ethanol control were added to a 1.7mL Megacult-C medium 
containing 50 ng/ml rhTPO, 10ng/ml rmIL-3, and 20ng/ml rhIL-6 (Stem Cell). 1.2ml 
cold collagen was added to the Megacult-C cell suspension and quickly mixed. 750μl of 
the suspension, or approximately 2500 cells, was added per chamber of a double chamber 
slide (Stem Cell Double Chamber Slide Kit #04963). The slides were placed in a 15cm 
plate along with an uncovered 35mm dish of water for humidity in a 37°C, 5% C02 
incubator for 7-10 days.  
At the end of the incubation period, the slides were removed from the incubator 
and dehydrated using filter paper layered on top of mesh spacers (Stem Cell Double 
Chamber Slide Kit #04963). After the filter paper was fully saturated, it was removed and 
the slides with mesh spacer were placed in a container of ice cold acetone for five 
minutes, gently releasing the mesh from the slide with slight agitation. Slides were air 
dried for 15 minutes and either stained immediately or stored in the dark at 4°C for up to 
a month. 
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If refrigerated, slides were brought to room temperature prior to staining. 
Acetylcholinesterase stain was prepared by dissolving 10mg of acetyhiocholiniodide 
(Sigma #A5751) in 0.1M sodium phosphate buffer, pH 6.0. Under constant stirring, the 
following were added in order: 1ml 0.1M sodium citrate, pH 6.0; 2ml 30mM copper 
sulphate, pH 6.0; 2ml 5 mM potassium ferricyanide solution (ACS Reagent #244023). 
Slides were completely covered with the staining solution and incubated for 5 hours at 
room temperature in a covered chamber. The staining solution was removed and slides 
were fixed in 95% ethanol for 10 minutes, followed by rinsing with lukewarm water. The 
slides were then air dried before counterstaining with Harris’ hematoxylin solution 
(Sigma 107K4356) for 30 seconds. Slides were rinsed with lukewarm water, air dried, 
and stored in covered containers at room temperature. Achetylcholinesterase-positive 
colonies were counted, and slides were photographed using an AMG Evos XL Core 
microscope (Fischer Scientific).   
CFC Assays with YFP-AF9 Transduced Af9
fl/fl
 Bone Marrow Progenitor Cells 
For CFC assays requiring expression of YFP-tagged AF9 constructs, 300,000 c-
kit+ cells were transduced with 750μl MSCV.YFP, MSCV.YFP.AF9(WT) or 
MSCV.YFP.AF9(mutant) virus in a 1mL total volume as described above. Cells were 
centrifuged at 3000 rpm, 33°C for 4 hours, and plated at 10
6
 cells/ml in RPMI + 10% 
FBS, 1% penicillin/streptomycin supplemented with 0.05mM -mercaptoethanol, 
100ng/ml SCF, 10ng/ml IL-3 and 10ng/ml IL-6 in 96-well plates overnight. 
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Approximately 30 hours later, cells were collected in PBS + 2% FBS and sorted for 
YFP+ cells using the FACS Aria Instrument (Becton Dickinson).  
Immediately after sorting, YFP+ cells were plated in cytokine-supplemented 
media with 200nM 4-hydroxytamoxifen (Sigma) or ethanol control in a 96-well plate for 
four hours at 37°C. After the four hour pre-treatment, cells were plated for myeloid, 
erythroid or megakaryocytic lineage differentiation as described above.  
Cytospins and Staining 
 Cells were harvested from methylcellulose, washed and resuspended at 20,000 
cells/200ul in 1x PBS. Cells were spun at 1000rpm for 4 minutes using the CytoSpin4 
ThermoSci cytospin onto charged microscope slides (Premiere, CA Scientific Co). The 
cells were air dried and stained with Hema 3 (Fisher Scientific). 
Surface Marker Staining by Flow Cytometry 
Cells collected from CFC assays for myeloid or erythroid lineage were 
resuspended in 500μl PBS + 2% FBS, and divided amongst two polystyrene FACs tubes. 
A separate tube of approximately 50,000 cells was resuspended in 200μl PBS + 2% FBS 
for an unlabeled control. Compensation controls were prepared by adding one drop of 
either α-Rat α-Hamster Igκ positive or negative compensation beads (BD Bioscience) to 
100μl 1x PBS. Specific antibody dilutions were prepared, and master mixes were 
prepared to assess surface marker expression of erythroid and myeloid lineage markers 
(Table 9).  
1μl of each antibody (eBioscience) was added to the appropriate compensation 
tubes, and the antibody cocktails were added to the samples. Tubes were kept on ice in 
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the dark for 20 minutes. 500μl of PBS + 2% FBS was added to each tube, gently mixed, 
and centrifuged at 1500 rpm for 7 minutes. The supernatant was carefully decanted and 
the cells were resuspended in the residual volume. Secondary conjugate antibodies were 
added to the appropriate tubes and incubated on ice in the dark for 20 minutes. An 
additional 500μl PBS + 2% FBS was added to wash the cells, gently mixed, and cells 
were spun down at 1500 rpm for 7 minutes. Compensation beads and antibody-bound 
cells were resuspended in 250μl PBS + 2% FBS and kept on ice in the dark until 
analyzed using the FACs CantoII or LSRFortessa instruments (BD Biosciences). Cell 
surface marker expression was analyzed using FlowJo (TreeStar Inc., Oregon). 
Table 9. FACs Antibodies for Erythroid and Myeloid Surface Markers   
Erythroid Lineage Cocktail Myeloid Lineage Cocktail 
            APC-CD117             APC-CD117 
            PE-CD71             PE-CD41 
            Biotin-Ter119 
            SA-PECy7 
            Biotin-CD11b 
            SA-APCCy7 
             PE-Cy7-Gr1 
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CHAPTER FOUR 
RESULTS 
AIM 1: To determine which AF9 complex interactions are necessary for 
normal hematopoietic development 
 
Cloning and Stable Expression of full length AF9 point mutants 
The C-terminus of AF9 has been shown to interact with four proteins, each of 
which is associated with gene activation or repression. We sought to elucidate the 
function of these protein interactions in normal hematopoiesis and leukemogenesis by 
engineering point mutations in AF9 predicted to either destabilize the protein, block its 
interaction with one or more known AF9 binding partners, or modify a potential 
phosphorylation site.  
Initial structural studies of AF9 from the Bushweller lab at the University of 
Virginia identified four potential residues as mutation targets. The C-terminal region of 
AF9 that has been shown to interact with multiple proteins is composed of three alpha 
helices and one beta strand (Figure 10A). Alpha helices generally follow the ἰ + 4 rule, in 
which the amine group of each amino acid donates a hydrogen bond to the carboxyl 
group of the amino acid four residues upstream
238
. There are approximately 3.6 residues 
per turn, and most commonly three helix turns correspond to ten amino acids total
239
.  
Three amino acid residues, E506, K557, and L562, were selected as they are 
located within α-helices in the AF9 C-terminus. Glutamate 506 is present in helix one, 
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and lysine 557 and leucine 562 are located in helix three (Figure 10A). Helix one 
and three are in close proximity to each other, and can form a potential protein-protein 
interaction interface.  
Polar amino acids often participate in salt bridges with amino acids of 
complementary charge, creating stable electrostatic bonds that are important for protein 
stability. Both E506 and K557 are charged residues that were mutated to an amino acid of 
the opposite charge. Negatively charged glutamate 506 was mutated to positively charged 
arginine, and positively charged lysine 557 was mutated to negatively charged glutamate. 
We hypothesized that reversing the charge would disrupt the structure of the helix and 
potential charge-charge interactions with other proteins at the helix interface.  
Leucine 562 is a hydrophobic amino acid buried within helix three (Figure 10A). 
Hydrophobic amino acids are often found in the core of protein structures, isolated from 
the aqueous environment
239
. Mutation to small, slightly polar alanine is expected to 
disrupt the proper folding of the helix, altering protein interactions mediated by the AF9 
structure in this region.  
 A fourth residue chosen for mutation was isoleucine at amino acid 538 (Figure 
8A). Isoleucine is a hydrophobic amino acid that prefers to be buried within hydrophobic 
cores. Isoleucine has two branches at the β-carbon position, making it a bulkier structure 
than amino acids with a single branch. Because of this, it is not often incorporated into α- 
helices, but is commonly found in β sheets239. Indeed, I538 is located at the C-terminal 
end of β strand one in the AF9 structure. β strand one and β strand two form an 
antiparallel β–sheet connected by a loop in the C-terminus of AF9. Mutation of I538 to 
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alanine was predicted to disrupt the folding of the β sheet, and therefore potentially 
altering any protein-protein interactions mediated by this secondary structure. 
Serine 565 was identified as a potential phosphorylation site. It is located at the C-
terminus of the AF9 protein, three amino acids from the end of the protein (Figure 8A). 
Two mutations were introduced to study the potential functional relevance of this residue: 
an alanine substitution mimicking an unphosphorylatable residue, or an aspartate 
substitution mimicking a constitutively phosphorylated serine.  
After the structure of AF9 was further resolved in complex with an AF4 peptide 
in 2013
156
, additional structurally-informed amino acid mutational targets in AF9 were 
identified. The D544R mutation was first identified through previous work in Dr. 
Hemenway’s laboratory. They mapped the interacting region of AF9 to AF4 amino acids 
760-770
157
. This region is highly conserved in all AFF family members, including a 
conserved lysine residue (Figure 6B). AF4(K764) resulted in a loss of binding to AF9 in 
a yeast two-hybrid assay
240
. Screening a mutagenized AF9 cDNA library for clones that 
could restore binding to the AF4(K764) mutant identified an aspartic acid at residue 544 
of AF9. Supporting structural studies in collaboration with the Bushweller laboratory 
characterized the AF9(D544)-AF4(K764) interaction as forming a stable salt bridge. 
Binding studies determined a dissociation constant 0.17mM for the interaction of AF9 
with AF4. Mutation of the aspartic acid at position 544 in AF9 to aspartic acid reduced 
the binding to wild type AF4 to Kd=7.39nM, indicating that the AF9-AF4 interaction 
mediated by residues D544-K764 is necessary for high affinity binding of the two 
proteins
156, 240
. 
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Figure 10. Engineering and Stable Expression of Full Length AF9 Point Mutants 
A 
 
B 
 
 
 
 
 
(A) Structure of AF9 solved in complex with AF4
156
 (PDB ID 2LM0) with point 
mutations examined in these studies indicated.  N- and C-terminal ends as well as the 
three alpha helices are noted. (B) Detection of FLAG-tagged full length AF9 mutants in 
Phoenix Ecotropic cells by western blot with Actin loading control.  
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AF9 aspartate 546, two residues C-terminal to the aspartate critical for interaction 
with AF4, was identified as mediating interaction with DOT1L (Figure 10A). Similar to 
the AF9-AF4 salt bridge interaction, AF9 is thought to interact with DOT1L via a charge-
charge interaction. There are three binding regions for AF9 on DOT1L: amino acids 628-
653, 863-878 and 878-900. These interaction sites have a conserved sequence of 
LxL/I/VxIxI/LxxL/V, clustering together five hydrophobic residues within a 10 amino 
acid region (unpublished data from the Bushweller lab). Structural studies identified AF9 
residue D546 as a potential candidate to mutate to inhibit binding of AF9 at all three 
DOT1L interfaces.  
To express the full length AF9 point mutants in bone marrow cells, the plasmids 
were packaged for retroviral transduction. For virus production, ecotropic Phoenix cells, 
engineered from the human embryonic kidney (HEK 293) cell line to stably express the 
retroviral packaging genes, were transfected with the AF9 plasmids. The supernatant 
containing retroviral particles was collected and concentrated. Virus titers were 
determined by serially diluting the virus and transducing Rat1a cells. Acceptable titers 
were in the 1x10
6
 to 1x10
7
 virus particle/mL range.   
To determine whether the mutant AF9 proteins were stably expressed, the 
transfected ecotropic Phoenix cells were harvested and protein lysates were prepared to 
assess expression of the AF9 point mutants.  As some of the mutants were predicted to 
disrupt local protein folding, it was important to show that introduction of amino acid 
substitutions in AF9 did not affect the stability of the protein. An anti-FLAG antibody 
was used to detect the AF9 point mutants, and Actin was used as a control for the amount 
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of protein loaded in the western blot. Mutants D544R, I538A, S565A and S565D all 
expressed comparably to the wild type AF9 protein (Figure 10B). A slight reduction in 
expression of D546R, E506R, K557E and L562A mutants was evident, however proteins 
are readily detected. All AF9 mutants are stably expressed and are of the expected size of 
65 kilodaltons, indicating that introducing point mutants into AF9 did not result in 
instability and degradation, and that these mutants can be used to assess the function of 
interactions mediated at these residues in the following experiments.  
Interaction of AF9(D546R) with DOT1L and AF4 
The binding between AF9 mutants D544R, E506R, I538A, K557E, L562A and 
S565D in the context of the C-terminal 376-568 amino acids of AF9 to DOT1L and AF4 
was assessed by coimmunoprecipitation studies by a former graduate student in the 
Hemenway lab, Dr. Bhavna Malik. The interaction between AF9 expressing the D546R 
mutation and AF4 or DOT1L had not yet been studied, and so I sought to examine the 
functional importance of this residue.  
The D546R point mutation was predicted to specifically disrupt binding to 
DOT1L while maintaining interaction with AF4; however, it was important to examine 
functionally how this mutation would affect binding between AF9 and these interacting 
partners. Coimmunoprecipitation studies were conducted to examine the binding of C-
terminal AF9 residues 470-568 and 376-568 to fragments of DOT1L and AF4. 
Approximately 75% of the MLL-AF9 fusions expressed in patients with MLL leukemia 
include AF9 residues 376-568. However, 12% of patients express a MLL-AF9 fusion 
including only amino acids 475-568 of AF9
154, 241
. Introduction of this MLL-AF9(475-
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568) fusion protein by homologous recombination into the endogenous Mll locus resulted 
in AML development in mice, indicating that this smaller 94 amino acid AF9 fragment is 
sufficient for transformation
147
. AF9 fragments 376-568 and 470-568 were tested for 
binding to AF4 and DOT1L in order to elucidate any potential differences in binding 
mediated by the 192 amino acid versus the 98 amino acid C-terminal tail of AF9.   
FLAG-tagged AF9(470-568) or AF9(376-568), either wild type or containing the 
D546R mutation, were coexpressed in HEK-293 cells with various fragments of GFP-
tagged AF4 or DOT1L to examine the interaction between these proteins. The AF9 
protein was immunoprecipitated using anti-FLAG antibody-conjugated agarose beads, 
and then FLAG-purified proteins were probed by western blots with an anti-GFP 
antibody.  
As mentioned above, unpublished binding studies from the Bushweller lab have 
identified three sites in DOT1L that interact with AF9: amino acids 628-653, 863-878, 
and 878-900. The D546R mutation in AF9 is predicted to disrupt binding to all three 
DOT1L sites, but coimmunoprecipitation studies were necessary to examine the 
interaction of this AF9 mutant with DOT1L. Constructs encompassing either the most N-
terminal interacting site [mDot1(479-659)] or the two downstream sites [hDOT1L(828-
1095)], in addition to a construct expressing the full length Dot1l protein, were used to 
assess binding to both C-terminal fragments of AF9, wild type or the D546R mutant. 
These sites are present and highly homologous between both human and mouse DOT1L 
proteins.  
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The AF9(470-568) D546R mutant exhibits more than a 70% reduction in binding 
to full length Dot1l or the DOT1L (828-1095) construct encompassing the two most C-
terminal interaction sites compared to wild type AF9 (Figure 11A). Coexpression with 
the Dot1l fragment containing the upstream AF9 interacting sequence (479-659) 
increased binding 5-fold with the D546R mutant as compared to wild type. Of note, 
coexpression of any DOT1L construct with AF9(D546R) mutant resulted in decreased 
FLAG-AF9 detected in the input. All three DOT1L constructs had similar input amounts 
regardless of coexpression with wild type or D546R mutant AF9 (Figure 11A).  
Similar results were obtained with the larger AF9(376-568) D546R mutant 
fragment (Figure 11B). Binding to full length Dot1l and DOT1L(828-1095) was 
decreased with the D546R mutant 30% and 80%, respectively, as compared to wild type. 
Interaction with the more N-terminal mDot1l(479-659) fragment was not significantly 
different between AF9(376-568) wild type or D546R mutant. Coexpression of 
AF9(D546R) with full length Dot1l or DOT1L(828-1095) resulted in decreased AF9 
levels in the input, whereas coexpression with Dot1l(479-659) did not alter AF9 levels. 
The input levels for all three GFP-tagged Dot1l constructs remained consistent (Figure 
9B).  
From these results, we conclude that AF9 residue D546 is involved in mediating 
interaction with DOT1L, specifically interaction with the full length protein or the 
DOT1L fragment encompassing two of the three AF9 binding sites (863-878 and 878-
900), but not the first site (628-653). 
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Figure 11. Interaction of AF9(D546R) fragments 470-568 and 376-568 with DOT1L  
A 
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B 
 
                 
 
 
 
 
 
 
 
 
Coimmunoprecipitation studies of AF9 fragments 470-568 (A) or 376-568 (B) and 
DOT1L constructs full-length mDotl, mDot1l (479-659) and hDOT1L(828-1095). 
Figures are representative of two independent experiments. Pixel analysis was performed 
using ImageJ software. Immunoprecipitated GFP-tagged DOT1L proteins were 
normalized to FLAG-AF9 input. * = p<0.05, ** = p<0.02. 
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Because AF9 is known to interact with AF4 amino acids 768-777
157
, a construct 
containing this minimal interaction domain (AF4 755-777) was used to assess the effect 
of the D546R mutation on the AF9-AF4 interaction. A second AF4 fragment containing a 
slightly larger region of AF4, including the AF9 interaction domain but lacking the 
bipartite nuclear localization signal (amino acids 647-871), was also used to examine 
AF9(D546R) binding.  
No statistically significant difference in binding of AF9(470-568) WT or D546R 
to the larger AF4 fragment (647-871) was evident, but the D546R mutant shows an 
almost 8-fold increase in binding to the AF4 755-777 fragment encompassing the 
minimal AF9 interaction domain, despite a loss of detectable AF9 in the input (Figure 
12A).   
No statistically significant differences in binding of AF9(376-568) WT or D546R 
were present with either AF4 construct, despite trends towards a slight reduction in 
binding with the D546R mutant compared to wild type (Figure 12B). Again, there is a 
reduction in detectable AF9(D546R) in the input samples of HEK293 cells cotransfected 
with AF4(755-777). In contrast to the AF9(470-568) fragment, there is also a reduction in 
AF9(376-568) D546R mutant when coexpressed with the larger 647-871 AF4 fragment 
(Figure 12B).  
From these results, we conclude that mutation of AF9 D546 to arginine does not 
significantly abrogate binding of AF9 to AF4. An exception to this is the interaction of 
the smaller AF9 fragment (470-568) with the minimal AF4 fragment (755-777), in which 
binding of AF9(D546R) is statistically increased compared to wild type.  
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Figure 12. Interaction of AF9(D546R) fragments 470-568 and 376-568 with AF4 
 
 
A 
 
 
B 
 
 
 
          Coimmunoprecipitation studies of AF9 fragments 470-568 (A) or 376-568 (B) and 
AF4(647-871) or AF4(755-777). Figures are representative of two independent 
experiments. Pixel analysis was performed using ImageJ software. Immunoprecipitated 
GFP-tagged AF4 proteins were normalized to FLAG-AF9 input., ** = p<0.02. 
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In vivo Deletion of Af9 Does Not Alter Levels of Hematopoietic Lineage-Specific 
Transcription Factors in Af9-Inducible Knockout Mouse Bone Marrow Cells 
The role of AF9 has not been well studied beyond its function in MLL fusion 
proteins. As reviewed in the previous chapter, the Af9 knockout mouse dies perinatally 
and exhibits skeletal defects as well as altered expression of developmental genes such as 
Hoxd4. The cause of death was not further examined in these mice
158
. An independent 
group overexpressed or knocked down AF9 using lentiviral expression vectors in CD34+ 
human cord blood cells
159
. They showed that overexpression of AF9 resulted in an 
expansion of erythroid and megakaryocytic colonies in a colony forming cell (CFC) 
assay. Conversely, knockdown of AF9 resulted in a complete loss of this compartment. 
These two studies together indicate a critical role for Af9 in embryonic development, as 
well as in differentiation of hematopoietic cells.  
Our laboratory, in conjunction with Dr. Hemenway’s group, sought to further 
assess the role of Af9 in an inducible knockout mouse system. Crosses were designed by 
Dr. Zeleznik-Le and Dr. Hemenway. The initial rounds of breeding produced mice that 
were heterozygous or homozygous for the Af9 allele flanked by two loxP sites. 
Additional crosses with B6.129-Gt(ROSA)Sor
tm1(cre/ERT2)Tyj
/J mice, which express a 
tamoxifen-inducible Cre recombinase, yielded Af9
fl/fl Cre/+
 mice. When tamoxifen is 
administered to these mice by intraperitonal injection, the tamoxifen is processed to the 
bioactive 4-OHT molecule which then binds to the estrogen response (ER) element in the 
ubiquitously expressed Rosa26 promoter. Cre recombinase expression is then turned on 
in all tissues, and the enzyme binds to and catalyzes DNA recombination between the 
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paired loxP sites, excising the Af9 gene. This system allows for conditional deletion of 
floxed region of Af9 at specific time points in all tissues.   
Homozygous floxed-Af9 and homozygous floxed-Af9 Cre mice were administered 
tamoxifen by I.P. injection at specific time points. Only mice with the Cre allele will 
excise the floxed Af9 gene upon tamoxifen treatment. Mice were sacrificed at set times 
after injection, and peripheral blood and bone marrow were assessed for hematopoietic 
development. Other members of the laboratory examined surface marker expression in 
the peripheral blood and bone marrow of these mice, while I assessed transcript levels of 
lineage-specific transcription factor genes in bone marrow cells. Based on previous 
studies, we hypothesized that Af9 is a critical regulator of erythroid/megakaryocyte 
(E/Meg) lineage commitment, and that loss of Af9 would result in a decrease or loss of 
differentiation of bone marrow cells to this lineage.  
As discussed in the previous chapter, expression of specific transcription factors is 
necessary for hematopoietic stem and progenitor cells differentiation to mature blood 
cells. Expression of Gata1 and Gata2 is required for progenitor cells to differentiate into 
the E/Meg lineage, whereas expression of Pu.1 and Cebpa is associated with 
granulocyte/macrophage (GM) lineage commitment (Figure 1). If Af9 is required for 
E/Meg lineage commitment, we expect to see a decrease in levels of mRNA encoding 
transcription factors associated with differentiation to this lineage (Gata1 and Gata2), 
with a possible compensatory increase in transcription factors associated with GM 
lineage commitment.  
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We do not see any significant changes in the transcript levels of erythroid (Gata1, Gata2) 
or myeloid (Pu.1, Cebpa) lineage transcription factor genes in mice  expressing Af9 compared to 
those null for Af9 expression (Figure 13).  
 
Figure 13. Expression of Lineage-Specific Transcription Factors in Af9 Inducible 
Knockout Bone Marrow Cells 
 
 
Transcript levels of erythroid lineage-associated transcription factor genes Gata1 and 
Gata2 and myeloid lineage-associated transcription factor genes Pu.1 and Cebpa in the 
bone marrow of Af9 
fl/fl 
or Af9
fl/fl cre/+
 mice after intraperitonal injection with tamoxifen. 
RNA was isolated from nine mice of each genotype, and cDNA was analyzed in 
triplicate. Expression was normalized to Gapdh, and error bars indicate standard 
deviation.  
 
Loss of Af9 Does Not Alter Hematopoietic Lineage Differentiation in vitro 
In addition to the ongoing in vivo studies in our laboratory, I assessed the 
differentiation ability of bone marrow cells lacking Af9 in vitro. Rather than 
administering tamoxifen to mice in vivo to induce deletion of Af9, c-kit+ bone marrow 
progenitor cells were isolated from Af9
fl/fl Cre/+
 mice that had not been exposed to 
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tamoxifen. Cells were then plated in semi-solid methylcellulose media with cytokines 
which potentiate differentiation of  the erythroid, myeloid or megakaryocytic lineages 
with or without 4-OHT, the bioactive derivative of tamoxifen, to induce deletion of Af9.   
To examine the ability of cells to differentiate along the erythroid lineage 
following loss of Af9, bone marrow progenitor cells from Af9
fl/fl Cre/+ 
mice were plated in 
methylcellulose with IL-3, IL-6 and EPO in the presence or absence of 4-OHT to 
examine the role of Af9 in erythroid cell development. Loss of Af9 did not alter the 
ability of bone marrow progenitor cells to differentiate to the erythroid lineage in this 
system. There was no difference in the number of colonies formed in cells expressing or 
lacking Af9 (Figure 14).  
 
Figure 14. Erythroid Colony Formation by Af9 Inducible Knockout Bone Marrow 
Progenitor Cells  
 
 
 
 
 
 
Erythroid colony formation in c-kit+ bone marrow progenitor cells isolated from Af9
fl/fl 
cre/+ 
mice. Cells were treated with 4-OHT or ethanol control in vitro and plated in 
methylcellulose in the presence of cytokines to promote differentiation to the erythroid 
lineage. Colonies were enumerated per 10,000 cells plated. Experiments were repeated in 
duplicate three times.  
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FACs analysis was used to examine changes in expression of cell surface markers 
associated with erythroid development, including CD71 and TER119, upon Af9 deletion. 
CD71 is a transmembrane glycoprotein present on the surface of proliferating cells, 
reticulocytes and erythroid precursor cells. TER119 is a cell surface antigen specific to 
erythroid cells, expressed on proerythroblasts through mature erythrocytes, but not 
expressed on earlier CFU-E and BFU-E cells. There was a significant reduction in 
expression of CD71 in cells lacking expression of Af9 compared to wild type, although 
there were no significant changes in expression of TER119. Levels of CD117, or the c-
Kit receptor present on all hematopoietic progenitor cells, also remained unchanged in 
wild-type cells or those lacking Af9 (Figure 15A).  
In addition, I assessed the surface marker expression of myeloid lineage-
associated cell surface markers, hypothesizing that any alterations in erythroid lineage 
differentiation and surface marker expression may results in a compensatory response in 
the myeloid lineage differentiation and surface marker expression. CD41 is the alpha 
subunit of the gpIIb/gpIIIa complex expressed on the surface of platelets and 
megakaryocytes. Gr-1 is a myeloid differentiation antigen expressed on granulocytes and 
monocytes. CD11b, also known as Mac-1, is a transmembrane protein expressed on most 
myeloid cells including granulocytes, monocytes, and dendritic cells. There were no 
significant changes in expression of the myeloid surface markers CD41, Gr-1 or CD11b 
in cells with or without Af9 (Figure 15B). We conclude based on these results that Af9 is 
not required for the formation of erythroid colonies in vitro despite a reduction in CD71 
surface marker staining in cells lacking Af9 expression.   
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Figure 15. Surface Marker Staining of Af9 Inducible Knockout Bone Marrow 
Progenitor Cells Plated for Erythroid Lineage Differentiation 
A 
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Surface marker staining of Af9
fl/fl cre/+
 mouse bone marrow progenitor cells plated for 
erythroid lineage differentiation. Unstained cells were used as a control, and the average 
Mean Fluorescence Intensity (MFI) was calculated using the geometric mean of 
fluorescence intensity of three experiments, * = p<0.05. (A) Expression of erythroid 
lineage specific markers Ter119 and CD71, along with the hematopoietic progenitor 
marker CD117 (B) Expression of CD117 and myeloid lineage-specific markers CD41, 
Gr-1 and CD11b.  
 
Next we examined the differentiation of inducible Af9 knockout cells to the 
myeloid lineage by plating c-kit+ bone marrow cells from Af9
fl/fl Cre/+ 
mice in cytokines 
to promote myeloid lineage differentiation: IL-3, IL-6, SCF and GM-CSF. Cells were 
plated in the presence of either 4-OHT or ethanol, and colony forming unit-granulocyte 
macrophage (CFU-GM) colony formation was assessed after 12 days. 
There was no significant change in colony formation of bone marrow cells with 
or without Af9 expression (Figure 16). Similarly, there was no significant change in 
myeloid-associated surface marker expression in these cells (Figure 17A). We also 
examined the expression of erythroid lineage surface markers in these cells, 
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hypothesizing that any alterations in the myeloid lineage could be compensated by 
increases or decreases in differentiation to the erythroid lineage and vice versa. We did 
not see any changes in expression of erythroid-associated surface markers (Figure 17B). 
From these results, we conclude that Af9 does not play a role in myeloid lineage 
differentiation in vitro. 
 
Figure 16. Myeloid Colony Formation by Af9 Inducible Knockout Bone Marrow 
Progenitor Cells  
 
Myeloid colony formation in c-kit+ bone marrow progenitor cells isolated from Af9
fl/fl 
cre/+ 
mice. Cells were treated with 4-OHT or ethanol control in vitro and plated in 
methylcellulose in the presence of cytokines to promote differentiation to the myeloid 
lineage. Colonies were enumerated per 10,000 cells plated. Experiments were repeated in 
duplicate three times.  
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Figure 17. Surface Marker Staining of Af9 Inducible Knockout Bone Marrow 
Progenitor Cells plated for Myeloid Lineage Differentiation 
A 
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Surface marker staining of Af9
fl/fl cre/+
 mouse bone marrow progenitor cells plated for 
myeloid lineage differentiation. Unstained cells were used as a control, and the average 
Mean Fluorescence Intensity (MFI) was calculated using the geometric mean of 
fluorescence intensity of three experiments. Expression of hematopoietic progenitor 
marker CD117 and (A) myeloid lineage-specific markers CD41, Gr-1 and CD11b or (B) 
erythroid lineage specific markers CD71 and TER119.  
 
We assessed the ability of bone marrow progenitor cells with or without Af9 to 
differentiate to the megakaryocytic lineage in vitro. We hypothesized that loss of Af9 
would result in a loss of differentiation to both erythroid and megakaryocytic lineages. To 
test this, cells were plated in chamber slides in a semi-solid media supplemented with 
TPO, IL-6 and IL-3, and either 4-OHT to induce recombination and deletion of Af9 or 
ethanol control. After seven days, the slides were fixed and stained for 
acetylcholinesterase activity (Figure 18A). Mouse megakaryocyte and early 
megakaryocyte progenitors express the acetycholinesterase enzyme. When incubated 
with acetylcholine substrate, the enzyme releases Cu
2+
 ions which precipitate as colorless 
copper thiocoline. Subsequent incubation with ammonium sulfide converts the colorless 
copper thiocoline molecules to brown-colored copper sulfate
242
. The slides also contain 
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myeloid cells which do not stain brown. Acetycholinesterase-positive megakaryocytes 
were counted, and no significant difference was seen between cells expressing or lacking 
Af9 (Figure 18B). As these cells are fixed on the slides, surface marker staining was not 
assessed. We conclude based on these assays that Af9 is not required for megakaryocyte 
lineage commitment in vitro.  
 
Figure 18. Acetylcholinesterase-Positive Megakaryocyte Staining of Af9 Inducible 
Knockout Bone Marrow Progenitor Cells 
 
A 
 
 
 
 
 
B 
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(A) Representative image of acetylcholinesterase-positive megakaryocytes among 
acetylcholinesterase-negative myeloid cells (left, 4X magnification). Higher 
magnification (10X) of positively-staining megakaryocytes (right). (B) Quantification of 
Acetylcholinesterase-positive in vitro differentiated megakaryocytes from Af9
fl/fl Cre/+
 
mouse bone marrow progenitor cells treated with 4-OHT or ethanol control. After plating 
in semi-solid medium in the presence of cytokines to promote megakaryocytic 
differentiation, chamber slides were dehydrated and stained for acetylcholinesterase 
activity. Acetylcholinesterase-positive colonies were counted and enumerated per 10,000 
cells plated. Experiments were conducted in duplicate three times.  
 
Together these results show that loss of Af9 in vitro does not alter lineage 
commitment of c-kit+ bone marrow cells to the myeloid or megakaryocytic lineages 
under these conditions. Erythroid colony formation was not affected by the loss of Af9, 
although there was a reduction in the early erythroid marker CD71.  
Re-expression of Wild-Type AF9 or AF9 Mutants S565A and S565D Does 
Not Alter in vitro Lineage Differentiation of Af9-Inducible Knockout Bone Marrow 
Progenitor Cells 
 
The first in vitro differentiation studies I conducted were based on the early 
hypothesis that loss of Af9 would result in a loss of cells differentiating to the erythroid 
and megakaryocyte compartment. Prior to obtaining the above described results, we 
tested whether re-expression of wild-type AF9 could rescue any defects in lineage 
commitment. Further, we wanted to see if expression of two AF9 mutants, S565A and 
S565D, would alter the ability of cells to differentiate to the erythroid lineage. These 
mutants were selected based on preliminary results from an earlier experiment that 
indicated the serine residue at 565 may be critical in mediating progenitor cell maturation 
(data not shown).  
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Bone marrow progenitor cells were isolated from Af9
fl/fl Cre/+   
mice, and were 
transduced with retrovirus encoding AF9(WT), AF9(S565A), AF9(S565D) or vector 
alone. As described previously, serine 565 near the C-terminus of AF9 was identified as a 
possible phosphorylation site. A mutation to alanine would prevent this residue from 
being phosphorylated, whereas mutation to an aspartic acid mimics constitutive 
phosphorylation. All constructs were YFP tagged, allowing for sorting of YFP+ cells 36 
hours after transduction. YFP+ cells were plated in methylcellulose in the presence of 
cytokines to promote erythroid lineage differentiation with or without 4-OHT, as 
described previously.  
Cells transduced with empty vector showed no difference in erythroid colony 
formation when treated with or without 4-OHT (Figure 19). This is consistent with the 
results shown in figure 12. Re-expression of AF9(WT) or either mutant (S565A or 
S565D) also did not significantly alter colony formation (Figure 19). The cells were also 
subjected to surface marker analysis, examining both erythroid and myeloid-associated 
surface markers as described previously. Consistent with colony formation data, there 
were no significant differences in expression of surface markers associated with erythroid 
(Figure 20A) or myeloid (Figure 20B) lineage upon loss of Af9, or re-expression of AF9 
WT or mutants compared to the ethanol-treated vector control.   
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Figure 19. Erythroid Colony Formation in Af9 Inducible Knockout Bone Marrow 
Progenitor Cells Re-Expressing AF9 Wild-type, S565A or S565D Mutants 
 
 
 
 
 
 
 
 
Erythroid colony formation by c-kit+ progenitor cells isolated from the bone 
marrow of Af9
fl/fl Cre/+
 mice. Cells were transduced with retroviruses encoding YFP-
tagged empty MSCV vector, full length wild-type AF9, or full length AF9 mutants 
S565A or S565D. YFP+ cells were plated in methylcellulose in the presence of cytokines 
to promote erythroid lineage differentiation, and 4-OHT to induce deletion of Af9 unless 
otherwise noted. Colonies were counted after four days and enumerated per 10,000 cells. 
The experiment was conducted in duplicate. 
 
From these results, we confirm that loss of Af9 does not alter the ability of c-kit+ 
murine bone marrow cells to form erythroid colonies in vitro under the conditions tested. 
Additionally, re-expression of wild-type AF9, or AF9 mutants S565A or S565D does not 
alter erythroid lineage commitment compared to the control cells.  
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Figure 20. Surface Marker Staining Profiles of Af9 Inducible Knockout Bone 
Marrow Progenitor Cells Re-Expressing Wild-type or Mutant AF9 plated for 
Erythroid Lineage Differentiation 
 
A 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
Surface marker staining of retrovirally transduced Af9
fl/fl cre/+
 mouse bone marrow 
progenitor cells plated for erythroid lineage differentiation. Unstained cells were used as 
a control, and the average Mean Fluorescence Intensity (MFI) was calculated using the 
geometric mean of fluorescence intensity. Expression of hematopoietic progenitor marker 
CD117 and erythroid lineage specific markers CD71 and TER119 (A) or myeloid 
lineage-specific markers CD41, Gr-1 and CD11b (B) was calculated.  
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AIM 2: To determine whether AF9 interactions with Af4 and Dot1l 
are necessary for leukemogenesis  
 
AF9 Interaction with AF4 Is Required for in vitro Leukemic Transformation 
As discussed previously, AF9 has been shown to interact with AF4 in part 
through AF9 residue D544 and AF4 residue K764. These charged amino acids form a salt 
bridge that promotes stable bonding between the two proteins with a Kd of 0.17nM
156
. 
Mutation of AF9 residue D544 to the positively charged arginine reduces this binding 43-
fold to 7.39nM
240
. Additionally, coimmunoprecipitation studies conducted in Dr. 
Hemenway’s laboratory indicated a loss of binding to AF4 when AF9 residue D544 is 
mutated to arginine
240
. Here, we sought to assess the functional relevance of the AF9-
AF4 interaction mediated by this salt bridge using an in vitro leukemic transformation 
assay.  
When normal bone marrow is plated in semi-solid methylcellulose media, the 
bone marrow progenitor cells will form colonies within the first week, but then will 
continue to differentiate and undergo cell cycle arrest. Hence, these untransformed cells 
will not form colonies after replating. When oncogenic fusion proteins such as MLL-AF9 
are introduced into bone marrow progenitor cells, the cells will be blocked from 
differentiating and will continue to form colonies upon subsequent replating. We 
hypothesized that the interaction of AF4 and AF9 in the context of the leukemia-causing 
MLL-AF9 fusion is critical for the ability of the oncoprotein to transform bone marrow 
cells. Loss of the AF9-AF4 interaction through mutation of the aspartic acid at residue 
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544 in AF9 to an arginine would result in a reduction in colony forming ability in the in 
vitro colony formation assay. 
As previously discussed, AF9 interacts with AF4 which binds to and stabilizes the 
pTEFb elongation complex. It is possible that AF9 in the context of the MLL-AF9 fusion 
recruits the pTEFb elongation complex to MLL target genes through interaction with 
AF4, resulting in aberrant transcription of genes that promote leukemogenesis. Loss of 
this AF9-AF4 interaction would no longer bring the pTEFb elongation complex to target 
genes, resulting in a loss of expression of genes required for the leukemic transformation 
program, and loss of serial replating ability. 
MLL-AF9 wild type, MLL-AF9(D544R) mutant or empty MSCVneo vector were 
retrovirally expressed in c-kit+ bone marrow cells isolated from wild type mice. 
Transduced cells were plated in methylcellulose media in the presence of cytokines to 
promote growth. Colonies were counted after one week prior to replating up to four 
times. Results indicate that while MLL-AF9(WT) transformed cells continue to form 
colonies throughout the four weeks of the assay, there is a significant reduction in colony 
formation in bone marrow cells expressing the MLL-AF9(D544R) fusion (Figure 21A). 
Loss of colony formation was not a result of a lack of MLL-AF9(D544R) expression, as 
this fusion protein was detected in cells harvested at the end of one week (Figure 21C). 
In addition to forming fewer colonies compared to wild-type, the MLL-
AF9(D5444R)-expressing bone marrow cells form more diffuse colonies (Figure 21B). 
The cells within those colonies appear more differentiated, with an increased cell size and 
the presence of granules characteristic of differentiated cells in the myeloid lineage. 
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MLL-AF9(WT)-expressing bone marrow cells appear blast-like; they are smaller in size, 
lack granules, and have a high nucleus-to-cytoplasm ratio upon staining with Wright-
Giemsa (Figure 21B).   
 
Figure 21. MLL-AF9(D544R) Colony Assay 
A B 
 
 
 
 
 
 
 
   C 
 
 
 
 
(A) Colony formation by c-kit+ progenitor cells expressing MLL-AF9(WT), MLL-
AF9(D544R) or vector control throughout four weeks of replating. Colony assays were 
conducted in duplicate a total of six times. (B) Representative colony photographs at 4X 
and 10X magnification (top), and cell morphology by cytospin followed by Wright-
Giemsa staining (bottom). (C) Western blot of bone marrow cells expressing empty 
vector, MLL-AF9(WT) or MLL-AF9(D544R) isolated after one week.  
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As previously mentioned, leukemic transformation by MLL fusion proteins is 
associated with an increase in expression of MLL target genes such as Meis1 and Hoxa9. 
While MLL-AF9(WT) transduced bone marrow cells show a 92-fold increase in 
expression of Hoxa9 and 43-fold increase in expression of Meis1 at week 1 compared to 
the MSCVneo control at week one, cells transduced with MLL-AF9(D544R) show a 
statistically significant reduction in expression, with only 13-fold increase in Hoxa9 
expression and 15-fold increase in Meis1 expression compared to MSCVneo control 
(Figure 22). 
 
Figure 22. Hoxa9 and Meis1 Expression in MLL-AF9(D544R) Transduced Bone 
Marrow Progenitor Cells 
A        B 
 
 
 
 
 
 
 
Relative expression of MLL target genes Hoxa9 (A) and Meis1 (B) in bone marrow 
progenitor cells transduced with retroviruses encoding MLL-AF9(WT), MLL-
AF9(D544R) or empty vector following one week in methylcellulose. Expression was 
normalized to Hprt and set relative to MSCVneo vector control. Three independent 
experiments were each performed in triplicate. Error bars indicate standard deviation. 
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These results indicate that the AF9-AF4 interaction mediated by the salt-bridge 
formed between AF9 residue D544 and the lysine at 764 of AF4 is required for efficient 
in vitro leukemic transformation. 
Genetic Complementation of MLL-AF9(D544R) Restores  
in vitro Transformation 
 
From the previous findings, we concluded that the AF9-AF4 interaction mediated 
by the AF9 D544 residues is required for transformation in vitro. We therefore 
hypothesized that coexpression of the MLL-AF9(D544R) mutant with an AF4 mutant 
substituting an aspartic acid for the positively charged lysine would restore the saline 
interaction and would rescue transformation ability in vitro.  
Since MLL-AF4 cannot transform bone marrow cells and we did not have access 
to full-length AF4 cDNA, we utilized the highly conserved AF4 homolog AF5 to further 
examine the requirement for the AF9-AF4/5 salt bridge interaction in leukemic 
transformation. Functionally, AF4 or AF5 are necessary to stabilize the pTEFb 
elongation complex, and can bind to AF9 or the AF9 homolog ENL. AF4 K764 is 
conserved in all AFF family members, and functionally corresponds to amino acid K717 
in AF5 (Figure 6B). Fluorescence anisotropy studies with fragments of AF9 and AF5 
indicate comparable affinity of binding between AF9 and AF5, and AF9 and AF4 (kD of 
0.2nM vs. 0.17nM, respectively)
240
.  
We hypothesized that reversing the positive charge at AF5 K717 to an aspartic 
acid with a negatively charged side chain would restore binding to the AF9(D544R) 
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mutant with a positive charge, thus rescuing colony forming ability and target gene 
expression. 
We first wanted to assess the ability of MLL-AF5(WT or K717D) to transform 
bone marrow progenitor cells. We hypothesized that MLL-AF5(WT) would transform 
cells, and that MLL-AF5(K717D) would not transform cells as it would not form a salt 
bridge with wild type AF9. As expected, MLL-AF5(WT) transduced bone marrow cells 
continually replate, whereas MLL-AF5(K717D) expressing cells show a reduction in 
colony formation (Figure 23A). This corresponds to a decrease in Meis1 expression in 
MLL-AF5(K717D)-expressing cells as compared to wild-type (Figure 23B). MLL-
AF5(WT) expressing cells exhibit greater than forty-fold increase in Meis1 expression 
over vector control at the end of week one whereas MLL-AF5(K717D) expressing cells 
express only a 27-fold increase. Interestingly, Hoxa9 expression was not altered in cells 
expressing the wild type or mutant fusion (Figure 23C). From these results, we conclude 
expression of the MLL-AF5(K717D) mutant in c-kit+ progenitor cells severely impairs 
the transformation ability of the MLL-AF5 fusion protein.  
To test whether genetic complementation of the AF9(D544R) mutation could 
rescue in vitro transformation ability, c-kit+ bone marrow progenitor cells were co-
transduced with YFP-tagged AF9(WT or D544R) and G418-resistant MLL-AF5(K717D) 
constructs. Cells were selected in G418 for one week before sorting for YFP+ cells to 
select for cells expressing both constructs.  
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Figure 23. MLL-AF5(K717D) Colony Assay and Hoxa9 and Meis1 Expression 
A 
 
 
 
 
 
 
 
B     
  C 
 
(A) Colony formation by c-kit+ progenitor cells expressing MLL-AF5(WT), MLL-
AF5(K717D) or vector control throughout three weeks of replating. Quantitative RT-
PCR of (B) Meis1 and (C) Hoxa9 expression in bone marrow cells isolated after one 
week in methylcellulose. Expression was normalized to Hprt and set relative to 
MSCVneo vector control. Three independent experiments were each performed in 
triplicate. Error bars indicate standard deviation. 
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Figure 24. Genetic Complementation of MLL-AF5(K717D) by AF9(D544R):  
Colony Assay and Expression of Hoxa9 and Meis1  
 
A 
 
 
 
 
 
 
 
B            C 
      
(A) Colony formation by c-kit+ progenitor cells co-expressing MLL-AF5(K717D) and 
AF9(WT or D544R). Quantitative RT-PCR of (B) Meis1 and (C) Hoxa9 expression in 
bone marrow cells isolated after one week in methylcellulose. Expression was normalized 
to Hprt and set relative to MSCVneo vector control. Three independent experiments were 
each performed in triplicate. Error bars indicate standard deviation. 
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While cells coexpressing MLL-AF5(K717D) and AF9(WT) are unable to serially 
replate in methylcellulose, coexpression of both MLL-AF5(K717D) and AF9(D544R) 
mutants restored colony formation ability (Figure 24A). This increase in colony 
formation corresponds to an increase in Meis1 expression compared to the MLL-
AF5(K717D)/AF9(WT) expressing cells (Figure 24B). Hoxa9 expression was 
significantly reduced in the cells co-expressing both mutant constructs (Figure 24C). This 
was a very surprising result and will be discussed further in the Discussion chapter.  
These results indicate that the electrostatic interaction between AF9 and AF4/AF5 
is necessary for in vitro leukemic transformation. Loss of the interaction through 
introduction of charge-repulsion in AF9 can be rescued by expression of a 
complementary charge in the AF5/AF4. 
AF9 Interaction with DOT1L is Required for in vitro Leukemic 
Transformation 
 
As previously mentioned, AF9 interacts with DOT1L at three regions: DOT1L 
628-653, 863-878 and 878-900. We hypothesized that mutation of aspartate D546 in AF9 
to arginine would reverse the charge at this location, preventing AF9 from interacting 
with DOT1L. Structural studies from the Bushweller lab indicate that this amino acid 
substitution reduces binding of AF9 to DOT1L at all three binding interfaces 
(unpublished data).  
To assess the relevance of the AF9-DOT1L interaction in leukemic 
transformation, c-kit+ bone marrow progenitor cells were retrovirally transduced with 
MLL-AF9 fusions, either wild type or D546R mutant. We predicted that cells expressing 
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the wild type fusion would serially replate for the duration of the experiment, whereas the 
MLL-AF9(D546R)-expressing cells would not. In cells expressing the wild type fusion 
gene, the AF9-DOT1L interaction would be maintained and Dot1l would be recruited via 
AF9 interaction to MLL target genes, leading to the deposition of the H3K79 methyl 
mark within the gene body of genes required for leukemic transformation. H3K79me2 is 
associated with expression of MLL fusion target genes, and loss of H3K79me2 is 
associated with a decrease in MLL target gene expression
212
. If the AF9-DOT1L 
interaction is inhibited in cells expressing MLL-AF9(D546R), then DOT1L cannot be 
recruited, and there would be a reduction in H3K79 methylation potentially coinciding 
with a decrease in expression of target genes necessary for transformation.  
Colony assays indicate that the MLL-AF9(WT) fusion-expressing cells 
continually replate for the duration of the experiment, whereas cells expressing the 
D546R mutant fusion have a statistically significant reduction in colony formation 
(Figure 25A). Both the colony and cell morphology were drastically different, with the 
MLL-AF9(WT) expressing bone marrow cells forming very tight, compact colonies 
comprised of mainly blast cells, while the MLL-AF(D546R) mutant expressing cells 
formed very few, very diffuse colonies composed of differentiated myeloid cells (Figure 
25B). To assure that both fusion proteins were equally expressed, western blot analysis 
was performed showing that MLL-AF9(WT) and (D546R) protein expression was 
detectable in bone marrow cells after week one (Figure 25C). 
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Figure 25. MLL-AF9(D546R) Colony Assay  
A 
 
 
 
 
 
 
 
B       C 
 
 
 
 
 
 
 
(A) Colony formation by c-kit+ progenitor cells expressing MLL-AF9(WT), MLL-
AF9(D546R) or vector control throughout four weeks of replating. The experiment was 
repeated eight times in duplicate. (B) Representative colony photographs at 4X and 10X 
magnification (top), and cell morphology by cytospin followed by Wright-Giemsa 
staining (bottom). (C) Western blot of bone marrow cells expressing empty vector, MLL-
AF9(WT) or MLL-AF9(D546R) isolated after one week.  
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If recruitment of DOT1L to MLL-AF9 target genes is required for successful 
elongation of transcripts, we would expect to see a decrease in Hoxa9 and Meis1 
transcript levels in cells expressing the D546R mutant. Quantitative reverse transcription 
PCR of bone marrow cells isolated after week one showed a significant reduction in 
Hoxa9 (Figure 26A) and Meis1 (Figure 26B) expression in MLL-AF9(D546R)-
expressing cells compared to MLL-AF9(WT).  
 
Figure 26. Hoxa9 and Meis1 Expression in MLL-AF9(D546R) Transduced Bone 
Marrow Progenitor Cells 
A            B 
 
   
 
Relative expression of MLL target genes Hoxa9 (A) and Meis1 (B) in bone marrow 
progenitor cells transduced with retroviruses encoding MLL-AF9(WT), MLL-
AF9(D546R) or empty vector following one week in methylcellulose. Expression was 
normalized to Hprt and set relative to MSCVneo vector control. Three independent 
experiments were each performed in triplicate. Error bars indicate standard deviation. 
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From these studies, we can conclude that disruption of the AF9-DOT1L 
interaction by charge reversal of AF9 aspartate residue 546 prevents in vitro leukemic 
transformation.  
MLL-AF9 Mutants E506R, I538A and K557E Do Not Alter the  
in vitro Leukemic Transformation Ability of the MLL-AF9 Oncogenic Fusion 
To test the functional effects of AF9 mutants E506R, I538A and K557E, all 
predicted to disrupt the structure of AF9 itself, c-kit+ bone marrow progenitors were 
retrovirally transduced with the empty MSCVneo vector which is not expected to 
transform cells, MLL-AF9(WT) which is known to transform progenitor cells, and the 
experimental mutants MLL-AF9(E506R), MLL-AF9(I538A) or MLL-AF9(K557E). If 
protein interactions mediated by secondary structure imposed by E506, I538, or K557 of 
AF9 are required for transformation, then mutation of these residues will result in a 
decrease in colony formation. 
There was no significant difference in the ability of MLL-AF9(WT) or mutant 
fusions to transform bone marrow progenitor cells over the course of the experiment 
(Figure 27A). Colony morphology was similar between all constructs, with the exception 
of cells expressing MLL-AF9(I538A) which exhibited a slightly more diffuse 
morphology and ragged edges compared to the tight, compact colonies formed by cells 
expressing the other constructs (Figure 26B). The individual cells within these colonies 
also appear slightly more differentiated than the MLL-AF9(WT) control cells (Figure 
26B).  
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Figure 27. MLL-AF9 Mutants E506R, I538A and K557E Colony Assay 
A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
(A) Colony formation by c-kit+ progenitor cells expressing MLL-AF9(WT), MLL-
AF9(E506R), MLL-AF9(I538A), MLL-AF9(K557E) or vector control throughout four 
weeks of replating. Experiments were conducted in duplicate five to six times. (B) 
Representative colony photographs at 4X and 10X magnification (top), and cell 
morphology by cytospin followed by Wright-Giemsa staining (bottom).  
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Target gene expression was also unaffected by expression of the mutants 
compared to wild type. Neither Hoxa9 nor Meis1 levels were statistically reduced in 
mutant-expressing cells compared to wild-type MLL-AF9-expressing cells (Figure 28).  
 
Figure 28. Hoxa9 and Meis1 Expression in MLL-AF9 Point Mutant-Transduced 
Bone Marrow Progenitor Cells 
A      B 
 
Relative expression of MLL target genes Hoxa9 (A) and Meis1 (B) in bone marrow 
progenitor cells transduced with retroviruses encoding MLL-AF9(WT), MLL-
AF9(E506R), MLL-AF9(I538A), MLL-AF9(K557E) or empty vector following one 
week in methylcellulose. Expression was normalized to Hprt and set relative to 
MSCVneo vector control. Three independent experiments were each performed in 
triplicate. Error bars indicate standard deviation. 
 
Based on these results, we conclude that residues E506, I538 and K557 are not 
critical for AF9 structure or mediating protein interactions required for in vitro leukemic 
transformation.  
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MLL-AF9 Fusion Proteins Resulting from Two Different Breakpoints in AF9 
Are Equal in Transforming Potential 
 
In MLL leukemia, the N-terminus of MLL breaks at the breakpoint cluster region 
and fuses with one of over 79 fusion partners. To date, five distinct breakpoint regions 
have been identified in AF9
154, 241, 243
, one of the most common MLL fusion partners. 
The most frequent breakpoint in AF9, occurring in approximately 75% of patients 
with t(9;11), results in a MLL fusion protein expressing amino acids 376-568 of AF9. 
The second most common breakpoint, occurring in 12% of patients, results in a shorter 
fragment of AF9 including amino acids 475-568
154, 241, 243
. Knock-in studies of MLL-
AF9(475-568) under the control of endogenous Mll regulatory elements results in AML 
development in mice, indicating that the 93 amino acids of AF9 present in this fusion are 
sufficient for transformation
147
. 
Because there is a one hundred amino acid difference between the fragment of 
AF9 most commonly found in patients and the construct that is used to study the function 
of the fusion in the laboratory, we sought to compare the constructs side-by-side in a 
colony formation assay. The presence or absence of additional residues could 
differentially modulate protein-protein interactions, and thus in vitro studies may not be 
an accurate representation of what is happening in vivo.  
To assess this, we transduced cells with retrovirus encoding MLL-AF9 fusions, 
either with the 192 C-terminal amino acids found in MLL patients (376-568) or the 
shorter 475-568 fragment, as well as a MSCVneo empty vector control. There were no 
statistically significant changes in colony formation during the first three rounds of 
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plating. By week four, the shorter fusion gained a statistically significant advantage 
(Figure 30A). There were no detectable changes in colony or cell morphology (Figure 
30B), and was there no significant change in Hoxa9 or Meis1 expression in cells 
expressing the MLL-AF9(376-568) or MLL-AF9(475-568) fusion (Figure 29A).  
 
Figure 29. MLL-AF9(376-568) and (475-568) Colony Assay 
A 
 
 
 
 
 
 
B   
 
(A) Colony formation by c-kit+ progenitor 
cells expressing wild-type MLL-AF9(376-
568), MLL-AF9(475-568) or vector control 
throughout four weeks of replating. (B) 
Representative colony photographs at 4X 
and 10X magnification (top), and cell 
morphology by cytospin followed by 
Wright-Giemsa staining (bottom).  
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Figure 30. Hoxa9 and Meis1 Expression in Bone Marrow Cells Transduced with 
MLL-AF9(376-568) or (475-568) 
A 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
Relative expression of MLL target genes Hoxa9 (A) and Meis1 (B) in bone marrow 
progenitor cells transduced with retroviruses encoding wild-type MLL-AF9(376-568), 
MLL-AF9(475-568) or empty vector following one week in methylcellulose. Expression 
was normalized to Hprt and set relative to MSCVneo vector control. Three independent 
experiments were each performed in triplicate. Error bars indicate standard deviation. 
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From these results, we conclude that there is no significant difference in the 
transformation ability of the MLL-AF9 fusion resulting from two different breakpoint 
regions of AF9 at weeks one, two and three. There is a significant increase in colony 
formation in cells expressing MLL-AF9(475-568) which will be further discussed. 
Productive Transcription Elongation is Altered in  
MLL-AF9(D544R and D546R)-expressing Bone Marrow Cells,  
but not MLL-AF9 Mutants E506R, I538A or K557E-expressing Cells 
 
We hypothesized that specific point mutations in the C-terminus of AF9 would 
disrupt binding to one or more of the proteins known to interact with AF9.  AF4, DOT1L 
and CBX8 have all been identified as members of P-TEFb-associated complexes. To 
examine whether these point mutations affect productive elongation, we used primers 
designed to amplify four regions of the Meis1 gene. The Meis1 genomic region is 
approximately 138 kilobases (kb), encoding a 3.3kb mRNA transcript containing 12 
exons. We hypothesized that the proper and stable assembly of the P-TEFb elongation 
complex is required for productive elongation of this long gene. Mutations in AF9 that 
disrupt binding to AF4, DOT1L or CBX8 would disrupt the formation or function of the 
Super Elongation Complex, and would prevent productive elongation as measured by 
quantitiative real-time PCR using primer sets that span the length of the transcript.  
Primer sets were used to assess transcription of four regions of Meis1 in MLL-
AF9 wild type or mutant-transduced bone marrow cells after one week in methycellulose. 
One primer set was located in exon 1, 21 nucleotides after the transcription start site 
(Figure 31A). The second primer set spanned exons 6 and 7, the third primer set spanned 
exons 8 and 9, and the final primer set was located in the last exon of Meis1.   
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Figure 31. Transcriptional Elongation of Meis1 in MLL-AF9 Wild-Type or Mutant 
Transformed Bone Marrow Progenitor Cells 
 
 
A 
 
B  
 
 
 
 
 
 
 
 
 
 
 
A) Meis1 locus encoding 12 exons in a 138 kb region (UCSC Genome Browser). Primer 
sets were designed to amplify regions within exon 1, exons 6/7, exons 8/9 or exon 12. B) 
Quantitative RT-PCR for expression of Meis1 with primers amplifying exon 1, exon 6/7, 
exon 8/9 or exon 12. Expression was normalized to Gapdh and set relative to MLL-
AF9(WT). Three independent experiments were each performed in triplicate. Error bars 
indicate standard error. 
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If AF9 interaction with AF4, DOT1L, or CBX8 is required for RNA polymerase 
II to successfully track along the length of the Meis1 gene, then expression of mutants 
disrupting these interactions would result in reduced expression of Meis1 at the 3’ end of 
the gene compared to the 5’ end.  
Bone marrow cells transduced with MLL-AF9(D544R) or (D546R) exhibit 
decreased expression of Meis1 when amplified using primers for exon 1 compared to 
MLL-AF9(WT)-transduced cells. MLL-AF9 mutants E506R, I538A, and K557E show a 
modest reduction in Meis1 expression using this primer set. Levels of Meis1 remain low 
in MLL-AF9(D544R or D546R) expressing cells when using primers for exon 6/7, exon 
8/9 and exon 12 compared to wild type. Expression levels of Meis1 as measured by the 
exon 6/7 primers indicate comparable levels of expression in the E506R, I538A and 
K557E mutants compared to MLL-AF9(WT) expressing cells. Analyzing transcript 
levels further down the Meis1 gene with the exon 8/9 primer set indicates a modest 
reduction in cells expressing MLL-AF9(E506R) whereas the I538A and K557E mutants 
are similar to wild type. Expression at the 3’ end of Meis1 using the exon 12 primer set 
indicates no change in expression in the E506R, I538A or K557E mutants compared to 
wild type.  
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CHAPTER FIVE 
DISCUSSION 
Aim One: The Role of Af9 in Hematopoiesis 
 In the first aim of my project, I sought to examine the role of Af9 in 
hematopoietic development, and to determine which protein interactions mediated by Af9 
were required for normal hematopoiesis. As mentioned previously, the C-terminal AHD 
of AF9 interacts with at least four proteins: AF4, DOT1L, CBX8 and BCoR. In 
collaboration with the laboratory of Dr. Bushweller at the University of Virginia, specific 
point mutations were identified that were predicted to disrupt binding to one partner 
protein while maintaining binding with the others. Using these AF9 mutants, we sought 
to elucidate which AF9-mediated protein interactions are required for proper 
hematopoietic development. 
 All point mutations were readily expressed, with mutants D544R, I538A, S565A 
and S565D expressing similarly to wild type AF9. The mutants D546R, E506R, K557E 
and L562A were expressed at levels slightly less than wild-type. While this reduction is 
minimal, it is not unexpected considering the location of these mutations within the 
structured AF9 protein.  
Residues E506, K557 and L562 are all present in alpha helices one or three of 
AF9 (Figure 8). The formation of alpha helical structure is highly sequence-dependent, 
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and disruption of the structure could result in misfolding and potential degradation. The 
D546 residue was identified as mediating a potential salt bridge interaction with DOT1L.  
It is possible that AF9 must bind to another protein to adopt structure and prevent 
degradation, and that mutation of this residue may inhibit the stabilizing interaction. The 
physiological role of intrinsically disordered proteins (IDPs) is not well understood, and 
we do not know if other proteins, such as heat shock proteins, are required for the 
stabilization of proteins like AF9 in vivo.  
AF9(D546R) Interaction with AF4 and DOT1L 
 As part of her dissertation studies, Dr. Bhavna Malik examined the interaction of 
AF9 point mutants with AF4, DOT1L and CBX8. She co-expressed the C-terminal 194 
amino acids of AF9 (376-568), wild type or mutants D544R, E506R, K557E, L562A, 
S565A or S565D with AF4, DOT1L or CBX8. The D546R mutation was later identified 
as a potential disruptor of binding between AF9 and DOT1L, and so I examined the 
interaction of AF9 wild type or D546R mutant with AF4 and DOT1L by 
coimmunoprecipitation.   
The C-terminal fragment of AF9 most often found in patients with MLL-AF9 
rearrangement (376-568) or a smaller fragment (470-568) that is sufficient to transform 
bone marrow cells and induce leukemia in a MLL-AF9 knock-in mouse model was 
coexpressed
147
 with full length Dot1l, Dot1l 479-659, or DOT1L 828-1095. As 
mentioned previously, the hydrophobic motif present in all AF9 binding partners (Figure 
32) is repeated three times in the DOT1L protein. The 479-659 construct encompasses 
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one site, whereas the 828-1095 fragment includes the two C-terminal hydrophobic motifs 
(referred to as sites two and three, Figure 33).  
 
Figure 32. Conservation of a Hydrophobic Motif in the AF9 Interacting Regions of 
AF4/AF5q31, DOT1L, BCoR and CBX8 
 
Conserved LxVxIxL/VxxL/V/I hydrophobic motif in AF9 interacting partners as 
identified by Leach et al.  
 
Coimmunoprecipitation studies show that expression of the AF9(D546R) mutant, 
either in the context of the larger AF9 C-terminal fragment (376-568) or the shorter 
fragment (470-568), results in reduced binding to full length Dot1l and to the fragment of 
DOT1L encompassing the two C-terminal hydrophobic motifs (Figure 33). These results 
indicate that the binding between AF9 and DOT1L is mediated in part by AF9 residue 
D546. 
Binding between AF9(376-568) and a Dot1l fragment including the site one 
hydrophobic motif was not significantly affected by the D546R mutant, whereas 
expression of AF9(D546R) in the context of the shorter AF9 fragment resulted in an 
increase in binding to the Dot1l fragment encompassing site one (Figure 33). The 
increase in binding between the shorter fragment of AF9(D546R) and Dot1l(479-659), 
which is also a trend but statistically insignificant with the larger AF9(D546R) fragment, 
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maybe be a result of different affinity binding between Dot1l site 1 versus sites 2 and 3. 
Higher-affinity interactions may be more drastically affected by the introduction of a 
mutation within the region, whereas lower affinity interactions may not be affected. Why 
the D546R mutation in the context of the short AF9 fragment enhances binding over wild 
type AF9 could be a result of enhanced affinity of the D546R mutant to a heat shock 
protein or other protein necessary to stabilize AF9, which is reduced upon inclusion of 
the additional amino acids in the larger fragment of AF9.  
 
Figure 33. AF9(WT or D546R) Binding to DOT1L 
 
Summary of immunoprecipitation studies with DOT1L full length, 479-659 or 828-1095 
and AF9(WT or D546R) fragments 470-568 and 376-568. Repeated hydrophobic motifs 
shown in Figure 32 are termed sites 1, 2 and 3. 
 
 
Indeed, work by Lin et al showed that AF9 interacts with HSP90 and associated 
co-chaperones HSP70 and p60/HOP
244
. The AF9-HSP90 interaction was identified using 
amino acids 475-568 of AF9, the same region of AF9 that interacts with AF4, DOT1L, 
CBX8 and BCoR. As discussed, structural studies suggest that AF9 binding to one of 
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these four partner proteins is mutually exclusive. It would be informative to compare 
binding of AF9 and HSP90 by HSQC spectral analysis to the HSQC spectra of AF9 in 
complex with AF4/DOT1L/CBX8/BCoR. If all five AF9-interacting proteins bind to the 
same residues of AF9 and induce the same structure, we would envision a sequential 
binding model in which AF9 is translated in the cytoplasm, is transported into the nucleus 
by through association with HSP90, and then is released by HSP90 to bind AF4, DOT1L, 
CBX8 or BCoR.  
Expression of the D546R mutant does not alter the binding to AF4. Coexpression 
of the same AF9 fragments (376-568 or 470-568), wild type or mutant, with two 
fragments of AF4 encompassing either the minimal AF9 interaction region (755-777) or a 
slightly larger region including the AF9 binding domain (647-871), did not result in any 
changes in binding between AF9 and AF4 (Figure 34). The exception to these results is 
seen upon coexpression of the shorter 470-568 AF9(D546R) fragment with the minimal 
AF4 fragment 755-777, which resulted in a statistically significant increase in binding. 
As with binding to Dot1l, it appears that expression of the mutant in the 98 amino acid 
fragment of AF9, but not the 192 amino acid fragment, enhances binding with the 
minimal fragment of AF4 (or Dot1l, as discussed above). It may be more energetically 
favorable for smaller proteins to interact
245
. Smaller proteins could have a lower degree 
of entropy, and thus require lower activation energy for the conformational change to 
occur upon binding to a partner protein. The electrostatic charges present also alter 
entropy, and this could explain why the mutant D546R binds better to the minimal 
fragment of AF9 compared to wild type AF9. Biochemical analyses would have to be 
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conducted to determine the thermodynamics of binding between the longer and short 
fragments of AF9 (wild type or D546R) with AF4 and DOT1L fragments.  
 
Figure 34. AF9(WT or D546R) Binding to AF4 
 
Summary of immunoprecipitation studies with AF4 fragments 755-777 and 647-871 and 
AF9(WT or D546R) fragments 470-568 and 376-568.  
 
In all of these coimmunoprecipitation studies, I overexpressed all proteins, either 
full length or fragments of proteins. Coimmunoprecipitation of endogenous proteins may 
show different results, as the additional domains in these proteins may also mediate 
binding of AF9 to a partner protein. However, the fragments examined here are the amino 
acids of AF9 present in MLL fusion proteins, and thus these studies are relevant in 
examining the role of these protein interactions in MLL-AF9 leukemias.   
Overall, these results highlight the importance of the AF9 D546 residue in 
mediating interaction between AF9 and DOT1L. The structural studies from the 
Bushweller lab identified a conserved hydrophobic motif present in all AF9 binding 
partners, and suggested that AF9 binding to any of the four proteins AF4, DOT1L, CBX8 
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or BCoR is mediated through this motif. However, the selective disruption of binding to 
DOT1L but not AF4 with the AF9(D546R) residue indicates that interaction between 
these two proteins is mediated, at least partially, through a region distinct from the 
hydrophobic motif.  
Of note, coexpression of AF9(D546R) with any of the four fragments used in 
these immunoprecipitation experiments resulted in decreased detectable AF9(D546R) 
protein in the input compared to wild-type, despite transfecting the same amount of 
DNA. This result was reproducible and was evident even when the amount of plasmid 
DNA transfected was adjusted in an attempt to normalize the input amounts, suggesting 
that AF9(D546R), in the context of the larger 376-568 or the shorter 470-568 fragment, is 
less stable than the same fragments of wild type AF9. This mutant was also expressed at 
a slightly lower level than wild type in the context of the full length protein as seen in 
Figure 8B. As discussed, this mutant may be less stable than wild type AF9 as a result of 
decreased affinity binding to a protein required for stabilization such as a heat shock 
protein. A recent study has also shown that the intrinsically disordered C-terminus of 
DNA glycosylase NEIL1 is stabilized through intramolecular, primarily electrostatic, 
interactions
246
. It is possible that the D546R mutation prevents potential intramolecular 
interactions from occurring, and thus the protein is degraded. 
As reviewed by Dyson and Wright, many transcriptional regulators are 
intrinsically disordered proteins (IDPs)
247
. The process of coupled folding and binding, in 
which an unstructured protein (or unstructured region of a protein) adopts a structure 
upon interaction with a target, can allow for rapid and promiscuous protein-protein 
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interaction. In the case of AF9, the ability to bind both activators and repressors could 
allow for differential regulation of gene targets depending on other, yet unknown signals 
in the cell. As disordered proteins are relatively unstable, they could be degraded without 
chaperoning by another protein. Whether AF9 is complexed to other proteins in vivo that 
promote its stability is unknown but would be an interesting question to pursue.  
Of the studies published on the complex components of the SEC, only the Biswas 
group identified proteins by biochemical purification of AF9
6
. The authors overexpressed 
FLAG-HA-tagged AF9 and examined associated proteins. We could interrogate 
additional AF9-interacting proteins, and determine which of the proteins are required for 
AF9 stability by knocking down candidates proteins and examining the levels of AF9.   
The Role of Af9 in Hematopoietic Differentiation 
 To examine the role of Af9 in in vitro hematopoietic differentiation, I isolated c-
kit+ progenitor cells from the bone marrow of Af9
fl/fl Cre/+
 mice and plated these cells in 
semi-solid media to promote the differentiation to erythroid, myeloid or megakaryocytic 
lineages in the presence or absence of 4-OHT. We hypothesized that loss of Af9 upon 4-
OHT treatment would result in a loss of erythroid and megakaryocyte colony formation, 
with a possible compensatory increase in myeloid lineage differentiation. However, 
results show that Af9 is not required for in vitro differentiation to erythroid, 
megakaryocyte, or myeloid lineages under the conditions tested here. 
Erythroid Lineage Differentiation 
While the number of erythroid colonies formed was not different in the presence 
or absence of Af9, there is a significant decrease in the mean fluorescence intensity (MFI) 
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of CD71 expression in cells null for Af9 compared to the ethanol control treated cells. 
CD71 is marker of early erythroid precursor cells, so the decrease in MFI suggests that 
while these cells are still expressing CD71, the level of expression is reduced upon loss of 
Af9. Af9 may therefore play a role in the differentiation to erythroid precursor cells, but 
this reduction is either not sufficient to alter overall colony formation ability, or it is 
occurring in only a subset of cells that are not required for colony formation. There was 
no change in Ter119 expression, and expression overall is low, which is consistent with 
previous reports that Ter119 is expressed later in erythroid differentiation than the time 
points examined here. 
Examination of myeloid markers CD41, Gr-1 and CD11b in cells plated for 
erythroid lineage differentiation did not indicate significant differences in cells 
expressing or lacking Af9. CD41 levels are low in both control and 4-OHT-treated cells, 
which is expected as CD41 is expressed on the surface of platelets and megakaryocytes, 
both mature cell types that would not be present at this early four day time point. We 
would expect to see CD41 expression, as well as expression of other myeloid surface 
markers, appear by twelve days in culture. Levels of Gr-1 and CD11b are elevated in 
these erythroid cytokine-cultured bone marrow cells, with an average MFI of 
approximately 2500 relative units for Gr-1 and CD11b, but levels are not as high as in 
Af9
fl/fl cre/+
 plated for myeloid differentiation in the presence or absence of 4-OHT with 
average MFIs of 3500 and 4000 for Gr-1 and CD11b, respectively. This indicates that 
despite being cultured in the presence of cytokines to promote erythroid lineage 
commitment, there is at least a subset of cells that differentiate to the myeloid lineage. 
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Interestingly, while the differences in MFI between ethanol and 4-OHT treated cells is 
not significant, there is a trend toward increased myeloid marker expression in cells 
lacking Af9. This would support our hypothesis that a loss of Af9 results in a loss of 
erythroid lineage commitment (decreased MFI of CD71) with concurrent compensation 
by myeloid lineage differentiation (increased MFI of Gr-1 and CD11b). Additional 
replicates may elucidate whether this is a real effect, or if it is just variability between 
experiments.  
Myeloid Lineage Differentiation 
There was no significant difference in myeloid colony formation in cells 
expressing or lacking Af9. Examination of surface marker expression does not indicate 
any statistically significant differences in the percent of positive cells or the mean 
fluorescence intensity of either myeloid (CD41, Gr-1, CD11b) or erythroid (CD71, 
Ter119) expression. Compared to cells plated for erythroid lineage differentiation, these 
myeloid-directed cells express higher levels of CD41, Gr-1 and CD11b. In terms of 
erythroid marker expression in these cells, we do see expression of CD71 in both control 
and 4-OHT-treated cells, but the average MFI for these cells is less than half of that in 
cells plated for erythroid lineage differentiation. Ter119 expression is elevated in the 
myeloid-cultured cells as compared to cells cultured in erythroid cytokines. This is likely 
a result of the later time point at which these cells were harvested, as Ter119 is expressed 
later in erythroid development than the time point at which the erythroid cultured cells 
were harvested.  
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The presence of erythroid markers on these cells suggests that at least a subset of 
cells are able to differentiate toward the erythroid lineage and acquire erythroid lineage 
markers, despite being cultured in the presence of cytokines to promote myeloid lineage 
differentiation.  This may partially be due to the c-kit+ selection of murine bone marrow 
cells for plating in these assays. C-kit is expressed on HSCs as well as committed 
progenitor cells, including the MEP and the GMP. Using this protocol, the cells plated 
were a heterogeneous population of stem and progenitor cells, which would express 
different surface markers depending on the stage of differentiation at the time of 
isolation. I could examine differences in surface marker expression and colony formation 
using lineage (Lin)-depleted cells, or isolating Lin-Sca1+c-kit+ cells (LSK) which enrich 
for HSCs.  
Megakaryocytic Lineage Differentiation 
As loss of Af9 does not alter erythroid or myeloid colony formation, it also does 
not alter megakaryocyte differentiation as detected by acetylcholinesterase staining. The 
method that I used to differentiate and quantify megakaryocyte differentiation does not 
allow for surface marker analysis, but based on colony formation alone, Af9 is not 
required for megakaryocytic development. Consistent with these in vitro studies on the 
role of Af9 in hematopoietic lineage differentiation, I did not see alterations in the levels 
of mRNA encoding erythroid or myeloid transcription factors in the bone marrow of 
Af9
fl/fl
 or Af9 
fl/fl Cre/+
 mice treated with tamoxifen. These results combined suggest that 
Af9 is not a master regulator of murine erythroid/megakaryocytic lineage commitment.  
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Re-expression of AF9 in Af9-null Bone Marrow Progenitor Cells 
In addition to examining the role of Af9 in hematopoietic development, I 
proposed to examine the role of specific Af9-partner protein interactions in hematopoietic 
development by re-expressing full length AF9 point mutants in Af9
fl/fl Cre/+
 c-kit+ bone 
marrow cells. We originally hypothesized that loss of Af9 would result in a loss of 
erythroid and megakaryocytic colony formation that could be rescued by re-expression of 
wild type AF9. These experiments were the first I conducted before obtaining the results 
described above, but these experiments support the findings I reported.  
Vector transduced cells formed the same number of colonies when plated for 
erythroid lineage commitment in the presence or absence of 4-OHT, just as untransduced 
cells formed the same number of colonies with or without 4-OHT treatment. Re-
expression of wild-type AF9 or AF9 mutants S565A or S565D did not alter colony 
forming ability. While there was no phenotype to rescue in this experiment, since loss of 
Af9 did not alter colony formation, these results also suggest that overexpression of AF9 
does not alter colony formation. Overexpression of AF9 in CD34+ CD38- human cord 
blood resulted in an increase in the E/Meg compartment
159
, whereas here I saw no change 
upon retroviral transduction of AF9 in c-kit+ cells. I did not compare the levels of 
overexpressed AF9 with endogenous levels of Af9, but I would expect that high-titer 
retroviral transduction of AF9 under the control of the Murine Stem Cell Virus promoter 
would result in very high expression of AF9 in these cells, likely over that of endogenous 
levels and therefore comparable to an overexpression system.  
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In the study by Pina and colleagues, lentiviral knockdown of AF9 in human cord 
blood resulted in a loss of erythroid progenitor colony formation. Here, complete genetic 
loss of Af9 in murine c-kit+ bone marrow cells as detected by genotyping PCR does not 
result in decreased colony formation. Overexpression of AF9 in human CD34+CD38- 
cells caused an expansion of erythroid/megakaryocytic cells, but re-expression of AF9 in 
Af9
-/- 
c-kit+ cells does not alter colony formation. These results indicate that Af9 does not 
play a role in hematopoietic differentiation in this system. 
Af9 is Not a Critical Regulator of Adult Murine Hematopoiesis 
The results described refute our hypothesis that Af9 is a critical regulator of 
erythroid and megakaryocytic lineage commitment. This is contrary to the study by Pina 
and colleagues
159
, but may align with the report of hematopoiesis in the constitutive Af9 
knockout mouse. Collins et al reported that hematopoiesis was normal
158
, but no data 
were provided so it is impossible to compare our findings. 
The discrepancy between our results and that of the Pina study could be a result of 
differences in human versus murine hematopoiesis. Those authors used human cord 
blood cells to examine the role of AF9 whereas we utilized a conditional Af9 knockout 
mouse. There are many similarities in hematopoietic development between mice and 
humans, but there are also many differences. A recent study compared the transcriptional 
profile of early, intermediate and late erythroid progenitor cells in humans and mice. 
These researchers found that at each stage of differentation, the top 500 most highly 
expressed genes in human were orthologous to only 30% of the top 500 most highly 
expressed genes in mice
248
. Phenotypically, erythropoiesis was not altered, but these 
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results suggest that the transcriptional regulation of this process is highly divergent 
between humans and mice. This is something to keep in mind when looking to translate 
studies of mouse cells to the human system. The use of humanized mouse models, in 
which human hematopoietic cells are grafted into mice, may provide a more translational 
approach to studying hematopoiesis
249
.  
 Of note in regard to human hematopoiesis, global transcriptome analysis showed 
that AF9 expression is highest in the HSC, and levels decrease by half by the CMP 
stage
159
. If AF9 is a critical player in erythroid/megakaryocytic development, we would 
expect high levels throughout differentiation to the CMP and MEP.  However, this may 
support the Adolfsson model of hematopoiesis in which the MEP arises directed from the 
ST-HSC without transit through a CMP stage
15
. High levels of AF9 could support 
differentiation directly to the erythroid/megakaryocytic lineage from the ST-HSC, 
playing a role in earlier hematopoietic lineage commitment rather than terminal 
differentiation from a later progenitor.  
The source of the cells in which the role of Af9 was assessed may also play an 
important role. The Pina et al study isolated human CD34+CD38- cord blood cells
159
. We 
isolated murine c-kit+ bone marrow cells. In addition to isolating cells from different 
species, there are several differences in cord blood versus bone marrow stem cells. 
Patients transplanted with umbilical cord blood stem cells exhibit a low severity Graft vs. 
Host Disease (GVHD) compared to patients transplanted with bone marrow stem cells, 
although the patients receiving cord blood stem cells had a delayed engraftment
250
. 
Umbilical cord blood also contains the largest percentage of CD34+CD38- stem cells 
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compared to bone marrow or granulocyte colony-stimulating factor-mobilized peripheral 
blood stem cells
251, 252
. A study published by the Staal lab directly compared the 
expression profile of CD34+ cells isolated from umbilical cord blood and bone marrow, 
and identified 51 differentially expressed genes
253
. These genes were involved in 
proliferation, apoptosis, differentiation and engraftment capacity, confirming that stem 
cells isolated from different sources may have different characteristics.  
Another reason we did not see an effect on hematopoietic differentiation in vitro 
upon loss of Af9 may be a result of compensation by Af9 homolog Enl. As previously 
discussed, Af9 and Enl are highly homologous in their N and C-terminal regions. While 
these proteins are generally expressed in different tissues (discussed in Chapter One), it is 
possible that loss of Af9 in hematopoietic cells could result in a compensatory increase in 
Enl expression.  
To test this hypothesis, we could transduce Af9
fl/fl Cre/+
 mice with control 
(scrambled) or Enl shRNAs and plate the cells with or without 4-OHT in cytokines for 
erythroid, myeloid or megakaryocytic lineage commitment. If Enl is compensating for 
loss of Af9 as a regulator of hematopoietic differentiation, then genetic loss of Af9 
combined with shRNA-mediated knockdown of Enl may result in a loss of E/Meg 
colonies, as we initially hypothesized. In addition to examining hematopoietic colony 
formation, we could also examine surface marker expression and expression of 
hematopoietic lineage transcription factors as previously described.  
Whether AF9 and ENL play redundant or distinct roles within the cell is an 
interesting question. The proteins are highly homologous, especially in the N and C 
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terminal regions. AF9 and ENL are interchangeable members of the SEC, however they 
show distinct tissue expression patterns. In leukemia, the MLL-AF9 fusion protein results 
in a myeloid leukemia, whereas MLL-ENL fusion proteins often present as biphenotypic 
or lymphoid leukemia. If the proteins are so similar, and the fusion partner dictates the 
leukemic phenotype in MLL recombined leukemias, we would expect MLL-AF9 and 
MLL-ENL to transform cells similarly. Further studies elucidating the role of these two 
homologs is needed to identify their function in both hematopoiesis and leukemogenesis. 
Aim Two: The Role of AF9 in Leukemogenesis 
In my second aim, I sought to determine whether protein interactions mediated by 
the C-terminus of AF9 in the context of the MLL-AF9 fusion protein were necessary for 
in vitro leukemic transformation. The first mutant fusion gene examined was MLL-
AF9(D544R). As previously described, this mutation is predicted to disrupt an 
electrostatic interaction mediated by AF9 aspartic acid D544 and AF4 lysine 764 by 
reversing the charge at the AF9 544 residue. Coimmunoprecipitation studies using the 
376-568 amino acid C-terminal fragment of AF9 shows that expression of the D544R 
mutant reduces binding to AF4 compared to wild type, while maintaining interaction with 
DOT1L and CBX8
240
.  
MLL-AF9(D544R) Mutation Decreases Leukemic Transformation Potential 
To assess the function of this mutation in vitro, I transduced c-kit+ bone marrow 
cells with retrovirus encoding the MLL-AF9 fusion, either wild type or D544R. Colony 
formation was significantly reduced in cells expressing the MLL-AF9(D544R) fusion 
compared to wild-type, and the colonies that did form were smaller and more diffuse than 
143 
 
 
 
the wild type control. The cells within these colonies were more differentiated than the 
blast-like MLL-AF9(WT) expressing cells. Expression of MLL target genes Hoxa9 and 
Meis1 were also reduced in these cells at the end of week one. Both Hoxa9 and Meis1 are 
shown to be upregulated in MLL leukemias, and are required for transformation
254
. 
The results indicate that the AF9 interaction with AF4 specifically is required for 
in vitro leukemic transformation. Because the D544R mutant was shown by 
coimmunoprecipitation studies to maintain interaction with DOT1L and CBX8
240
, this 
suggests that the selective loss of interaction with AF4 is responsible for decreased 
transformation ability. 
These findings are further supported by binding data from the Bushweller lab, 
indicating that the dissociation constant between fragments of wild type AF9 and AF4 is 
0.17nM. Mutation of wild type AF9 to D544R results in a decrease in binding affinity to 
a kD of 9.6nM. Charge reversal of AF4 lysine residue K717 to positively charged 
asparagine restored binding to AF9(D544R) in colocalization studies conducted by Dr. 
Ming-jin Chang, supporting the hypothesis that  this salt bridge interaction is required for 
binding between AF9 and AF4
240
.  
Transformation is Rescued by Restoration of the AF4-AF9 Salt Bridge Interaction 
 We hypothesized that like the colocalization studies, complementary charge 
reversal of AF4 K764 to glutamate could rescue the loss of colony formation by the 
MLL-AF9(D544R) mutant-expressing cells. The original experimental design was to 
coexpress MLL-AF9(D544R) with AF4(WT or K764), but overexpression of AF4 was 
toxic to cells. MLL-AF4 does not transform progenitor cells
7
, so coexpression of MLL-
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AF4(WT or K764E) with AF9(WT or D544R) was not an option. We therefore utilized 
the AF4 homolog AF5q31 which, as shown in Figure 6B, is highly homologous to AF4. 
AF4 K764 is equivalent to AF5q31 K717, a conserved lysine in members of the AF4 
family that mediates the salt bridge interaction with AF9. We do not have access to the 
AF5 clone, and thus our experimental design was to coexpress MLL-AF5q31(WT or 
K717D) with full length AF9 (WT or D544R).  
 We confirmed the findings by Yokoyama that MLL-AF5 efficiently transforms 
bone marrow progenitor cells. Expression of MLL-AF5(K717D) results in reduced 
colony forming ability, supporting our model that the charge reversal introduced by this 
amino acid substitution prevents interaction with AF9 at amino acid D544. We also 
examined MLL target gene expression in these cells and saw a significant reduction in 
Meis1 expression in MLL-AF5(K717D)-expressing cells compared to wild type. 
Interestingly, Hoxa9 was not altered between these mutants. 
As far as I am aware, there have been no studies published showing differential 
expression of Hoxa9 and Meis1 in colony assays with MLL fusion proteins. Hoxa9 and 
Meis1 are specifically upregulated in ALL cases with MLL translocations compared to 
non-MLL recombined ALLs
255, 256
. Additionally, transcriptional analysis of Hoxa9 and 
Meis1 show upregulation of both genes in 13 of 14 examined ALL cases with MLL-AF4 
translocations, and eight of eight AML patients with MLL recombination
257
. A previous 
study showed that expression of Hoxa9 or Meis1 alone could not transform bone marrow 
cells and cause leukemia, but coexpression of Hoxa9 and Meis1 resulted in leukemia 
development and death in mice with a median latency of 67 days
258
. Based on these 
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findings, we expected to see an increase in Hoxa9 and Meis1 in cells expressing MLL-
AF5(WT), with a decrease in expression of both genes in cells expressing MLL-
AF5(K717D), correlating with colony formation. However, that was not what we saw.  
The N-terminus of MLL that is present in the fusion proteins directs the fusion to 
gene targets, and it is thought that the C-terminal fusion partner provides a gain-of-
function that results in aberrant expression of gene targets. I expect that both MLL-AF5 
wild type and K717D are both being recruited to gene targets, and that could be 
confirmed with chromatin immunoprecipitation studies. It is therefore likely that the 
additional components being recruited to these loci are either different, or are 
differentially required, between MLL-AF5 wild type and mutant expressing cells. 
In terms of the general recruitment to target loci, AF5 and AF4 interchangeably 
participate in the P-TEFb elongation complex. Both proteins bind directly to Cyclin T1 or 
T2 of the P-TEFb dimer; residues 1-308 of AF4 and 1-300 of AF5 have been shown to 
mediate this interaction
183, 188
. In the MLL fusion protein, the fusion point within AF4 
occurs around amino acid 360, thus the MLL-AF4 fusion does not retain Cyclin T1 
binding. AF4 and family members homo- and hetero-dimerize with other members of the 
family via their C-terminal homology domain, with a preference for heterodimerization
7
. 
Therefore, in the example of the experiment discussed here, MLL recruits the MLL-AF5 
fusion to the target gene. AF5 then homodimerizes with full length AF5 or 
heterodimerizes with AF4. The recruited AF4/5 can then bind to Cyclin T1 that interacts 
with CDK9 to form P-TEFb, which binds to RNA Pol II. The recruited AF4/5, as well as 
the portion of AF5 in the MLL fusion, can also bind to AF9/ENL through the minimal 
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AF9/ENL interaction domain conserved in these proteins. AF9/ENL stabilize the P-TEFb 
elongation complex and aid in its processivity during transcription.  
The presence of the AF5(K717D) mutation disrupts the salt bridge interaction 
between AF5 and AF9, and that would occur regardless of the loci to which it is targeted. 
Therefore, the most likely explanation is that the proper formation of this SEC is required 
at Meis1 to a greater degree than it is at Hoxa9. Meis1 is a much longer gene than Hoxa9, 
encompassing a genomic region of 138 kilobases compared to only 5.6 kilobases for 
Hoxa9. As RNA polymerase transcribes a gene, it often stalls and requires the 
components of the SEC to overcome the stall and continue to process along the template 
DNA. Without the proper formation of this complex, the Polymerase may be unable to 
complete transcription of Meis1, whereas the association with SEC components may be 
less necessary at Hoxa9.  
In regard to the restoration of the salt bridge interaction by charge reversal on 
both AF9 and AF5, coexpression of MLL-AF5(K717D) with AF9(WT) did not transform 
bone marrow progenitor cells, whereas coexpression of both mutants MLL-AF5(K717D) 
with AF9(D544R) resulted in increased colony formation through the third week of 
replating. Corresponding to this serial replating ability was an increase in Meis1 
expression compared to the MLL-AF5(K717D)  + AF9(WT) expressing cells. Hoxa9 
expression again seems to be differentially regulated from Meis1 expression in this 
system. The hypothesis described above is applicable in this example as well, although I 
would not necessarily expect to see a decrease in Hoxa9 expression in cells expressing 
both mutants compared to expressing MLL-AF5(K717D) + AF9(WT); if proper 
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formation of the SEC is not required for elongation of Hoxa9, I would expect to see no 
changes in the levels.  
A possible explanation for the decrease in Hoxa9 expression in cells expressing 
both MLL-AF5(K717D) and AF9(D544R) compared to cells expressing MLL-
AF5(K717D) and AF9(WT) may be a result of simply overexpressing two mutants that 
can bind to endogenous SEC proteins required for transcription at Hoxa9. Perhaps 
overexpression of both an AF5 mutant and an AF9 mutant act in a dominant negative 
manner, binding to endogenous proteins AF4/AF5, AF9/ENL, or DOT1L, and preventing 
formation of the SEC that may be required for the high levels of transcription occurring 
at the Hoxa9 locus.  
These results are perplexing, but the presence of the mutations was verified in the 
cDNA used in these samples. RNA was isolated from three independent experiments and 
the results were consistent. ChIP analysis for SEC components such as AF4/AF5, 
AF9/ENL and P-TEFb components CDK9 and Cyclin T1/2 at the Meis1 and Hoxa9 loci 
may shed light on any differential regulation between these two genes previously thought 
to play the similar roles in leukemogenesis.  
 These findings highlight the requirement for the AF9-AF4/AF5 salt bridge 
interaction in leukemic transformation. As previously described, AF9 interacts with a 
region of hydrophobic residues in AF4 (also conserved in AF5, Figure 32). This 
hydrophobic region is present in other AF9 interacting proteins DOT1L, CBX8 and 
BCoR. These results show that mutation of AF9 at aspartic acid D544 selectively disrupts 
binding to AF4, while maintaining binding to DOT1L and CBX8 (BCoR binding was not 
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assessed). These results show that the AHD of AF9 likely interacts with proteins through 
both the hydrophobic motif shared by all proteins, but also through additional interactions 
that may be specific to each partner protein.  
AF4 K764 is located within the hydrophobic motif conserved in AF9 binding 
partners (Figure 32). While the charge-reversal studies support the conclusion that the 
electrostatic interaction between AF9 and AF4/AF5 is required for transformation, an 
alternative hypothesis is that mutation of K764E, or K717D in the case of AF5q31, 
disrupts the organization of the hydrophobic motif. Hydrophobic residues often associate 
in the core of proteins to remain isolated from the aqueous environment. Disrupting the 
charge on an amino acid within this motif may alter the packing altogether, losing the 
binding interface with AF9, and that could result in the loss of transformation. However 
the complementation experiment suggests that this is not the case, because coexpression 
of AF5(K717D) with AF9(D544R) restores transformation ability. If the hydrophobic 
motif was disrupted by the AF5(K717D) mutation, coexpression of AF9(D544R) would 
not be able to rescue the folding of that motif.  
Disruption of AF9 binding to AF4 specifically by this mutation provides an 
attractive target to develop small molecule inhibitors. The Hemenway lab has designed 
and tested AF4 mimetic peptides that disrupt the AF4-AF9 interaction. These peptides 
show cytotoxicity specifically in MLL fusion-expressing cell lines, although the 
mechanism is not well understood
157, 189, 259
.  
 It would be informative to examine whether the salt bridge interaction mediated 
by AF9 homolog ENL with AF4 family members is also necessary for leukemic 
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transformation. AF9 and ENL are highly homologous, and AF9 aspartate 544 is 
conserved in ENL (Figure 4D). As either AF9 or ENL can participate in the P-TEFb 
elongation complex, and both are fusion partners of MLL, it is likely that an electrostatic 
interaction between ENL and AF4 family members would also be required for 
leukemogenesis.  
MLL-AF9(D546R) Reduces Leukemic Transformation Potential 
 The AF9 D546R mutant was predicted to specifically disrupt binding to DOT1L 
while maintaining binding to AF4 and CBX8. Coimmunoprecipitation studies confirmed 
that expression of AF9(376-568) D546R reduced binding to DOT1L compared to the 
wild type AF9 fragment, while maintaining interaction with AF4 (CBX8 binding studies 
are ongoing). Similar to the D544-K764 electrostatic interaction between AF9 and AF4 
discussed above, AF9 D546 likely mediates an electrostatic interaction with a negatively 
charged residue in DOT1L.  
 To test the effect of this mutation on in vitro transforming ability, c-kit+ 
progenitor cells were retrovirally transduced with MLL-AF9, wild type or D546R 
mutant. Cells expressing MLL-AF9(D546R) showed decreased colony formation 
compared to the wild-type fusion, and the colonies that did form were very small and 
diffuse. The cells within these colonies were differentiated compared to the blast 
morphology in the MLL-AF9(WT)-expressing cells. Both Hoxa9 and Meis1 expression 
were significantly reduced in MLL-AF9(D546R) expressing cells compared to the wild 
type control, indicating that the interaction mediated by AF9 residue D546 is required for 
leukemic transformation in vitro. 
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 Identification of the residue on DOT1L mediating the interaction with AF9 D546 
would allow for similar complementation studies conducted with the D544R mutant to 
confirm that it is indeed a salt bridge interaction between these two proteins that, when 
disrupted, results in a loss of transforming potential.  
The D546 residue is two amino acids downstream of the D544 residue that 
mediates AF4 interaction, yet these mutants seem to be selective for disrupting binding to 
DOT1L and AF4, respectively. This is entirely plausible as structural studies indicate that 
AF9 likely interacts with only one protein at a time. The AHD of AF9 is a small stretch 
of 94 amino acids, and studies of the chemical shift of AF9 with AF4, DOT1L, CBX8 or 
BCoR suggest that all four proteins bind to the same region of AF9 via a conserved 
hydrophobic motif. Biochemical purification studies have also shown that AF9 and 
DOT1L exist in a complex distinct from AF9 and AF4 and the other PTEF-b proteins, 
further supporting the hypothesis that AF9 interacts singly with one of the four identified 
proteins to mediate specific effects within the cell.  
It would be very useful to examine the effects of a double AF9(D544R/D546R) 
mutant in both binding studies and in in vitro colony formation assays. While MLL-
AF9(D544R)-expressing cells had reduced colony formation ability compared to wild-
type, and expression of MLL-AF9(D546R) in bone marrow cells almost completely 
abolished colony formation, there were colonies at the end of each of four weeks, 
indicating that transformation was not completely inhibited in the cells. This may be 
because the D544R-mutant cells can retain binding to Dot1l, and the D546R-mutant cells 
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retain binding to Af4. The double mutant would presumably be unable to bind to both 
proteins, and thus we may see a complete loss of colony formation.  
MLL-AF9 Mutants E506R, I538A and K557E Do Not Alter Transformation Ability 
Expression of additional MLL-AF9 mutants E506R, I538A and K557E did not 
result in reduced colony formation compared to MLL-AF9(WT). There were no changes 
in target gene expression, nor any gross alterations in colony or cell morphology. Of note, 
however, is the MLL-AF9(I538A) mutation. This mutant was predicted to disrupt 
binding to both AF4 and DOT1L. We expected to see a loss of colony formation ability 
in bone marrow progenitors expressing this fusion, although results showed that 
expression of MLL-AF9(I538A) transforms cells to the same degree as MLL-AF9(WT). 
The colonies formed by MLL-AF9(I538A)-expressing cells, however, often had a dense 
core surrounded by more diffuse cells that themselves appeared partially differentiated 
compared to the wild type control.  
Unpublished coimmunopreciptiation studies by Dr. Malik indicate that mutation 
of AF9 residue I538 to alanine results in a loss of binding to AF4 and DOT1L, but this 
mutant enhances binding to CBX8 compared to AF9(WT). If this is the case, it is 
possible that the enhanced AF9-CBX8 interaction is leading the recruitment of CBX8 to 
genes targeted by the MLL-AF9 fusion. CBX8 may then deposit repressive histone marks 
to turn off gene expression, which could explain the partially differentiated phenotype. In 
our studies, expression of MLL-AF9(I538A) does not result in a decrease in Hoxa9 or 
Meis1 expression in bone marrow cells at week one, but perhaps we would see a decrease 
if we examined later time points, or if we examined other MLL target genes. It would be 
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interesting to examine the effect of this mutant in vivo, as we would expect leukemia to 
develop based on the colony assay results, but the phenotype of the leukemia or the time 
of onset may be different compared to MLL-AF9(WT) control.  
Transformation Potential of MLL-AF9 Fusions Resulting from Two Different 
Breakpoints in AF9 
 
I also examined the transformation ability of MLL-AF9 fusions containing either 
93 or 194 amino acids of AF9. To date, five breakpoint regions in AF9 have been 
identified in patients with t(9;11)(p22;q23) rearrangements
241
. Of the reported cases in 
the literature, approximately 75% of MLL-AF9 fusions expressed in patients include 
amino acids 375-568 of AF9 in frame with 5’ MLL. These region was first identified by 
Nakamura and colleagues as site A. Found less frequently, in approximately 12% of 
patients with t(9;11), is a MLL fusion including amino acids 475-568 of AF9
154
. A 
knock-in mouse model in which MLL-AF9(475-568) was introduced via homologous 
recombination into the endogenous Mll locus resulted in development of AML in mice, 
indicating that this shorter C-terminal region of AF9 is sufficient for transformation
147
. 
The AHD of AF9 that mediates protein-protein interactions is fully present in 
both the long and short form of the MLL-AF9 fusions. However, it was possible that the 
100 amino acid difference between these two fusions could mediate additional 
interactions that would alter transformation ability. I tested this in vitro by expressing the 
long and short fusions in bone marrow cells, and assessing serial replating ability. I did 
not see a statistically significant difference in colony formation ability between the cells 
expressing either fusions until week four, at which point MLL-AF9(475-568)-expressing 
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cells formed more colonies than cells expressing the longer form. It would be interesting 
to examine whether the enhanced colony formation ability in cells expressing the short 
form fusion would continue for subsequent replatings. In regard to human leukemia, it 
would be interesting to examine the survival rates of patients harboring MLL-AF9 
fusions resulting from the different AF9 breakpoint regions.    
Neither Hoxa9 nor Meis1 expression levels were significantly different between 
cells expressing MLL-AF9 fusions with the long or short AF9 C-terminal tail at the end 
of week one. This result is consistent with the colony formation between cells expressing 
these constructs at the end of week one. However, we may expect to see increased Hoxa9 
and Meis1 levels at week four, the time point in which the MLL-AF9(475-568)-
expressing cells exhibited enhanced colony forming ability over MLL-AF9(376-568) 
expressing cells.  
It would be interesting to examine the affinity of binding between the long and 
short form of the C-terminal AF9 tail with known AF9-interacting partners. If the shorter 
form is indeed more transforming, perhaps this region binds to certain “activating” 
proteins with higher affinity than does the longer form, or the longer form may bind to 
proteins with repressive function with higher affinity. In terms of the coupled folding of 
intrinsically disordered proteins, it may require less energy to induce structure of a 93 
amino acid fragment as compared to 194 amino acids, making it easier for this smaller 
fragment to bind to proteins that interact with AF9 and confer an “activating” function.  
Elucidating any differences in protein interactions between the long and short C-
terminus of AF9 would be useful in understanding the mechanisms of transformation 
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mediated by these different MLL-AF9 fusion proteins, and could potentially inform 
different treatment options for patients expressing the long or short MLL-AF9 fusion.  
Transcription Elongation in Cells Expressing MLL-AF9 Mutants 
All of the point mutants were engineered to disrupt binding of AF9 to AF4, 
DOT1L, CBX8 or BCoR. We hypothesized that loss of AF9 interaction with one or more 
of these proteins would result in decreased colony formation and target gene expression, 
and indeed that was what we saw. The D544R mutation, which disrupts binding to AF4, 
and the D546R mutation, which disrupt binding to DOT1L, both resulted in decreased 
colony formation. To assess whether the interaction of AF9 with AF4 or DOT1L is 
required for productive elongation of the RNA Polymerase II complex, we designed 
primer sets spanning the length of the 138 kb Meis1 genomic region, hypothesizing that 
the SEC would be unable to assemble or function properly to promote productive 
elongation. 
We saw reduced expression of Meis1 at all four genomic regions in cells 
transduced with the D544R or D546R mutants compared to the wild type control, 
supporting our model that decreased colony formation and target gene expression is a 
result of disrupting required AF9-mediated protein interactions in the SEC. Interestingly, 
we saw increased expression levels at the 3’ end of the gene compared to the 5’ end in 
cells expressing either of these mutants. This could be a result of primer efficiency; 
perhaps the exon 6/7, exon 8/9 and exon 12 primer sets amplify their target more 
efficiently than the exon 1 primer set. The 5’ end of the transcript could also be degraded. 
If the RNA Pol II complex is stalled for too long, the RNA Polymerase II complex can be 
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ubiquitylated and targeted for degradation
260
. Capping enzymes, as well as splicing 
factors and proteins responsible for 3’ polyadenylation often exert their functions 
cotranscriptionally with RNA Pol II
261, 262. A study in yeast showed that 5’ capping is an 
early event in transcriptional elongation
263
. It could therefore be possible that RNA 
Polymerase II cannot successfully elongate target gene transcripts in cells expressing the 
MLL-AF9 D544R or D546R mutant. As a result, the nascent transcript is uncapped and is 
degraded from the 5’ end. 
The MLL-AF9 E506R, I538A and K557E mutants also show decreased 
expression of Meis1 using the exon 1 primer set. These results suggest that all MLL-AF9 
point mutants studied here exhibit defects in transcription initiation. It would be 
interesting to examine RNA Pol II occupancy throughout the Meis1 locus in cells 
transduced with these MLL-AF9 mutants. We could also assess the phosphorylation state 
of the CTD of RNA Pol II to discern whether Pol II is stalled at initiation or is in the 
productive elongation stage.  
Model for AF9 Interaction with AF4 and DOT1L in Leukemogenesis 
Overall, these studies have highlighted the requirement for AF9 interaction with 
Af4 and Dot1l in in vitro models of leukemogenesis in the murine system. The use of 
structurally-informed point mutations identified critical interactions that could potentially 
be targeted by small molecule inhibitors to treat patients with MLL leukemia.  
I used genetic mutation of AF9 in the context of the MLL-AF9 fusion protein to 
disrupt binding with Af4 or Dot1l. We hypothesize that disrupting the AF9-AF4 
interaction prevents P-TEFb from being recruited and/or stabilized at MLL target gene 
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promoters, resulting in decreased expression of genes required for leukemogenesis 
(Figure 35). We do see a decrease in target gene expression, but it would be interesting to 
see if the SEC is being recruited to these loci upon loss of AF9-AF4 binding.  
 
Figure 35. Model of AF9 Interaction with AF4 and DOT1L at MLL Target Genes 
 
 
 
 
 
 
 
 
MLL fusions are recruited to MLL target genes via the N-terminal DNA binding activity 
of MLL. The C-terminal AF9/ENL portion of the fusion protein recruits SEC proteins 
AF4/AF5 which interact with P-TEFb to stabilize RNA polymerase. Downstream within 
the gene body, AF9 interacts with DOT1L, which deposits methyl marks at H3K79. As 
shown, mutations that disrupt AF9 interation with AF4/AF5 or DOT1L result in 
decreased target gene expression. These protein-protein interactions are therefore 
attractive targets for developing therapeutics for the treatment of MLL leukemias. 
 
Similarly, we see that loss of AF9-DOT1L interaction results in reduced colony 
formation, decreased target gene expression and differentiation of the leukemic blast 
cells. However, the mechanism is not understood. DOT1L is the H3K79 histone 
methyltransferase, so we hypothesize that loss of AF9-DOT1L interaction results in a 
loss of H3K79 methylation at genes targeted by MLL-AF9. ChIP-seq studies addressing 
this question are ongoing by our collaborators at the University of Virginia.  
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Furthermore, the function of H3K79 methylation is not well understood. This 
mark is often enriched in gene bodies
264
 and DOT1L has been identified in several 
studies as a member of the Super Elongation Complex
5, 187
, thus it is hypothesized the 
DOT1L and H3K79 methylation play a role in transcriptional elongation. This mark is 
associated with actively transcribed genes in genome-wide studies in Drosophila
265
 and 
mammalian cells
266
. At least one study in yeast, and an additional ChIP-seq study using 
human CD4+ T cells, failed to find this correlation
267, 268
. In fact, H3K79me3 was 
associated with gene repression in these CD4+ T cells. It is clear from our studies and 
others, especially those utilizing Dot1l
-/-
 mice, that Dot1l is required for leukemic 
transformation by MLL fusions, although more work needs to be done to determine the 
mechanism.  
MLL-rearranged leukemias are very complex, but the use of structurally-informed 
mutational analyses to dissect the mechanisms of leukemogenesis has proved to be a very 
helpful method in studying the function of these fusion proteins. It is our hope that this 
knowledge can be used in developing small molecule inhibitors and targeted therapeutics 
to disrupt interactions required for leukemic transformation.  
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